Cyclic compounds with selective KRAS inhibitory activity relative to HRAS and NRAS, and pharmaceutical compositions containing such compounds.

TWI945431BActive Publication Date: 2026-11-11CHUGAI PHARMA CO LTD
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
TW112116268
Authority / Receiving Office
TW · TW
Patent Type
Patents
Current Assignee / Owner
Priority Date
2022-05-06
Filing Date
2023-05-02
Publication Date
2026-11-11
Estimated Expiration
2043-05-01

AI Technical Summary

Technical Problem

Current technologies lack compounds that selectively inhibit KRAS relative to HRAS and NRAS, and there is a need for drug-like peptides that effectively target RAS mutant cancers without sufficient pharmacological effects on tumor cells.

Method used

Development of cyclic compounds, represented by specific formulas, that selectively interact with KRAS compared to HRAS and NRAS, inhibiting the proliferation of tumor cells with RAS mutations.

Benefits of technology

The cyclic compounds demonstrate selective inhibition of KRAS, effectively inhibiting the proliferation of tumor cells with RAS mutations, addressing the lack of selective inhibitors in existing technologies.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000112_0000
    Figure 00000112_0000
  • Figure 00000112_0001
    Figure 00000112_0001
  • Figure 00000113_0000
    Figure 00000113_0000
Patent Text Reader

Abstract

A cyclic compound that selectively inhibits KRAS was discovered. Furthermore, interactions between the cyclic compound and specific amino acid residues of KRAS were found.
Need to check novelty before this filing date? Find Prior Art

Description

Cyclic compounds with selective KRAS inhibition relative to HRAS and NRAS The present invention, in one aspect, relates to a cyclic compound that has selective KRAS inhibition relative to HRAS and NRAS. RAS is a protein belonging to the small GTPase family, and KRAS, NRAS, and HRAS are known. RAS is defined as an activated state or an inactivated state according to its binding state with GDP or GTP, and is activated by the exchange reaction of converting GDP to GTP caused by GEF (guanine nucleotide exchange factor), and is not activated by the GTP hydrolysis reaction caused by GAP (GTPase-activating proteins) (non-patent literature 1). Activated RAS activates a variety of downstream signals such as MAPK pathways, PI3K / Akt pathways, and RAL pathways to induce cell proliferation, survival, and differentiation. The persistent activation of RAS plays an important role in the occurrence or progression of cancer. It is known that in cancer, the RAS-RAF-MEK-ERK pathway is activated (non-patent literature 2) by the activation of upstream signals of RAS, the persistent activation of RAS, and / or the active mutation of RAS. These active mutations of RAS are confirmed in a variety of cancer types. G12, G13, and Q61 are known hot spots for RAS mutations, and high-frequency mutations of KRAS at G12 and NRAS at Q61 have been confirmed. Furthermore, these mutations are known to correlate with patient prognosis (Non-Patent Document 3). On the other hand, for tough targets, such as those typified by the inhibition of protein-protein interactions, medium-molecular compounds (molecular weight 500-2000 g / mol) are likely superior to smaller compounds. Furthermore, compared to antibodies, medium-molecular compounds have superior intracellular transport potential. Among physiologically active medium-molecular compounds, peptide drugs represent a class of high-value molecules already on the market, with over 40 on the market (Non-Patent Document 4). Representative examples of these peptide drugs include cyclosporine A and polymyxin B. These peptides contain several unnatural amino acids. Since unnatural amino acids are naturally not encoded in mRNA, their inclusion in naturally derived cyclosporine A or polymyxin B is of significant significance. After discovering that naturally derived peptides are useful as medicines, attention has been focused on peptides that are pharmacologically active and can be absorbed by the body, and peptides with a molecular weight of approximately 500 to 2000 g / mol have been actively studied (Non-Patent Document 5). The use of medium-molecular peptides under conditions of enhanced membrane permeability and metabolic stability (necessary for satisfying drug-likeness) that can contribute to improved in vivo dynamics has been reported (Patent Document 1). Furthermore, it has been found that a medium-molecular-weight peptide is a necessary condition for the drug-like properties of a cyclic peptide to contribute to the improvement of in vivo dynamics (Patent Document 2). Peptides that bind to RAS have been discovered, and the binding sites of cyclic peptides and RAS have been analyzed through X-ray structural analysis (Non-Patent Documents 6, 7, and 8). In addition, cyclic peptides that inhibit the binding of RAS and SOS have been discovered (Patent Document 3). In addition, in binding and competition assays between specific compounds and RAS, cyclic peptides that inhibit the binding of RAS have been discovered (Patent Document 4). [Prior Art Documents] [Patent Documents] [Patent Document 1] International Publication No. 2013 / 100132 [Patent Document 2] International Publication No. 2018 / 225864 [Patent Document 3] International Publication No. 2012 / 122059 [Patent Document 4] International Publication No. 2017 / 181061 [Non-Patent Document] [Non-patent document 1] Nat. Rev. Drug Discov. 2014 Nov;13(11):828-851. [Non-patent document 2] Nat. Rev. Drug Discov. 2014 Dec;13(12):928-942. [Non-patent document 3] Nat. Rev. Drug Discov. 2016 Nov;15(11):771-785. [Non-patent document 4] Future Med. Chem. 2009, 1, 1289-1310. [Non-patent document 5] Current Topics in Medicinal Chemistry, 2013, Vol. 13, No. 7, 821-836. [Non-patent document 6] Biochem. Biophys. Res. Commun. 2017, 484, 605-611. [Non-patent document 7] Bioorg. Med. Chem. Lett. 2017, 27, 2757-2761. [Non-patent document 8] ACS Med. Chem. Lett. 2017, 8, 732-736. [Problems to be Solved by the Invention] The present invention relates to cyclic compounds effective against RAS-mutant cancers and unnatural amino acid and peptide compounds useful in their production. Patent Documents 1 and 2 describe drug-like peptides, but neither describes peptides with antitumor effects against cancers including RAS-mutant cancers. Patent Document 3 describes inhibition of RAS-SOS binding, and Patent Document 4 describes peptides that compete with compounds that bind to RAS. However, none of these cited documents demonstrate pharmacological effects, particularly effects on tumor cells. Furthermore, none of these cited documents describe drug-like peptides. Non-Patent Document 1 details the relationship between RAS and cancer. While this document describes molecules that bind to RAS and demonstrate efficacy in previous clinical trials, it does not identify compounds specifically effective against RAS-mutant cancers as pharmaceuticals, nor does it disclose drug-like cyclic peptides. Non-Patent Document 2 details RAS and the RAF-MEK-ERK pathway downstream of RAS. While this document suggests the potential for treating RAS-mutant cancers via inhibitors of RAF, MEK, and ERK, it does not disclose compounds that directly inhibit RAS. Non-Patent Document 3 describes compounds that inhibit RAS function by binding to the GTP / GDP binding site of RAS and their mechanisms. This document details interactions with the GTP / GDP binding site, but does not disclose pharmacological effects, particularly on tumor cells. Non-Patent Document 4 describes peptides used as pharmaceuticals, but does not describe drug-like peptides or peptides useful for RAS-mutant cancers. Non-Patent Document 5 describes the molecular structure and pharmacokinetics of cyclic peptides, but does not describe compounds useful for RAS-mutant cancers. Non-Patent Documents 6 to 8 describe peptides that bind to RAS, but except that their effects are limited to tumor cells, they do not describe drug-like peptides. Furthermore, as far as the present inventors are aware, there are no reports of compounds that have a sufficiently selective KRAS inhibitory effect over HRAS and NRAS. The inventors have diligently searched for cyclic compounds with selective KRAS inhibitory activity relative to HRAS and NRAS, and have discovered cyclic compounds that selectively interact with KRAS compared to HRAS and NRAS. Furthermore, they discovered that these cyclic compounds have a pharmacological effect of inhibiting the proliferation of tumor cells harboring RAS mutations. The present invention, in a non-limiting embodiment, comprises the following: [1] A cyclic compound represented by formula (1), or a salt thereof or a solvent thereof: [Chemical 1] Where, L 1 is a single bond; R 1 is C 1~C 7 alkyl, or R 1 and R 5 together form a divalent group. In this case, the partial structure of the cyclic compound represented by formula (1): *-CR 1Q 1-L 1-CO-NP 2-CR 2Q 2-CO-NP 3-CR 3Q 3-CO-NP 4-CR 4Q 4-CO-NP 5-CR 5Q 5-* is represented by the following formula: [Chemical 2] Where: X 2 is -L 1-CO-NP 2-CR 2Q 2-CO-NP 3-CR 3Q 3-CO-NP 4-CR 4Q 4-CO-NP 5-, [Chemistry 3] is a single bond or a double bond, [Chemical 4] Indicates [5] In the case of a double bond, the stereochemistry may be either E or Z, n is 0, 1 or 2, m is 0, 1, 2, 3 or 4, * indicates the bonding point to the adjacent atom; P 1 is C 1~C 6 alkyl; Q 1 is hydrogen; R 2 for C 1~C 6-alkyl; P 2 is hydrogen; Q 2 is hydrogen; R 3 is hydrogen, or R 3 and P 3. R 3-bonded carbon atoms, and P The three nitrogen atoms bonded together form a 4-7 membered saturated heterocyclic ring; 3 and P 3 except when forming a 4- to 7-membered saturated heterocyclic ring, P 3 for C 1~C 6 alkyl, or C 3~C 8-cycloalkyl; Q 3 is hydrogen; R 4 and P 5 together form a divalent group. In this case, the partial structure *-CR in the cyclic compound represented by formula (1) 4Q 4-CO-NP 5-* is represented by the following formula: [Chemical 6] ; P 4 for C 1~C 6 alkyl; Q 4 is hydrogen, in R 1 and R 5 Except for the case of forming a divalent group, R 5 is available through the selection of C 1~C 6 alkyl, C 1~C 6 haloalkyl and C 3~C 8 benzyl substituted by one or more groups selected from the group consisting of cycloalkyl; Q 5 is hydrogen, R 6 is hydrogen; P 6 for C 1~C 6 alkyl, Q 6 is hydrogen, R 7 is independently selected from halogen, C 1~C 6 haloalkyl, and C 1~C 6 phenylethyl substituted by one or more groups consisting of alkoxy groups; 7 is hydrogen, Q 7 is hydrogen, R 8 and P 8. R 8-bonded carbon atoms, and P The 8-bonded nitrogen atoms together form a 4-7 membered saturated heterocyclic ring, which can be 1~C 6 alkoxy substituted; Q 8 is hydrogen, R 9 and Q 9. and R 9 and Q 9 bonded carbon atoms together form a 3-8 membered alicyclic ring, which may be fused to one or more C 1~C 6 alkyl substituted; P 9 is hydrogen or C 1~C 6 alkyl, R 10 C 1~C 6 alkyl, or C 3~C 8-cycloalkyl; P 10 C 1~C 6 alkyl, Q 10 is hydrogen, and L 11 -CH 2-, R 11 For two C 1~C 6-alkylaminocarbonyl, or 4-8 membered cyclic aminocarbonyl; P 11 C 1~C 6 alkyl, Q 11is hydrogen, the cyclic compound represented by formula (1) is a cyclic compound selected from the group consisting of: PP1574: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-N-ethyl-27-isobutyl-N,4,19,22,26,32,35-heptamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecacyclo-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 ]Tetradec-38-ene-17,1'-cyclopentane]-23-carboxamide, PP1650: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-27-isobutyl-N,N,3',3',4,19,22,26,32,35-decamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecacyclo-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 ]tetradec-38-ene-17,1'-cyclobutane]-23-carboxamide, PP1827: (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z,47E)-19-cyclopentyl-7-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-11-ethoxy-N-ethyl-N,3,18,21,25,31,34-heptamethyl-29-[(1S)-1-methylpropyl]-2,5,8,14,17,20,24,27,30,33,55-undecacyclo-spiro[3,6,9,15,18,21,25,28,31,34,41-undecaazapentacyclo[24.15.11.2 43,46 .1 35,41 .0 9,13]pentacarbonyl-37,43(54),44,46(53),47-pentaene-16,1'-cyclobutane]-22-carboxamide, PP1830: (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z,47E)-19-cyclopentyl-11-ethoxy-N-ethyl-7-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-N,3,3',3',18,21,25,31,34-nonamethyl-29-[(1S)-1-methylpropyl]-2,5,8,14,17,20,24,27,30,33,55-undecacyclo-spiro[3,6,9,15,18,21,25,28,31,34,41-undecacyclopentacyclo[24,15,11,2 43,46 .1 35,41 .0 9,13 ]pentacarbonyl-37,43(54),44,46(53),47-pentaene-16,1'-cyclobutane]-22-carboxamide, PP2093: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-32-cyclopropyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-N,N,3',3',4,19,22,26,35-nonamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecacyclo-27-propyl-2-(p-tolylmethyl)spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 ]tetradec-38-ene-17,1'-cyclobutane]-23-carboxamide, PP2260: (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z)-19-cyclopentyl-11-ethoxy-N-ethyl-7-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-N,3,3',3',18,21,25,31,34-nonamethyl-29-[(1S)-1-methylpropyl]-2,5,8,14,17,20,24,27,30,33,55-undecacyclo-spiro[3,6,9,15,18,21,25,28,31,34,41-undecaazapentacyclo[24.15.11.2 43,46 .1 35,41.0 9,13 ]pentacarbonyl-37,43(54),44,46(53)-tetraene-16,1'-cyclobutane]-22-carboxamide, PP2316: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-32-cyclopropyl-12-ethoxy-8-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-N,N,4,16,19,22,26,35-octamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecacyclo-27-propyl-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 ]tetradec-38-ene-17,1'-cyclobutane]-23-carboxamide, PP2320: (1S,4S,10S,13S,17S,20S,26S,28R,32S,38S,42Z)-20-cyclopentyl-28-ethoxy-32-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-N,N,2,14,18,21,24,36-octamethyl-10-[(1S)-1-methylpropyl]-3,9,12,15,19,22,25,31,34,37,45-undecacyclo-13-propyl-38-[[4-(trifluoromethyl)phenyl]methyl]spiro[2,8,11,14,18,21,24,30,33,36,39-undecaazatetracyclo[37.5.1.0 4,8 .0 26,30 ]pentadec-42-ene-23,1'-cyclobutane]-17-carboxamide, PP2328: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-32-cyclopropyl-12-ethoxy-8-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-N,N,4,16,19,22,26,35-octamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecacyclo-27-propyl-2-(p-tolylmethyl)spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14]tetradec-38-ene-17,1'-cyclobutane]-23-carboxamide, PP2574: (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z,47E)-19-cyclopentyl-7-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-11-ethoxy-3,3',3',18,21,25,31,34-octamethyl-29-[(1S)-1-methylpropyl]-22-(pyrrolidine-1-carbonyl)spiro[3,6,9,15,18,21,25,28,31,34,41-undecaazapentacyclo[24.15.10.2 43,46 .1 35,41 .0 9,13 ]pentacontan-37,43(53),44,46(52),47-pentaene-16,1'-cyclobutane]-2,5,8,14,17,20,24,27,30,33,54-undecanone, PP2576: (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z,47E)-7-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-11-ethoxy-19-(1-ethylpropyl)-3,3',3',18,21,25,31,34-octamethyl-29-[(1S)-1-methylpropyl]-22-(pyrrolidine-1-carbonyl)spiro[3,6,9,15,18,21,25,28,31,34,41-undecaazapentacyclo[24.15.10.2 43,46 .1 35,41 .0 9,13 ]pentacontan-37,43(53),44,46(52),47-pentaene-16,1'-cyclobutane]-2,5,8,14,17,20,24,27,30,33,54-undecanone, PP2583: (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z,47E)-19-cyclopentyl-31-cyclopropyl-7-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-11-ethoxy-3,3',3',18,21,25,34-heptamethyl-29-[(1S)-1-methylpropyl]-22-(pyrrolidine-1-carbonyl)spiro[3,6,9,15,18,21,25,28,31,34,41-undecaazapentacyclo[24.15.10.2 43,46.1 35,41 .0 9,13 ]pentacontan-37,43(53),44,46(52),47-pentaene-16,1'-cyclobutane]-2,5,8,14,17,20,24,27,30,33,54-undecanone, PP2687: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-12-ethoxy-2-[(4-ethylphenyl)methyl]-27-isobutyl-8-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-N,N,3',3',4,19,22,26,32,35-decamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecacyclo-1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 ]tetradec-38-ene-17,1'-cyclobutane]-23-carboxamide, PP2691: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-2-[(4-cyclopropylphenyl)methyl]-12-ethoxy-27-isobutyl-8-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-N,N,3',3',4,19,22,26,32,35-decamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecacyclo ... 10,14 ]tetradec-38-ene-17,1'-cyclobutane]-23-carboxamide, PP2957: (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z,47E)-31-cyclopropyl-7-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-11-ethoxy-19-(1-ethylpropyl)-3,18,21,25,34-pentamethyl-29-[(1S)-1-methylpropyl]-22-(pyrrolidine-1-carbonyl)spiro[3,6,9,15,18,21,25,28,31,34,41-undecaazapentacyclo[24.15.10.2 43,46 .1 35,41.0 9,13 ]pentacontan-37,43(53),44,46(52),47-pentaene-16,1'-cyclobutane]-2,5,8,14,17,20,24,27,30,33,54-undecanone, PP3033: (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z)-19-cyclopentyl-11-ethoxy-7-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-3,18,21,25,31,34-hexamethyl-29-[(1S)-1-methylpropyl]-22-(piperidine-1-carbonyl)spiro[3,6,9,15,18,21,25,28,31,34,41-undecaazapentacyclo[24.15.11.2 43,46 .1 35,41 .0 9,13 ]pentacarbonyl-37,43(54),44,46(53)-tetraene-16,1'-cyclobutane]-2,5,8,14,17,20,24,27,30,33,55-undecanone, PP3034: (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z)-19-cyclopentyl-11-ethoxy-7-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-3,3',3',18,21,25,31,34-octamethyl-29-[(1S)-1-methylpropyl]-22-(pyrrolidine-1-carbonyl)spiro[3,6,9,15,18,21,25,28,31,34,41-undecaazapentacyclo[24,15,11,2 43,46 .1 35,41 .0 9,13]pentacarbonyl-37,43(54),44,46(53)-tetraene-16,1'-cyclobutane]-2,5,8,14,17,20,24,27,30,33,55-undecanone, PP3036: (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z)-19-cyclopentyl-11-ethoxy-7-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-3,3',3',18,21,25,31,34-octamethyl-29-[(1S)-1-methylpropyl]-22-(piperidine-1-carbonyl)spiro[3,6,9,15,18,21,25,28,31,34,41-undecaazapentacyclo[24.15.10.2 43,46 .1 35,41 .0 9,13 ]54-tetradecanoic acid-37,43(53),44,46(52)-tetraene-16,1'-cyclobutane]-2,5,8,14,17,20,24,27,30,33,54-undecanone, PP3037: (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z)-19-cyclopentyl-11-ethoxy-7-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-3,3',3',18,21,25,31,34-octamethyl-29-[(1S)-1-methylpropyl]-22-(pyrrolidine-1-carbonyl)spiro[3,6,9,15,18,21,25,28,31,34,41-undecaazapentacyclo[24.15.10.2 43,46 .1 35,41 .0 9,13 ]54-tetradecanoic acid-37,43(53),44,46(52)-tetraene-16,1'-cyclobutane]-2,5,8,14,17,20,24,27,30,33,54-undecanone, PP3047: (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z,47E)-7-[2-(3,4-dichlorophenyl)ethyl]-11-ethoxy-19-(1-ethylpropyl)-3,18,21,25,31,34-hexamethyl-29-[(1S)-1-methylpropyl]-22-(pyrrolidine-1-carbonyl)spiro[3,6,9,15,18,21,25,28,31,34,41-undecaazapentacyclo[24.15.11.2 43,46 .1 35,41 .0 9,13 ]pentacarbonyl-37,43(54),44,46(53),47-pentaene-16,1'-cyclobutane]-2,5,8,14,17,20,24,27,30,33,55-undecanone, PP3093: (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z)-19-cyclopentyl-11-ethoxy-7-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-3,3',3',18,21,25,31,34-octamethyl-29-[(1S)-1-methylpropyl]-22-(piperidine-1-carbonyl)spiro[3,6,9,15,18,21,25,28,31,34,41-undecaazapentacyclo[24.15.9.2 43,46 .1 35,41 .0 9,13 ]Fifty-three carbon-37,43(52),44,46(51)-tetraene-16,1'-cyclobutane]-2,5,8,14,17,20,24,27,30,33,53-undecanone, PP3094: (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z)-19-cyclopentyl-7-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-3,3',3',18,21,25,31,34-octamethyl-29-[(1S)-1-methylpropyl]-11-propoxy-22-(pyrrolidine-1-carbonyl)spiro[3,6,9,15,18,21,25,28,31,34,41-undecaazapentacyclo[24,15,9,2 43,46 .1 35,41 .0 9,13]Fifty-three carbon-37,43(52),44,46(51)-tetraene-16,1'-cyclobutane]-2,5,8,14,17,20,24,27,30,33,53-undecanone, PP3095: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-32-cyclopropyl-12-ethoxy-8-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-4,16,19,22,26,35-hexamethyl-30-[(1S)-1-methylpropyl]-23-(piperidine-1-carbonyl)-27-propyl-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 ]tetradec-38-ene-17,1'-cyclobutane]-3,6,9,15,18,21,25,28,31,34,42-undecanone, PP3096: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-32-cyclopropyl-12-ethoxy-8-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-4,16,19,22,26,35-hexamethyl-30-[(1S)-1-methylpropyl]-23-(piperidine-1-carbonyl)-27-propyl-2-(p-tolylmethyl)spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 ]tetradec-38-ene-17,1'-cyclobutane]-3,6,9,15,18,21,25,28,31,34,42-undecanone, PP3097: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-32-cyclopropyl-12-ethoxy-8-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-4,16,19,22,26,35-hexamethyl-30-[(1S)-1-methylpropyl]-27-propyl-23-(pyrrolidine-1-carbonyl)-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14]tetradec-38-ene-17,1'-cyclobutane]-3,6,9,15,18,21,25,28,31,34,42-undecanone, PP3098: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-32-cyclopropyl-12-ethoxy-8-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-4,16,19,22,26,35-hexamethyl-30-[(1S)-1-methylpropyl]-27-propyl-2-(p-tolylmethyl)-23-(pyrrolidine-1-carbonyl)spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 ]tetradec-38-ene-17,1'-cyclobutane]-3,6,9,15,18,21,25,28,31,34,42-undecanone, PP3099: (1S,4S,10S,13S,17S,20S,26S,28R,32S,38S,42Z)-20-cyclopentyl-28-ethoxy-32-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-2,14,18,21,24,36-hexamethyl-10-[(1S)-1-methylpropyl]-17-(piperidine-1-carbonyl)-13-propyl-38-[[4-(trifluoromethyl)phenyl]methyl]spiro[2,8,11,14,18,21,24,30,33,36,39-undecaazatetracyclo[37.5.1.0 4,8 .0 26,30 ]pentacontan-42-ene-23,1'-cyclobutane]-3,9,12,15,19,22,25,31,34,37,45-undecanone, PP3100: (1S,4S,10S,13S,17S,20S,26S,28R,32S,38S,42Z)-20-cyclopentyl-28-ethoxy-32-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-2,14,18,21,24,36-hexamethyl-10-[(1S)-1-methylpropyl]-17-(piperidine-1-carbonyl)-13-propyl-38-(p-tolylmethyl)spiro[2,8,11,14,18,21,24,30,33,36,39-undecaazatetracyclo[37.5.1.0 4,8 .0 26,30]pentadec-42-ene-23,1'-cyclobutane]-3,9,12,15,19,22,25,31,34,37,45-undecanone, PP3101: (1S,4S,10S,13S,17S,20S,26S,28R,32S,38S,42Z)-20-cyclopentyl-28-ethoxy-32-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-2,14,18,21,24,36-hexamethyl-10-[(1S)-1-methylpropyl]-13-propyl-17-(pyrrolidine-1-carbonyl)-38-[[4-(trifluoromethyl)phenyl]methyl]spiro[2,8,11,14,18,21,24,30,33,36,39-undecaazatetracyclo[37.5.1.0 4,8 .0 26,30 ]pentadec-42-ene-23,1'-cyclobutane]-3,9,12,15,19,22,25,31,34,37,45-undecanone, PP3102: (1S,4S,10S,13S,17S,20S,26S,28R,32S,38S,42Z)-20-cyclopentyl-28-ethoxy-32-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-2,14,18,21,24,36-hexamethyl-10-[(1S)-1-methylpropyl]-13-propyl-38-(p-tolylmethyl)-17-(pyrrolidine-1-carbonyl)spiro[2,8,11,14,18,21,24,30,33,36,39-undecaazatetracyclo[37.5.1.0 4,8 .0 26,30 ]pentadec-42-ene-23,1'-cyclobutane]-3,9,12,15,19,22,25,31,34,37,45-undecanone, PP3103: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-12-ethoxy-8-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-4,16,19,22,26,32,35-heptamethyl-30-[(1S)-1-methylpropyl]-23-(piperidine-1-carbonyl)-27-propyl-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14]tetradec-38-ene-17,1'-cyclobutane]-3,6,9,15,18,21,25,28,31,34,42-undecanone, PP3104: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-12-ethoxy-8-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-4,16,19,22,26,32,35-heptamethyl-30-[(1S)-1-methylpropyl]-23-(piperidine-1-carbonyl)-27-propyl-2-(p-tolylmethyl)spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 ]tetradec-38-ene-17,1'-cyclobutane]-3,6,9,15,18,21,25,28,31,34,42-undecanone, PP3105: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-12-ethoxy-8-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-4,16,19,22,26,32,35-heptamethyl-30-[(1S)-1-methylpropyl]-27-propyl-23-(pyrrolidine-1-carbonyl)-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 ]tetradec-38-ene-17,1'-cyclobutane]-3,6,9,15,18,21,25,28,31,34,42-undecanone, PP3106: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-12-ethoxy-8-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-4,16,19,22,26,32,35-heptamethyl-30-[(1S)-1-methylpropyl]-27-propyl-2-(p-tolylmethyl)-23-(pyrrolidine-1-carbonyl)spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14]tetradec-38-ene-17,1'-cyclobutane]-3,6,9,15,18,21,25,28,31,34,42-undecanone, PP3110: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-32-cyclopropyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-4,16,19,22,26,35-hexamethyl-30-[(1S)-1-methylpropyl]-23-(piperidine-1-carbonyl)-27-propyl-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 ]tetradec-38-ene-17,1'-cyclobutane]-3,6,9,15,18,21,25,28,31,34,42-undecanone, PP3111: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-32-cyclopropyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-4,16,19,22,26,35-hexamethyl-30-[(1S)-1-methylpropyl]-23-(piperidine-1-carbonyl)-27-propyl-2-(p-tolylmethyl)spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 ]tetradec-38-ene-17,1'-cyclobutane]-3,6,9,15,18,21,25,28,31,34,42-undecanone, PP3112: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-32-cyclopropyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-4,16,19,22,26,35-hexamethyl-30-[(1S)-1-methylpropyl]-27-propyl-23-(pyrrolidine-1-carbonyl)-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14]tetradec-38-ene-17,1'-cyclobutane]-3,6,9,15,18,21,25,28,31,34,42-undecanone, PP3113: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-32-cyclopropyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-4,16,19,22,26,35-hexamethyl-30-[(1S)-1-methylpropyl]-27-propyl-2-(p-tolylmethyl)-23-(pyrrolidine-1-carbonyl)spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 ]tetradec-38-ene-17,1'-cyclobutane]-3,6,9,15,18,21,25,28,31,34,42-undecanone, PP3114: (1S,4S,10S,13S,17S,20S,26S,28R,32S,38S,42Z)-20-cyclopentyl-32-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-28-ethoxy-2,14,18,21,24,36-hexamethyl-10-[(1S)-1-methylpropyl]-17-(piperidine-1-carbonyl)-13-propyl-38-[[4-(trifluoromethyl)phenyl]methyl]spiro[2,8,11,14,18,21,24,30,33,36,39-undecaazatetracyclo[37.5.1.0 4,8 .0 26,30 ]pentacontan-42-ene-23,1'-cyclobutane]-3,9,12,15,19,22,25,31,34,37,45-undecanone, PP3115: (1S,4S,10S,13S,17S,20S,26S,28R,32S,38S,42Z)-20-cyclopentyl-32-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-28-ethoxy-2,14,18,21,24,36-hexamethyl-10-[(1S)-1-methylpropyl]-17-(piperidine-1-carbonyl)-13-propyl-38-(p-tolylmethyl)spiro[2,8,11,14,18,21,24,30,33,36,39-undecaazatetracyclo[37.5.1.0 4,8 .0 26,30]pentacontan-42-ene-23,1'-cyclobutane]-3,9,12,15,19,22,25,31,34,37,45-undecanone, PP3116: (1S,4S,10S,13S,17S,20S,26S,28R,32S,38S,42Z)-20-cyclopentyl-32-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-28-ethoxy-2,14,18,21,24,36-hexamethyl-10-[(1S)-1-methylpropyl]-13-propyl-17-(pyrrolidine-1-carbonyl)-38-[[4-(trifluoromethyl)phenyl]methyl]spiro[2,8,11,14,18,21,24,30,33,36,39-undecaazatetracyclo[37.5.1.0 4,8 .0 26,30 ]pentacontan-42-ene-23,1'-cyclobutane]-3,9,12,15,19,22,25,31,34,37,45-undecanone, PP3117: (1S,4S,10S,13S,17S,20S,26S,28R,32S,38S,42Z)-20-cyclopentyl-32-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-28-ethoxy-2,14,18,21,24,36-hexamethyl-10-[(1S)-1-methylpropyl]-13-propyl-38-(p-tolylmethyl)-17-(pyrrolidine-1-carbonyl)spiro[2,8,11,14,18,21,24,30,33,36,39-undecaazatetracyclo[37.5.1.0 4,8 .0 26,30 ]pentacontan-42-ene-23,1'-cyclobutane]-3,9,12,15,19,22,25,31,34,37,45-undecanone, PP3118: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-4,16,19,22,26,32,35-heptamethyl-30-[(1S)-1-methylpropyl]-23-(piperidine-1-carbonyl)-27-propyl-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14]tetradec-38-ene-17,1'-cyclobutane]-3,6,9,15,18,21,25,28,31,34,42-undecanone, PP3119: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-4,16,19,22,26,32,35-heptamethyl-30-[(1S)-1-methylpropyl]-23-(piperidine-1-carbonyl)-27-propyl-2-(p-tolylmethyl)spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 ]tetradec-38-ene-17,1'-cyclobutane]-3,6,9,15,18,21,25,28,31,34,42-undecanone, PP3120: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-4,16,19,22,26,32,35-heptamethyl-30-[(1S)-1-methylpropyl]-27-propyl-23-(pyrrolidine-1-carbonyl)-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 ]tetradec-38-ene-17,1'-cyclobutane]-3,6,9,15,18,21,25,28,31,34,42-undecanone, PP3121: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-4,16,19,22,26,32,35-heptamethyl-30-[(1S)-1-methylpropyl]-27-propyl-2-(p-tolylmethyl)-23-(pyrrolidine-1-carbonyl)spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14]Tetradodec-38-ene-17,1'-cyclobutane]-3,6,9,15,18,21,25,28,31,34,42-undecanone, (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z,47Z)-19-cyclopentyl-7-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-11-ethoxy-N-ethyl-N,3,18,21,25,31,34-heptamethyl-29-[(1S)-1-methylpropyl]-2,5,8,14,17,20,24,27,30,33,55-undecacyclo-spiro[3,6,9,15,18,21,25,28,31,34,41-undecacyclopentacyclo[24,15,11,25,31,34-heptamethyl-29-[(1S)-1-methylpropyl] 43,46 .1 35,41 .0 9,13 ]pentacarbonyl-37,43(54),44,46(53),47-pentaene-16,1'-cyclobutane]-22-carboxamide, (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z,47Z)-19-cyclopentyl-11-ethoxy-N-ethyl-7-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-N,3,3',3',18,21,25,31,34-nonamethyl-29-[(1S)-1-methylpropyl]-2,5,8,14,17,20,24,27,30,33,55-undecacyclo-spiro[3,6,9,15,18,21,25,28,31,34,41-undecacyclopentacyclo[24,15,11,2 43,46 .1 35,41 .0 9,13 ]pentacarbonyl-37,43(54),44,46(53),47-pentaene-16,1'-cyclobutane]-22-carboxamide, (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z,47Z)-19-cyclopentyl-7-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-11-ethoxy-3,3',3',18,21,25,31,34-octamethyl-29-[(1S)-1-methylpropyl]-22-(pyrrolidine-1-carbonyl)spiro[3,6,9,15,18,21,25,28,31,34,41-undecaazapentacyclo[24.15.10.2 43,46 .1 35,41 .0 9,13 ]54-tetradecanoic acid-37,43(53),44,46(52),47-pentaene-16,1'-cyclobutane]-2,5,8,14,17,20,24,27,30,33,54-undecanone, (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z,47Z)-7-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-11-ethoxy-19-(1-ethylpropyl)-3,3',3',18,21,25,31,34-octamethyl-29-[(1S)-1-methylpropyl]-22-(pyrrolidine-1-carbonyl)spiro[3,6,9,15,18,21,25,28,31,34,41-undecaazapentacyclo[24.15.10.2 43,46 .1 35,41 .0 9,13 ]54-tetradecanoic acid-37,43(53),44,46(52),47-pentaene-16,1'-cyclobutane]-2,5,8,14,17,20,24,27,30,33,54-undecanone, (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z,47Z)-19-cyclopentyl-31-cyclopropyl-7-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-11-ethoxy-3,3',3',18,21,25,34-heptamethyl-29-[(1S)-1-methylpropyl]-22-(pyrrolidine-1-carbonyl)spiro[3,6,9,15,18,21,25,28,31,34,41-undecaazapentacyclo[24.15.10.2 43,46 .1 35,41 .0 9,13]54-tetradecanoic acid-37,43(53),44,46(52),47-pentaene-16,1'-cyclobutane]-2,5,8,14,17,20,24,27,30,33,54-undecanone, (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z,47Z)-31-cyclopropyl-7-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-11-ethoxy-19-(1-ethylpropyl)-3,18,21,25,34-pentamethyl-29-[(1S)-1-methylpropyl]-22-(pyrrolidine-1-carbonyl)spiro[3,6,9,15,18,21,25,28,31,34,41-undecaazapentacyclo[24,15,10.2 43,46 .1 35,41 .0 9,13 ]penta-37,43(53),44,46(52),47-penta-16,1'-cyclobutane]-2,5,8,14,17,20,24,27,30,33,54-undecanone, and (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z,47Z)-7-[2-(3 ,4-dichlorophenyl)ethyl]-11-ethoxy-19-(1-ethylpropyl)-3,18,21,25,31,34-hexamethyl-29-[(1S)-1-methylpropyl]-22-(pyrrolidine-1-carbonyl)spiro[3,6,9,15,18,21,25,28,31,34,41-undecazapentacyclo[24.15.11.2 43,46 .1 35,41 .0 9,13 ]pentacarbonyl-37,43(54),44,46(53),47-pentaene-16,1'-cyclobutane]-2,5,8,14,17,20,24,27,30,33,55-undecanone. [2] The cyclic compound as described in [1], or its salt or solvent mixture thereof, wherein the aforementioned formula (1) is represented by formula (2): [Chemical 7] (Where, [Chem. 8] n、m、P 1. R 2. R 3. P 3. P 4. P 6. R 7. R 8. P 8. R 9. P 9. Q 9. R 10 、P 10 、R 11 , and P 11 The cyclic compound represented by formula (2) is selected from the group consisting of: PP1827: (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z,47E)-19-cyclopentyl-7-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-11-ethoxy-N-ethyl-N,3,18,21,25,31,34-heptamethyl-29-[(1S)-1-methylpropyl]-2,5,8,14,17,20,24,27,30,33,55-undecacyclo-spiro[3,6,9,15,18,21,25,28,31,34,41-undecacyclopentacyclo[24.15.11.2 43,46 .1 35,41 .0 9,13 ]pentacarbonyl-37,43(54),44,46(53),47-pentaene-16,1'-cyclobutane]-22-carboxamide, PP1830: (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z,47E)-19-cyclopentyl-11-ethoxy-N-ethyl-7-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-N,3,3',3',18,21,25,31,34-nonamethyl-29-[(1S)-1-methylpropyl]-2,5,8,14,17,20,24,27,30,33,55-undecacyclo-spiro[3,6,9,15,18,21,25,28,31,34,41-undecacyclopentacyclo[24,15,11,2 43,46 .1 35,41 .0 9,13]pentacarbonyl-37,43(54),44,46(53),47-pentaene-16,1'-cyclobutane]-22-carboxamide, PP2260: (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z)-19-cyclopentyl-11-ethoxy-N-ethyl-7-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-N,3,3',3',18,21,25,31,34-nonamethyl-29-[(1S)-1-methylpropyl]-2,5,8,14,17,20,24,27,30,33,55-undecacyclo-spiro[3,6,9,15,18,21,25,28,31,34,41-undecacyclopentacyclo[24,15,11,2 43,46 .1 35,41 .0 9,13 ]pentacarbonyl-37,43(54),44,46(53)-tetraene-16,1'-cyclobutane]-22-carboxamide, PP2574: (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z,47E)-19-cyclopentyl-7-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-11-ethoxy-3,3',3',18,21,25,31,34-octamethyl-29-[(1S)-1-methylpropyl]-22-(pyrrolidine-1-carbonyl)spiro[3,6,9,15,18,21,25,28,31,34,41-undecaazapentacyclo[24.15.10.2 43,46 .1 35,41 .0 9,13 ]pentacontan-37,43(53),44,46(52),47-pentaene-16,1'-cyclobutane]-2,5,8,14,17,20,24,27,30,33,54-undecanone, PP2576: (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z,47E)-7-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-11-ethoxy-19-(1-ethylpropyl)-3,3',3',18,21,25,31,34-octamethyl-29-[(1S)-1-methylpropyl]-22-(pyrrolidine-1-carbonyl)spiro[3,6,9,15,18,21,25,28,31,34,41-undecaazapentacyclo[24.15.10.2 43,46 .1 35,41 .0 9,13 ]pentacontan-37,43(53),44,46(52),47-pentaene-16,1'-cyclobutane]-2,5,8,14,17,20,24,27,30,33,54-undecanone, PP2583: (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z,47E)-19-cyclopentyl-31-cyclopropyl-7-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-11-ethoxy-3,3',3',18,21,25,34-heptamethyl-29-[(1S)-1-methylpropyl]-22-(pyrrolidine-1-carbonyl)spiro[3,6,9,15,18,21,25,28,31,34,41-undecaazapentacyclo[24.15.10.2 43,46 .1 35,41 .0 9,13 ]pentacontan-37,43(53),44,46(52),47-pentaene-16,1'-cyclobutane]-2,5,8,14,17,20,24,27,30,33,54-undecanone, PP2957: (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z,47E)-31-cyclopropyl-7-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-11-ethoxy-19-(1-ethylpropyl)-3,18,21,25,34-pentamethyl-29-[(1S)-1-methylpropyl]-22-(pyrrolidine-1-carbonyl)spiro[3,6,9,15,18,21,25,28,31,34,41-undecaazapentacyclo[24,15,10,25,34]- 43,46 .1 35,41 .0 9,13]pentacontan-37,43(53),44,46(52),47-pentaene-16,1'-cyclobutane]-2,5,8,14,17,20,24,27,30,33,54-undecanone, PP3033: (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z)-19-cyclopentyl-11-ethoxy-7-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-3,18,21,25,31,34-hexamethyl-29-[(1S)-1-methylpropyl]-22-(piperidine-1-carbonyl)spiro[3,6,9,15,18,21,25,28,31,34,41-undecaazapentacyclo[24.15.11.2 43,46 .1 35,41 .0 9,13 ]pentacarbonyl-37,43(54),44,46(53)-tetraene-16,1'-cyclobutane]-2,5,8,14,17,20,24,27,30,33,55-undecanone, PP3034: (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z)-19-cyclopentyl-11-ethoxy-7-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-3,3',3',18,21,25,31,34-octamethyl-29-[(1S)-1-methylpropyl]-22-(pyrrolidine-1-carbonyl)spiro[3,6,9,15,18,21,25,28,31,34,41-undecaazapentacyclo[24,15,11,2 43,46 .1 35,41 .0 9,13 ]pentacarbonyl-37,43(54),44,46(53)-tetraene-16,1'-cyclobutane]-2,5,8,14,17,20,24,27,30,33,55-undecanone, PP3036: (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z)-19-cyclopentyl-11-ethoxy-7-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-3,3',3',18,21,25,31,34-octamethyl-29-[(1S)-1-methylpropyl]-22-(piperidine-1-carbonyl)spiro[3,6,9,15,18,21,25,28,31,34,41-undecaazapentacyclo[24.15.10.2 43,46 .1 35,41 .0 9,13 ]54-tetradecanoic acid-37,43(53),44,46(52)-tetraene-16,1'-cyclobutane]-2,5,8,14,17,20,24,27,30,33,54-undecanone, PP3037: (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z)-19-cyclopentyl-11-ethoxy-7-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-3,3',3',18,21,25,31,34-octamethyl-29-[(1S)-1-methylpropyl]-22-(pyrrolidine-1-carbonyl)spiro[3,6,9,15,18,21,25,28,31,34,41-undecaazapentacyclo[24.15.10.2 43,46 .1 35,41 .0 9,13 ]54-tetradecanoic acid-37,43(53),44,46(52)-tetraene-16,1'-cyclobutane]-2,5,8,14,17,20,24,27,30,33,54-undecanone, PP3047: (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z,47E)-7-[2-(3,4-dichlorophenyl)ethyl]-11-ethoxy-19-(1-ethylpropyl)-3,18,21,25,31,34-hexamethyl-29-[(1S)-1-methylpropyl]-22-(pyrrolidine-1-carbonyl)spiro[3,6,9,15,18,21,25,28,31,34,41-undecaazapentacyclo[24.15.11.2 43,46 .1 35,41 .0 9,13]pentacarbonyl-37,43(54),44,46(53),47-pentaene-16,1'-cyclobutane]-2,5,8,14,17,20,24,27,30,33,55-undecanone, PP3093: (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z)-19-cyclopentyl-11-ethoxy-7-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-3,3',3',18,21,25,31,34-octamethyl-29-[(1S)-1-methylpropyl]-22-(piperidine-1-carbonyl)spiro[3,6,9,15,18,21,25,28,31,34,41-undecaazapentacyclo[24.15.9.2 43,46 .1 35,41 .0 9,13 ]Fifty-three carbon-37,43(52),44,46(51)-tetraene-16,1'-cyclobutane]-2,5,8,14,17,20,24,27,30,33,53-undecanone, PP3094: (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z)-19-cyclopentyl-7-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-3,3',3',18,21,25,31,34-octamethyl-29-[(1S)-1-methylpropyl]-11-propoxy-22-(pyrrolidine-1-carbonyl)spiro[3,6,9,15,18,21,25,28,31,34,41-undecaazapentacyclo[24,15,9,2 43,46 .1 35,41 .0 9,13]Fifty-three carbon-37,43(52),44,46(51)-tetraene-16,1'-cyclobutane]-2,5,8,14,17,20,24,27,30,33,53-undecanone, (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z,47Z)-19-cyclopentyl-7-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-11-ethoxy-N-ethyl-N,3,18,21,25,31,34-heptamethyl-29-[(1S)-1-methylpropyl]-2,5,8,14,17,20,24,27,30,33,55-undecacyclo-spiro[3,6,9,15,18,21,25,28,31,34,41-undecacyclopentacyclo[24,15,11,25,31,34-heptamethyl-29-[(1S)-1-methylpropyl] 43,46 .1 35,41 .0 9,13 ]pentacarbonyl-37,43(54),44,46(53),47-pentaene-16,1'-cyclobutane]-22-carboxamide, (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z,47Z)-19-cyclopentyl-11-ethoxy-N-ethyl-7-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-N,3,3',3',18,21,25,31,34-nonamethyl-29-[(1S)-1-methylpropyl]-2,5,8,14,17,20,24,27,30,33,55-undecacyclo-spiro[3,6,9,15,18,21,25,28,31,34,41-undecacyclopentacyclo[24,15,11,2 43,46 .1 35,41 .0 9,13 ]pentacarbonyl-37,43(54),44,46(53),47-pentaene-16,1'-cyclobutane]-22-carboxamide, (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z,47Z)-19-cyclopentyl-7-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-11-ethoxy-3,3',3',18,21,25,31,34-octamethyl-29-[(1S)-1-methylpropyl]-22-(pyrrolidine-1-carbonyl)spiro[3,6,9,15,18,21,25,28,31,34,41-undecaazapentacyclo[24.15.10.2 43,46 .1 35,41 .0 9,13 ]54-tetradecanoic acid-37,43(53),44,46(52),47-pentaene-16,1'-cyclobutane]-2,5,8,14,17,20,24,27,30,33,54-undecanone, (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z,47Z)-7-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-11-ethoxy-19-(1-ethylpropyl)-3,3',3',18,21,25,31,34-octamethyl-29-[(1S)-1-methylpropyl]-22-(pyrrolidine-1-carbonyl)spiro[3,6,9,15,18,21,25,28,31,34,41-undecaazapentacyclo[24.15.10.2 43,46 .1 35,41 .0 9,13 ]54-tetradecanoic acid-37,43(53),44,46(52),47-pentaene-16,1'-cyclobutane]-2,5,8,14,17,20,24,27,30,33,54-undecanone, (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z,47Z)-19-cyclopentyl-31-cyclopropyl-7-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-11-ethoxy-3,3',3',18,21,25,34-heptamethyl-29-[(1S)-1-methylpropyl]-22-(pyrrolidine-1-carbonyl)spiro[3,6,9,15,18,21,25,28,31,34,41-undecaazapentacyclo[24.15.10.2 43,46 .1 35,41 .0 9,13]54-tetradecanoic acid-37,43(53),44,46(52),47-pentaene-16,1'-cyclobutane]-2,5,8,14,17,20,24,27,30,33,54-undecanone, (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z,47Z)-31-cyclopropyl-7-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-11-ethoxy-19-(1-ethylpropyl)-3,18,21,25,34-pentamethyl-29-[(1S)-1-methylpropyl]-22-(pyrrolidine-1-carbonyl)spiro[3,6,9,15,18,21,25,28,31,34,41-undecaazapentacyclo[24,15,10.2 43,46 .1 35,41 .0 9,13 ]penta-37,43(53),44,46(52),47-penta-16,1'-cyclobutane]-2,5,8,14,17,20,24,27,30,33,54-undecanone, and (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z,47Z)-7-[2-(3 ,4-dichlorophenyl)ethyl]-11-ethoxy-19-(1-ethylpropyl)-3,18,21,25,31,34-hexamethyl-29-[(1S)-1-methylpropyl]-22-(pyrrolidine-1-carbonyl)spiro[3,6,9,15,18,21,25,28,31,34,41-undecazapentacyclo[24.15.11.2 43,46 .1 35,41 .0 9,13 ]pentacarbonyl-37,43(54),44,46(53),47-pentaene-16,1'-cyclobutane]-2,5,8,14,17,20,24,27,30,33,55-undecanone. [3] The cyclic compound as described in [1], or its salt or solvent mixture thereof, wherein the aforementioned formula (1) is represented by formula (3): [Chemical 9] (Where R 1 is C 1~C 7-alkyl; R 5 is available through the selection of C 1~C 6 alkyl, C 1~C 6 haloalkyl, and C 3~C Benzyl substituted by one or more groups selected from the group consisting of 8-cycloalkyl; [Chemical 10] n、m、P 1. R 2. R 3. P 3. P 4. P 6. R 7. R 8. P 8. R 9. P 9. Q 9. R 10 、P 10 、R 11 , and P 11 (meaning the same as [1]), the cyclic compound represented by formula (3) is selected from the group consisting of: PP1574: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-N-ethyl-27-isobutyl-N,4,19,22,26,32,35-heptamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecacyclo-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14]Tetradec-38-ene-17,1'-cyclopentane]-23-carboxamide, PP1650: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-27-isobutyl-N,N,3',3',4,19,22,26,32,35-decamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecacyclo-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 ]tetradec-38-ene-17,1'-cyclobutane]-23-carboxamide, PP2093: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-32-cyclopropyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-N,N,3',3',4,19,22,26,35-nonamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecacyclo-27-propyl-2-(p-tolylmethyl)spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 ]tetradec-38-ene-17,1'-cyclobutane]-23-carboxamide, PP2316: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-32-cyclopropyl-12-ethoxy-8-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-N,N,4,16,19,22,26,35-octamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecacyclo-27-propyl-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14]tetradec-38-ene-17,1'-cyclobutane]-23-carboxamide, PP2320: (1S,4S,10S,13S,17S,20S,26S,28R,32S,38S,42Z)-20-cyclopentyl-28-ethoxy-32-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-N,N,2,14,18,21,24,36-octamethyl-10-[(1S)-1-methylpropyl]-3,9,12,15,19,22,25,31,34,37,45-undecacyclo-13-propyl-38-[[4-(trifluoromethyl)phenyl]methyl]spiro[2,8,11,14,18,21,24,30,33,36,39-undecaazatetracyclo[37.5.1.0 4,8 .0 26,30 ]pentadec-42-ene-23,1'-cyclobutane]-17-carboxamide, PP2328: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-32-cyclopropyl-12-ethoxy-8-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-N,N,4,16,19,22,26,35-octamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecacyclo-27-propyl-2-(p-tolylmethyl)spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 ]tetradec-38-ene-17,1'-cyclobutane]-23-carboxamide, PP2687: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-12-ethoxy-2-[(4-ethylphenyl)methyl]-27-isobutyl-8-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-N,N,3',3',4,19,22,26,32,35-decamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecacyclo-1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14]tetradec-38-ene-17,1'-cyclobutane]-23-carboxamide, PP2691: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-2-[(4-cyclopropylphenyl)methyl]-12-ethoxy-27-isobutyl-8-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-N,N,3',3',4,19,22,26,32,35-decamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecacyclo ... 10,14 ]tetradec-38-ene-17,1'-cyclobutane]-23-carboxamide, PP3095: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-32-cyclopropyl-12-ethoxy-8-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-4,16,19,22,26,35-hexamethyl-30-[(1S)-1-methylpropyl]-23-(piperidine-1-carbonyl)-27-propyl-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 ]tetradec-38-ene-17,1'-cyclobutane]-3,6,9,15,18,21,25,28,31,34,42-undecanone, PP3096: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-32-cyclopropyl-12-ethoxy-8-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-4,16,19,22,26,35-hexamethyl-30-[(1S)-1-methylpropyl]-23-(piperidine-1-carbonyl)-27-propyl-2-(p-tolylmethyl)spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14]tetradec-38-ene-17,1'-cyclobutane]-3,6,9,15,18,21,25,28,31,34,42-undecanone, PP3097: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-32-cyclopropyl-12-ethoxy-8-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-4,16,19,22,26,35-hexamethyl-30-[(1S)-1-methylpropyl]-27-propyl-23-(pyrrolidine-1-carbonyl)-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 ]tetradec-38-ene-17,1'-cyclobutane]-3,6,9,15,18,21,25,28,31,34,42-undecanone, PP3098: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-32-cyclopropyl-12-ethoxy-8-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-4,16,19,22,26,35-hexamethyl-30-[(1S)-1-methylpropyl]-27-propyl-2-(p-tolylmethyl)-23-(pyrrolidine-1-carbonyl)spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 ]tetradec-38-ene-17,1'-cyclobutane]-3,6,9,15,18,21,25,28,31,34,42-undecanone, PP3099: (1S,4S,10S,13S,17S,20S,26S,28R,32S,38S,42Z)-20-cyclopentyl-28-ethoxy-32-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-2,14,18,21,24,36-hexamethyl-10-[(1S)-1-methylpropyl]-17-(piperidine-1-carbonyl)-13-propyl-38-[[4-(trifluoromethyl)phenyl]methyl]spiro[2,8,11,14,18,21,24,30,33,36,39-undecaazatetracyclo[37.5.1.0 4,8 .0 26,30]pentacontan-42-ene-23,1'-cyclobutane]-3,9,12,15,19,22,25,31,34,37,45-undecanone, PP3100: (1S,4S,10S,13S,17S,20S,26S,28R,32S,38S,42Z)-20-cyclopentyl-28-ethoxy-32-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-2,14,18,21,24,36-hexamethyl-10-[(1S)-1-methylpropyl]-17-(piperidine-1-carbonyl)-13-propyl-38-(p-tolylmethyl)spiro[2,8,11,14,18,21,24,30,33,36,39-undecaazatetracyclo[37.5.1.0 4,8 .0 26,30 ]pentadec-42-ene-23,1'-cyclobutane]-3,9,12,15,19,22,25,31,34,37,45-undecanone, PP3101: (1S,4S,10S,13S,17S,20S,26S,28R,32S,38S,42Z)-20-cyclopentyl-28-ethoxy-32-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-2,14,18,21,24,36-hexamethyl-10-[(1S)-1-methylpropyl]-13-propyl-17-(pyrrolidine-1-carbonyl)-38-[[4-(trifluoromethyl)phenyl]methyl]spiro[2,8,11,14,18,21,24,30,33,36,39-undecaazatetracyclo[37.5.1.0 4,8 .0 26,30 ]pentadec-42-ene-23,1'-cyclobutane]-3,9,12,15,19,22,25,31,34,37,45-undecanone, PP3102: (1S,4S,10S,13S,17S,20S,26S,28R,32S,38S,42Z)-20-cyclopentyl-28-ethoxy-32-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-2,14,18,21,24,36-hexamethyl-10-[(1S)-1-methylpropyl]-13-propyl-38-(p-tolylmethyl)-17-(pyrrolidine-1-carbonyl)spiro[2,8,11,14,18,21,24,30,33,36,39-undecaazatetracyclo[37.5.1.0 4,8 .0 26,30]pentadec-42-ene-23,1'-cyclobutane]-3,9,12,15,19,22,25,31,34,37,45-undecanone, PP3103: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-12-ethoxy-8-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-4,16,19,22,26,32,35-heptamethyl-30-[(1S)-1-methylpropyl]-23-(piperidine-1-carbonyl)-27-propyl-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 ]tetradec-38-ene-17,1'-cyclobutane]-3,6,9,15,18,21,25,28,31,34,42-undecanone, PP3104: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-12-ethoxy-8-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-4,16,19,22,26,32,35-heptamethyl-30-[(1S)-1-methylpropyl]-23-(piperidine-1-carbonyl)-27-propyl-2-(p-tolylmethyl)spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 ]tetradec-38-ene-17,1'-cyclobutane]-3,6,9,15,18,21,25,28,31,34,42-undecanone, PP3105: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-12-ethoxy-8-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-4,16,19,22,26,32,35-heptamethyl-30-[(1S)-1-methylpropyl]-27-propyl-23-(pyrrolidine-1-carbonyl)-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14]tetradec-38-ene-17,1'-cyclobutane]-3,6,9,15,18,21,25,28,31,34,42-undecanone, PP3106: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-12-ethoxy-8-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-4,16,19,22,26,32,35-heptamethyl-30-[(1S)-1-methylpropyl]-27-propyl-2-(p-tolylmethyl)-23-(pyrrolidine-1-carbonyl)spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 ]tetradec-38-ene-17,1'-cyclobutane]-3,6,9,15,18,21,25,28,31,34,42-undecanone, PP3110: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-32-cyclopropyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-4,16,19,22,26,35-hexamethyl-30-[(1S)-1-methylpropyl]-23-(piperidine-1-carbonyl)-27-propyl-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 ]tetradec-38-ene-17,1'-cyclobutane]-3,6,9,15,18,21,25,28,31,34,42-undecanone, PP3111: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-32-cyclopropyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-4,16,19,22,26,35-hexamethyl-30-[(1S)-1-methylpropyl]-23-(piperidine-1-carbonyl)-27-propyl-2-(p-tolylmethyl)spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14]tetradec-38-ene-17,1'-cyclobutane]-3,6,9,15,18,21,25,28,31,34,42-undecanone, PP3112: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-32-cyclopropyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-4,16,19,22,26,35-hexamethyl-30-[(1S)-1-methylpropyl]-27-propyl-23-(pyrrolidine-1-carbonyl)-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 ]tetradec-38-ene-17,1'-cyclobutane]-3,6,9,15,18,21,25,28,31,34,42-undecanone, PP3113: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-32-cyclopropyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-4,16,19,22,26,35-hexamethyl-30-[(1S)-1-methylpropyl]-27-propyl-2-(p-tolylmethyl)-23-(pyrrolidine-1-carbonyl)spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 ]tetradec-38-ene-17,1'-cyclobutane]-3,6,9,15,18,21,25,28,31,34,42-undecanone, PP3114: (1S,4S,10S,13S,17S,20S,26S,28R,32S,38S,42Z)-20-cyclopentyl-32-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-28-ethoxy-2,14,18,21,24,36-hexamethyl-10-[(1S)-1-methylpropyl]-17-(piperidine-1-carbonyl)-13-propyl-38-[[4-(trifluoromethyl)phenyl]methyl]spiro[2,8,11,14,18,21,24,30,33,36,39-undecaazatetracyclo[37.5.1.0 4,8 .0 26,30]pentacontan-42-ene-23,1'-cyclobutane]-3,9,12,15,19,22,25,31,34,37,45-undecanone, PP3115: (1S,4S,10S,13S,17S,20S,26S,28R,32S,38S,42Z)-20-cyclopentyl-32-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-28-ethoxy-2,14,18,21,24,36-hexamethyl-10-[(1S)-1-methylpropyl]-17-(piperidine-1-carbonyl)-13-propyl-38-(p-tolylmethyl)spiro[2,8,11,14,18,21,24,30,33,36,39-undecaazatetracyclo[37.5.1.0 4,8 .0 26,30 ]pentacontan-42-ene-23,1'-cyclobutane]-3,9,12,15,19,22,25,31,34,37,45-undecanone, PP3116: (1S,4S,10S,13S,17S,20S,26S,28R,32S,38S,42Z)-20-cyclopentyl-32-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-28-ethoxy-2,14,18,21,24,36-hexamethyl-10-[(1S)-1-methylpropyl]-13-propyl-17-(pyrrolidine-1-carbonyl)-38-[[4-(trifluoromethyl)phenyl]methyl]spiro[2,8,11,14,18,21,24,30,33,36,39-undecaazatetracyclo[37.5.1.0 4,8 .0 26,30 ]pentacontan-42-ene-23,1'-cyclobutane]-3,9,12,15,19,22,25,31,34,37,45-undecanone, PP3117: (1S,4S,10S,13S,17S,20S,26S,28R,32S,38S,42Z)-20-cyclopentyl-32-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-28-ethoxy-2,14,18,21,24,36-hexamethyl-10-[(1S)-1-methylpropyl]-13-propyl-38-(p-tolylmethyl)-17-(pyrrolidine-1-carbonyl)spiro[2,8,11,14,18,21,24,30,33,36,39-undecaazatetracyclo[37.5.1.0 4,8 .0 26,30]pentacontan-42-ene-23,1'-cyclobutane]-3,9,12,15,19,22,25,31,34,37,45-undecanone, PP3118: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-4,16,19,22,26,32,35-heptamethyl-30-[(1S)-1-methylpropyl]-23-(piperidine-1-carbonyl)-27-propyl-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 ]tetradec-38-ene-17,1'-cyclobutane]-3,6,9,15,18,21,25,28,31,34,42-undecanone, PP3119: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-4,16,19,22,26,32,35-heptamethyl-30-[(1S)-1-methylpropyl]-23-(piperidine-1-carbonyl)-27-propyl-2-(p-tolylmethyl)spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 ]tetradec-38-ene-17,1'-cyclobutane]-3,6,9,15,18,21,25,28,31,34,42-undecanone, PP3120: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-4,16,19,22,26,32,35-heptamethyl-30-[(1S)-1-methylpropyl]-27-propyl-23-(pyrrolidine-1-carbonyl)-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14]tetradodec-38-ene-17,1'-cyclobutane]-3,6,9,15,18,21,25,28,31,34,42-undecanone, and PP3121: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-4,16,19,22,26,32,35-heptamethyl-30-[(1S)-1-methylpropyl]-27-propyl-2-(p-tolylmethyl)-23-(pyrrolidine-1-carbonyl)spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 [4-1] A cyclic compound, or a salt thereof, or a solvent thereof, which is PP1574: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-N-ethyl-27-isobutyl-N,4,19,22,26,32,35-heptamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecacyclo-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 ]tetradec-38-ene-17,1'-cyclopentane]-23-carboxamide. 〔4-2〕A cyclic compound, or a salt thereof, or a solvent thereof, which is PP1650: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-27-isobutyl-N,N,3',3',4,19,22,26,32,35-decamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecacyclo-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14]Tetradec-38-ene-17,1'-cyclobutane]-23-carboxamide. [4-3] A cyclic compound, or a salt thereof, or a solvent thereof, which is PP1827: (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z,47E)-19-cyclopentyl-7-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-11-ethoxy-N-ethyl-N,3,18,21,25,31,34-heptamethyl-29-[(1S)-1-methylpropyl]-2,5,8,14,17,20,24,27,30,33,55-undecacyclo-spiro[3,6,9,15,18,21,25,28,31,34,41-undecaazapentacyclo[24.15.11.2 43,46 .1 35,41 .0 9,13 ]pentacarbonyl-37,43(54),44,46(53),47-pentaene-16,1'-cyclobutane]-22-carboxamide. [4-4] A cyclic compound, or a salt thereof, or a solvent thereof, which is PP1830: (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z,47E)-19-cyclopentyl-11-ethoxy-N-ethyl-7-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-N,3,3',3',18,21,25,31,34-nonamethyl-29-[(1S)-1-methylpropyl]-2,5,8,14,17,20,24,27,30,33,55-undecacyclo-spiro[3,6,9,15,18,21,25,28,31,34,41-undecaazapentacyclo[24.15.11.2 43,46 .1 35,41 .0 9,13] Pentadecanoic acid-37,43(54),44,46(53),47-pentaene-16,1'-cyclobutane]-22-carboxamide. 〔4-5〕A cyclic compound, or a salt thereof, or a solvent thereof, which is PP2093: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-32-cyclopropyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-N,N,3',3',4,19,22,26,35-nonamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecacyclo-27-propyl-2-(p-tolylmethyl)spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 ]Tetradec-38-ene-17,1'-cyclobutane]-23-carboxamide. [4-6] A cyclic compound, or a salt thereof, or a solvent thereof, which is PP2260: (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z)-19-cyclopentyl-11-ethoxy-N-ethyl-7-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-N,3,3',3',18,21,25,31,34-nonamethyl-29-[(1S)-1-methylpropyl]-2,5,8,14,17,20,24,27,30,33,55-undecacyclo-spiro[3,6,9,15,18,21,25,28,31,34,41-undecaazapentacyclo[24.15.11.2 43,46 .1 35,41 .0 9,13] Pentadecanoic acid-37,43(54),44,46(53)-tetraene-16,1'-cyclobutane]-22-carboxamide. 〔4-7〕A cyclic compound, or a salt thereof, or a solvent thereof, which is PP2316: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-32-cyclopropyl-12-ethoxy-8-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-N,N,4,16,19,22,26,35-octamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecacyclo-27-propyl-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 ]tetradec-38-ene-17,1'-cyclobutane]-23-carboxamide. 〔4-8〕A cyclic compound, or a salt thereof, or a solvent thereof, which is PP2320: (1S,4S,10S,13S,17S,20S,26S,28R,32S,38S,42Z)-20-cyclopentyl-28-ethoxy-32-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-N,N,2,14,18,21,24,36-octamethyl-10-[(1S)-1-methylpropyl]-3,9,12,15,19,22,25,31,34,37,45-undecacyclo-13-propyl-38-[[4-(trifluoromethyl)phenyl]methyl]spiro[2,8,11,14,18,21,24,30,33,36,39-undecaazatetracyclo[37.5.1.0 4,8 .0 26,30]pentadec-42-ene-23,1'-cyclobutane]-17-carboxamide. [4-9] A cyclic compound, or a salt thereof, or a solvent thereof, which is PP2328: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-32-cyclopropyl-12-ethoxy-8-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-N,N,4,16,19,22,26,35-octamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecacyclo-27-propyl-2-(p-tolylmethyl)spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 ]Tetradec-38-ene-17,1'-cyclobutane]-23-carboxamide. [4-10] A cyclic compound, or a salt thereof, or a solvent thereof, which is PP2574: (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z,47E)-19-cyclopentyl-7-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-11-ethoxy-3,3',3',18,21,25,31,34-octamethyl-29-[(1S)-1-methylpropyl]-22-(pyrrolidine-1-carbonyl)spiro[3,6,9,15,18,21,25,28,31,34,41-undecaazapentacyclo[24.15.10.2 43,46 .1 35,41 .0 9,13 ]pentacontan-37,43(53),44,46(52),47-pentaene-16,1'-cyclobutane]-2,5,8,14,17,20,24,27,30,33,54-undecanone. [4-11] A cyclic compound, or a salt thereof, or a solvent thereof, which is PP2576: (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z,47E)-7-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-11-ethoxy-19-(1-ethylpropyl)-3,3',3',18,21,25,31,34-octamethyl-29-[(1S)-1-methylpropyl]-22-(pyrrolidine-1-carbonyl)spiro[3,6,9,15,18,21,25,28,31,34,41-undecaazapentacyclo[24.15.10.2 43,46 .1 35,41 .0 9,13 ]pentacontan-37,43(53),44,46(52),47-pentaene-16,1'-cyclobutane]-2,5,8,14,17,20,24,27,30,33,54-undecanone. [4-12] A cyclic compound, or a salt thereof, or a solvent thereof, which is PP2583: (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z,47E)-19-cyclopentyl-31-cyclopropyl-7-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-11-ethoxy-3,3',3',18,21,25,34-heptamethyl-29-[(1S)-1-methylpropyl]-22-(pyrrolidine-1-carbonyl)spiro[3,6,9,15,18,21,25,28,31,34,41-undecaazapentacyclo[24.15.10.2 43,46 .1 35,41 .0 9,13 ] pentadeca-37,43(53),44,46(52),47-penta-16,1'-cyclobutane]-2,5,8,14,17,20,24,27,30,33,54-undecanone. 〔4-13〕A cyclic compound, or a salt thereof, or a solvent thereof, which is PP2687: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-12-ethoxy-2-[(4-ethylphenyl)methyl]-27-isobutyl-8-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-N,N,3',3',4,19,22,26,32,35-decamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecacyclo-1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14]tetradec-38-ene-17,1'-cyclobutane]-23-carboxamide. [4-14] A cyclic compound, or a salt thereof, or a solvent thereof, which is PP2691: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-2-[(4-cyclopropylphenyl)methyl]-12-ethoxy-27-isobutyl-8-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-N,N,3',3',4,19,22,26,32,35-decamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecacyclo ... 10,14 ]Tetradec-38-ene-17,1'-cyclobutane]-23-carboxamide. [4-15] A cyclic compound, or a salt thereof, or a solvent thereof, which is PP2957: (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z,47E)-31-cyclopropyl-7-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-11-ethoxy-19-(1-ethylpropyl)-3,18,21,25,34-pentamethyl-29-[(1S)-1-methylpropyl]-22-(pyrrolidine-1-carbonyl)spiro[3,6,9,15,18,21,25,28,31,34,41-undecaazapentacyclo[24.15.10.2 43,46 .1 35,41 .0 9,13 ]pentacontan-37,43(53),44,46(52),47-pentaene-16,1'-cyclobutane]-2,5,8,14,17,20,24,27,30,33,54-undecanone. [4-16] A cyclic compound, or a salt thereof, or a solvent thereof, which is PP3033: (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z)-19-cyclopentyl-11-ethoxy-7-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-3,18,21,25,31,34-hexamethyl-29-[(1S)-1-methylpropyl]-22-(piperidine-1-carbonyl)spiro[3,6,9,15,18,21,25,28,31,34,41-undecaazapentacyclo[24.15.11.2 43,46.1 35,41 .0 9,13 ]pentacarbonyl-37,43(54),44,46(53)-tetraene-16,1'-cyclobutane]-2,5,8,14,17,20,24,27,30,33,55-undecanone. [4-17] A cyclic compound, or a salt thereof, or a solvent thereof, which is PP3034: (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z)-19-cyclopentyl-11-ethoxy-7-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-3,3',3',18,21,25,31,34-octamethyl-29-[(1S)-1-methylpropyl]-22-(pyrrolidine-1-carbonyl)spiro[3,6,9,15,18,21,25,28,31,34,41-undecaazapentacyclo[24.15.11.2 43,46 .1 35,41 .0 9,13 ]pentacarbonyl-37,43(54),44,46(53)-tetraene-16,1'-cyclobutane]-2,5,8,14,17,20,24,27,30,33,55-undecanone. [4-18] A cyclic compound, or a salt thereof, or a solvent thereof, which is PP3036: (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z)-19-cyclopentyl-11-ethoxy-7-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-3,3',3',18,21,25,31,34-octamethyl-29-[(1S)-1-methylpropyl]-22-(piperidine-1-carbonyl)spiro[3,6,9,15,18,21,25,28,31,34,41-undecazapentacyclo[24.15.10.2 43,46 .1 35,41 .0 9,13]Fifty-tetracarbon-37,43(53),44,46(52)-tetraene-16,1'-cyclobutane]-2,5,8,14,17,20,24,27,30,33,54-undecanone. [4-19] A cyclic compound, or a salt thereof, or a solvent thereof, which is PP3037: (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z)-19-cyclopentyl-11-ethoxy-7-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-3,3',3',18,21,25,31,34-octamethyl-29-[(1S)-1-methylpropyl]-22-(pyrrolidine-1-carbonyl)spiro[3,6,9,15,18,21,25,28,31,34,41-undecaazapentacyclo[24.15.10.2 43,46 .1 35,41 .0 9,13 ]Fifty-tetracarbon-37,43(53),44,46(52)-tetraene-16,1'-cyclobutane]-2,5,8,14,17,20,24,27,30,33,54-undecanone. [4-20] A cyclic compound, or a salt thereof, or a solvent thereof, which is PP3047: (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z,47E)-7-[2-(3,4-dichlorophenyl)ethyl]-11-ethoxy-19-(1-ethylpropyl)-3,18,21,25,31,34-hexamethyl-29-[(1S)-1-methylpropyl]-22-(pyrrolidine-1-carbonyl)spiro[3,6,9,15,18,21,25,28,31,34,41-undecaazapentacyclo[24.15.11.2 43,46 .1 35,41 .0 9,13]pentacarbonyl-37,43(54),44,46(53),47-pentaene-16,1'-cyclobutane]-2,5,8,14,17,20,24,27,30,33,55-undecanone. [4-21] A cyclic compound, or a salt thereof, or a solvent thereof, which is PP3093: (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z)-19-cyclopentyl-11-ethoxy-7-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-3,3',3',18,21,25,31,34-octamethyl-29-[(1S)-1-methylpropyl]-22-(piperidine-1-carbonyl)spiro[3,6,9,15,18,21,25,28,31,34,41-undecaazapentacyclo[24.15.9.2 43,46 .1 35,41 .0 9,13 ]Fifty-three carbon-37,43(52),44,46(51)-tetraene-16,1'-cyclobutane]-2,5,8,14,17,20,24,27,30,33,53-undecanone. [4-22] A cyclic compound, or a salt thereof, or a solvent thereof, which is PP3094: (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z)-19-cyclopentyl-7-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-3,3',3',18,21,25,31,34-octamethyl-29-[(1S)-1-methylpropyl]-11-propoxy-22-(pyrrolidine-1-carbonyl)spiro[3,6,9,15,18,21,25,28,31,34,41-undecaazapentacyclo[24.15.9.2 43,46 .1 35,41 .0 9,13]Fifty-three carbon-37,43(52),44,46(51)-tetraene-16,1'-cyclobutane]-2,5,8,14,17,20,24,27,30,33,53-undecanone. [4-23] A cyclic compound, or a salt thereof, or a solvent thereof, which is PP3095: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-32-cyclopropyl-12-ethoxy-8-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-4,16,19,22,26,35-hexamethyl-30-[(1S)-1-methylpropyl]-23-(piperidine-1-carbonyl)-27-propyl-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 ]tetradec-38-ene-17,1'-cyclobutane]-3,6,9,15,18,21,25,28,31,34,42-undecanone. [4-24] A cyclic compound, or a salt thereof, or a solvent thereof, which is PP3096: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-32-cyclopropyl-12-ethoxy-8-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-4,16,19,22,26,35-hexamethyl-30-[(1S)-1-methylpropyl]-23-(piperidine-1-carbonyl)-27-propyl-2-(p-tolylmethyl)spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 ]tetradec-38-ene-17,1'-cyclobutane]-3,6,9,15,18,21,25,28,31,34,42-undecanone. [4-25] A cyclic compound, or a salt thereof, or a solvent thereof, which is PP3097: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-32-cyclopropyl-12-ethoxy-8-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-4,16,19,22,26,35-hexamethyl-30-[(1S)-1-methylpropyl]-27-propyl-23-(pyrrolidine-1-carbonyl)-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 ]tetradec-38-ene-17,1'-cyclobutane]-3,6,9,15,18,21,25,28,31,34,42-undecanone. [4-26] A cyclic compound, or a salt thereof, or a solvent thereof, which is PP3098: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-32-cyclopropyl-12-ethoxy-8-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-4,16,19,22,26,35-hexamethyl-30-[(1S)-1-methylpropyl]-27-propyl-2-(p-tolylmethyl)-23-(pyrrolidine-1-carbonyl)spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 ]tetradec-38-ene-17,1'-cyclobutane]-3,6,9,15,18,21,25,28,31,34,42-undecanone. [4-27] A cyclic compound, or a salt thereof, or a solvent thereof, which is PP3099: (1S,4S,10S,13S,17S,20S,26S,28R,32S,38S,42Z)-20-cyclopentyl-28-ethoxy-32-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-2,14,18,21,24,36-hexamethyl-10-[(1S)-1-methylpropyl]-17-(piperidine-1-carbonyl)-13-propyl-38-[[4-(trifluoromethyl)phenyl]methyl]spiro[2,8,11,14,18,21,24,30,33,36,39-undecaazatetracyclo[37.5.1.0 4,8 .0 26,30 ]pentatetradec-42-ene-23,1'-cyclobutane]-3,9,12,15,19,22,25,31,34,37,45-undecanone. [4-28] A cyclic compound, or a salt thereof, or a solvent thereof, which is PP3100: (1S,4S,10S,13S,17S,20S,26S,28R,32S,38S,42Z)-20-cyclopentyl-28-ethoxy-32-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-2,14,18,21,24,36-hexamethyl-10-[(1S)-1-methylpropyl]-17-(piperidine-1-carbonyl)-13-propyl-38-(p-tolylmethyl)spiro[2,8,11,14,18,21,24,30,33,36,39-undecaazatetracyclo[37.5.1.0 4,8 .0 26,30 ]pentatetradec-42-ene-23,1'-cyclobutane]-3,9,12,15,19,22,25,31,34,37,45-undecanone. [4-29] A cyclic compound, or a salt thereof, or a solvent thereof, which is PP3101: (1S,4S,10S,13S,17S,20S,26S,28R,32S,38S,42Z)-20-cyclopentyl-28-ethoxy-32-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-2,14,18,21,24,36-hexamethyl-10-[(1S)-1-methylpropyl]-13-propyl-17-(pyrrolidine-1-carbonyl)-38-[[4-(trifluoromethyl)phenyl]methyl]spiro[2,8,11,14,18,21,24,30,33,36,39-undecaazatetracyclo[37.5.1.0 4,8 .0 26,30 ]pentatetradec-42-ene-23,1'-cyclobutane]-3,9,12,15,19,22,25,31,34,37,45-undecanone. [4-30] A cyclic compound, or a salt thereof, or a solvent thereof, which is PP3102: (1S,4S,10S,13S,17S,20S,26S,28R,32S,38S,42Z)-20-cyclopentyl-28-ethoxy-32-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-2,14,18,21,24,36-hexamethyl-10-[(1S)-1-methylpropyl]-13-propyl-38-(p-tolylmethyl)-17-(pyrrolidine-1-carbonyl)spiro[2,8,11,14,18,21,24,30,33,36,39-undecaazatetracyclo[37.5.1.0 4,8 .0 26,30]pentatetradec-42-ene-23,1'-cyclobutane]-3,9,12,15,19,22,25,31,34,37,45-undecanone. [4-31] A cyclic compound, or a salt thereof, or a solvent thereof, which is PP3103: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-12-ethoxy-8-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-4,16,19,22,26,32,35-heptamethyl-30-[(1S)-1-methylpropyl]-23-(piperidine-1-carbonyl)-27-propyl-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 ]tetradec-38-ene-17,1'-cyclobutane]-3,6,9,15,18,21,25,28,31,34,42-undecanone. [4-32] A cyclic compound, or a salt thereof, or a solvent thereof, which is PP3104: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-12-ethoxy-8-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-4,16,19,22,26,32,35-heptamethyl-30-[(1S)-1-methylpropyl]-23-(piperidine-1-carbonyl)-27-propyl-2-(p-tolylmethyl)spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 ]tetradec-38-ene-17,1'-cyclobutane]-3,6,9,15,18,21,25,28,31,34,42-undecanone. [4-33] A cyclic compound, or a salt thereof, or a solvent thereof, which is PP3105: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-12-ethoxy-8-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-4,16,19,22,26,32,35-heptamethyl-30-[(1S)-1-methylpropyl]-27-propyl-23-(pyrrolidine-1-carbonyl)-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14]tetradec-38-ene-17,1'-cyclobutane]-3,6,9,15,18,21,25,28,31,34,42-undecanone. [4-34] A cyclic compound, or a salt thereof, or a solvent thereof, which is PP3106: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-12-ethoxy-8-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-4,16,19,22,26,32,35-heptamethyl-30-[(1S)-1-methylpropyl]-27-propyl-2-(p-tolylmethyl)-23-(pyrrolidine-1-carbonyl)spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 ]tetradec-38-ene-17,1'-cyclobutane]-3,6,9,15,18,21,25,28,31,34,42-undecanone. [4-35] A cyclic compound, or a salt thereof, or a solvent thereof, which is PP3110: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-32-cyclopropyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-4,16,19,22,26,35-hexamethyl-30-[(1S)-1-methylpropyl]-23-(piperidine-1-carbonyl)-27-propyl-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 ]tetradec-38-ene-17,1'-cyclobutane]-3,6,9,15,18,21,25,28,31,34,42-undecanone. [4-36] A cyclic compound, or a salt thereof, or a solvent thereof, which is PP3111: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-32-cyclopropyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-4,16,19,22,26,35-hexamethyl-30-[(1S)-1-methylpropyl]-23-(piperidine-1-carbonyl)-27-propyl-2-(p-tolylmethyl)spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14]tetradec-38-ene-17,1'-cyclobutane]-3,6,9,15,18,21,25,28,31,34,42-undecanone. [4-37] A cyclic compound, or a salt thereof, or a solvent thereof, which is PP3112: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-32-cyclopropyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-4,16,19,22,26,35-hexamethyl-30-[(1S)-1-methylpropyl]-27-propyl-23-(pyrrolidine-1-carbonyl)-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 ]tetradec-38-ene-17,1'-cyclobutane]-3,6,9,15,18,21,25,28,31,34,42-undecanone. [4-38] A cyclic compound, or a salt thereof, or a solvent thereof, which is PP3113: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-32-cyclopropyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-4,16,19,22,26,35-hexamethyl-30-[(1S)-1-methylpropyl]-27-propyl-2-(p-tolylmethyl)-23-(pyrrolidine-1-carbonyl)spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 ]tetradec-38-ene-17,1'-cyclobutane]-3,6,9,15,18,21,25,28,31,34,42-undecanone. [4-39] A cyclic compound, or a salt thereof, or a solvent thereof, which is PP3114: (1S,4S,10S,13S,17S,20S,26S,28R,32S,38S,42Z)-20-cyclopentyl-32-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-28-ethoxy-2,14,18,21,24,36-hexamethyl-10-[(1S)-1-methylpropyl]-17-(piperidine-1-carbonyl)-13-propyl-38-[[4-(trifluoromethyl)phenyl]methyl]spiro[2,8,11,14,18,21,24,30,33,36,39-undecaazatetracyclo[37.5.1.0 4,8 .0 26,30 ]pentatetradec-42-ene-23,1'-cyclobutane]-3,9,12,15,19,22,25,31,34,37,45-undecanone. [4-40] A cyclic compound, or a salt thereof, or a solvent thereof, which is PP3115: (1S,4S,10S,13S,17S,20S,26S,28R,32S,38S,42Z)-20-cyclopentyl-32-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-28-ethoxy-2,14,18,21,24,36-hexamethyl-10-[(1S)-1-methylpropyl]-17-(piperidine-1-carbonyl)-13-propyl-38-(p-tolylmethyl)spiro[2,8,11,14,18,21,24,30,33,36,39-undecaazatetracyclo[37.5.1.0 4,8 .0 26,30 ]pentatetradec-42-ene-23,1'-cyclobutane]-3,9,12,15,19,22,25,31,34,37,45-undecanone. [4-41] A cyclic compound, or a salt thereof, or a solvent thereof, which is PP3116: (1S,4S,10S,13S,17S,20S,26S,28R,32S,38S,42Z)-20-cyclopentyl-32-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-28-ethoxy-2,14,18,21,24,36-hexamethyl-10-[(1S)-1-methylpropyl]-13-propyl-17-(pyrrolidine-1-carbonyl)-38-[[4-(trifluoromethyl)phenyl]methyl]spiro[2,8,11,14,18,21,24,30,33,36,39-undecaazatetracyclo[37.5.1.0 4,8 .0 26,30]pentatetradec-42-ene-23,1'-cyclobutane]-3,9,12,15,19,22,25,31,34,37,45-undecanone. [4-42] A cyclic compound, or a salt thereof, or a solvent thereof, which is PP3117: (1S,4S,10S,13S,17S,20S,26S,28R,32S,38S,42Z)-20-cyclopentyl-32-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-28-ethoxy-2,14,18,21,24,36-hexamethyl-10-[(1S)-1-methylpropyl]-13-propyl-38-(p-tolylmethyl)-17-(pyrrolidine-1-carbonyl)spiro[2,8,11,14,18,21,24,30,33,36,39-undecaazatetracyclo[37.5.1.0 4,8 .0 26,30 ]pentatetradec-42-ene-23,1'-cyclobutane]-3,9,12,15,19,22,25,31,34,37,45-undecanone. [4-43] A cyclic compound, or a salt thereof, or a solvent thereof, which is PP3118: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-4,16,19,22,26,32,35-heptamethyl-30-[(1S)-1-methylpropyl]-23-(piperidine-1-carbonyl)-27-propyl-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 ]tetradec-38-ene-17,1'-cyclobutane]-3,6,9,15,18,21,25,28,31,34,42-undecanone. [4-44] A cyclic compound, or a salt thereof, or a solvent thereof, which is PP3119: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-4,16,19,22,26,32,35-heptamethyl-30-[(1S)-1-methylpropyl]-23-(piperidine-1-carbonyl)-27-propyl-2-(p-tolylmethyl)spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 ]tetradec-38-ene-17,1'-cyclobutane]-3,6,9,15,18,21,25,28,31,34,42-undecanone. [4-45] A cyclic compound, or a salt thereof, or a solvent thereof, which is PP3120: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-4,16,19,22,26,32,35-heptamethyl-30-[(1S)-1-methylpropyl]-27-propyl-23-(pyrrolidine-1-carbonyl)-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 ]tetradec-38-ene-17,1'-cyclobutane]-3,6,9,15,18,21,25,28,31,34,42-undecanone. [4-46] A cyclic compound, or a salt thereof, or a solvent thereof, which is PP3121: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-4,16,19,22,26,32,35-heptamethyl-30-[(1S)-1-methylpropyl]-27-propyl-2-(p-tolylmethyl)-23-(pyrrolidine-1-carbonyl)spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 ]tetradec-38-ene-17,1'-cyclobutane]-3,6,9,15,18,21,25,28,31,34,42-undecanone. [4-47] A (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z,47Z)-19-cyclopentyl-7-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-11-ethoxy-N-ethyl-N,3,18,21,25,31,34-heptamethyl-29-[(1S)-1-methylpropyl]-2,5,8,14,17,20,24,27,30,33,55-undecacyclo-spiro[3,6,9,15,18,21,25,28,31,34,41-undecaazapentacyclo[24.15.11.2 43,46 .1 35,41.0 9,13 ]pentacarbonyl-37,43(54),44,46(53),47-pentaene-16,1'-cyclobutane]-22-carboxamide, or a salt thereof or a solvent thereof. [4-48] A (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z,47Z)-19-cyclopentyl-11-ethoxy-N-ethyl-7-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-N,3,3',3',18,21,25,31,34-nonamethyl-29-[(1S)-1-methylpropyl]-2,5,8,14,17,20,24,27,30,33,55-undecacyclo-spiro[3,6,9,15,18,21,25,28,31,34,41-undecaazapentacyclo[24.15.11.2 43,46 .1 35,41 .0 9,13 ]pentacarbonyl-37,43(54),44,46(53),47-pentaene-16,1'-cyclobutane]-22-carboxamide, or a salt thereof or a solvent thereof. [4-49] A (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z,47Z)-19-cyclopentyl-7-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-11-ethoxy-3,3',3',18,21,25,31,34-octamethyl-29-[(1S)-1-methylpropyl]-22-(pyrrolidine-1-carbonyl)spiro[3,6,9,15,18,21,25,28,31,34,41-undecaazapentacyclo[24.15.10.2 43,46 .1 35,41 .0 9,13]pentacontan-37,43(53),44,46(52),47-pentaene-16,1'-cyclobutane]-2,5,8,14,17,20,24,27,30,33,54-undecanone, or a salt thereof or a solvent thereof. [4-50] A (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z,47Z)-7-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-11-ethoxy-19-(1-ethylpropyl)-3,3',3',18,21,25,31,34-octamethyl-29-[(1S)-1-methylpropyl]-22-(pyrrolidine-1-carbonyl)spiro[3,6,9,15,18,21,25,28,31,34,41-undecaazapentacyclo[24.15.10.2] 43,46 .1 35,41 .0 9,13 ]pentacontan-37,43(53),44,46(52),47-pentaene-16,1'-cyclobutane]-2,5,8,14,17,20,24,27,30,33,54-undecanone, or a salt thereof or a solvent thereof. [4-51] A (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z,47Z)-19-cyclopentyl-31-cyclopropyl-7-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-11-ethoxy-3,3',3',18,21,25,34-heptamethyl-29-[(1S)-1-methylpropyl]-22-(pyrrolidine-1-carbonyl)spiro[3,6,9,15,18,21,25,28,31,34,41-undecaazapentacyclo[24.15.10.2 43,46 .1 35,41 .0 9,13]pentacontan-37,43(53),44,46(52),47-pentaene-16,1'-cyclobutane]-2,5,8,14,17,20,24,27,30,33,54-undecanone, or a salt thereof or a solvent thereof. [4-52] A (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z,47Z)-31-cyclopropyl-7-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-11-ethoxy-19-(1-ethylpropyl)-3,18,21,25,34-pentamethyl-29-[(1S)-1-methylpropyl]-22-(pyrrolidine-1-carbonyl)spiro[3,6,9,15,18,21,25,28,31,34,41-undecaazapentacyclo[24.15.10.2] 43,46 .1 35,41 .0 9,13 ]pentacontan-37,43(53),44,46(52),47-pentaene-16,1'-cyclobutane]-2,5,8,14,17,20,24,27,30,33,54-undecanone, or a salt thereof or a solvent thereof. [4-53] A (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z,47Z)-7-[2-(3,4-dichlorophenyl)ethyl]-11-ethoxy-19-(1-ethylpropyl)-3,18,21,25,31,34-hexamethyl-29-[(1S)-1-methylpropyl]-22-(pyrrolidine-1-carbonyl)spiro[3,6,9,15,18,21,25,28,31,34,41-undecaazapentacyclo[24.15.11.2 43,46 .1 35,41 .0 9,13] Pentadecanoic acid-37,43(54),44,46(53),47-pentaene-16,1'-cyclobutane]-2,5,8,14,17,20,24,27,30,33,55-undecanone, or a salt thereof or a solvent thereof. [5] A cyclic compound as described in any one of [1] to [4-53], or a salt thereof. [6] A cyclic compound as described in any one of [1] to [4-53], or a solvent thereof. [7] A cyclic compound as described in any one of [1] to [4-53], or a solvent thereof. [8] A cyclic compound as described in any one of [1] to [4-53]. [9] The cyclic compound, or salt thereof, or solvent thereof as described in any one of [1] to [4-53], which binds to KRAS.

[10] The cyclic compound, or salt thereof, or solvent thereof as described in any one of [1] to [4-53], which inhibits KRAS.

[11] The cyclic compound, or salt thereof, or solvent thereof as described in any one of [1] to [4-53], which has high selectivity for KRAS.

[12] The cyclic compound, or salt thereof, or solvent thereof as described in any one of [1] to [4-53], which has a higher selectivity than PP1820: (3S,9S,12S,17S,20S,23S,27S,30S,36S)-3-[2-[3-chloro-4-(trifluoromethyl)phenyl]ethyl]-30-cyclopentyl-23-isobutyl-9-(isopentyloxymethyl)-N,N,7,17​​,18,24,28,31-octamethyl-20-[(1S)-1-methylpropyl]-2,5,8,11,16,19,22,25,29,32,35-undecacyclo-10-propyl-spiro[1,4,7,10,15,18,21,24,28,31,34-undecaazatricyclo[34.3.0.0 12,15

[13] The cyclic compound, or salt thereof, or solvent complex thereof as described in any one of [1] to [4-53], which selectively binds to KRAS.

[14] The cyclic compound, or salt thereof, or solvent complex thereof as described in any one of [1] to [4-53], which selectively inhibits KRAS.

[15] The cyclic compound, or salt thereof, or solvent complex thereof as described in any one of [1] to [4-53], which has a higher KRAS selectivity than nonatriacontane-3,3,1'-cyclobutane-2,7-carboxamide (KRAS selectivity relative to NRAS and / or KRAS selectivity relative to HRAS).

[16] The cyclic compound, or a salt thereof, or a solvent conjugate thereof as described in

[15] , wherein the KRAS binding activity is 5-fold, 7-fold, 10-fold, 15-fold, or 20-fold greater than the NRAS binding activity and HRAS binding activity.

[17] The cyclic compound, or a salt thereof, or a solvent conjugate thereof as described in any one of [1] to [4-53], wherein the KRAS inhibitory activity is 3-fold greater than the NRAS inhibitory activity and HRAS inhibitory activity.

[18] The cyclic compound, or a salt thereof, or a solvent conjugate thereof as described in

[17] , wherein the KRAS inhibitory activity is 5-fold, 7-fold, 10-fold, 15-fold, or 20-fold greater than the NRAS inhibitory activity and HRAS inhibitory activity.

[19] A pharmaceutical composition comprising the cyclic compound, or a salt thereof, or a solvent conjugate thereof as described in any one of [1] to [4-53].

[20] A pharmaceutical composition for selectively inhibiting KRAS in a subject, comprising a cyclic compound as described in any one of [1] to [4-53], or a salt thereof, or a solvent thereof.

[21] The pharmaceutical composition as described in

[20] , wherein the KRAS inhibitory activity of the aforementioned compound is 3 times or more relative to the NRAS inhibitory activity and HRAS inhibitory activity of the aforementioned compound.

[22] The pharmaceutical composition as described in

[21] , wherein the KRAS inhibitory activity of the aforementioned compound is 5 times, 7 times, 10 times, 15 times, or 20 times or more relative to the NRAS inhibitory activity and HRAS inhibitory activity of the aforementioned compound.

[23] A pharmaceutical composition for treating or preventing cancer in a subject, comprising an effective amount of a cyclic compound as described in any one of [1] to [4-53], or a salt thereof, or a solvent thereof.

[24] The pharmaceutical composition as described in

[23] , wherein the cancer is lung cancer.

[25] The pharmaceutical composition of any one of

[20] to

[24] , wherein the subject is a human.

[26] The cyclic compound of any one of [1] to [4-53], or a salt thereof or a solvent thereof, for use in treating or preventing cancer in a subject.

[27] The cyclic compound, or a salt thereof, or a solvent thereof as described in

[26] , wherein the cancer is lung cancer.

[28] The cyclic compound, or a salt thereof, or a solvent thereof as described in any one of [1] to [4-53], for use in selectively inhibiting KRAS in a subject.

[29] The cyclic compound, or a salt thereof, or a solvent thereof as described in any one of

[26] to

[28] , wherein the subject is a human.

[30] Use of the cyclic compound, or a salt thereof, or a solvent thereof as described in any one of [1] to [4-53], for the manufacture of a medicament for treating or preventing cancer in a subject.

[31] The use as described in

[30] , wherein the cancer is lung cancer.

[32] Use of the cyclic compound, or a salt thereof, or a solvent thereof as described in any one of [1] to [4-53], for the manufacture of a medicament for selectively inhibiting KRAS in a subject.

[33] The use as described in any one of

[30] to

[32] , wherein the subject is a human.

[34] A method for treating or preventing cancer in a subject, comprising administering to a subject in need thereof an effective amount of a cyclic compound as described in any one of [1] to [4-53], or a salt thereof, or a solvent thereof.

[35] The method as described in

[34] , wherein the cancer is lung cancer.

[36] A method for selectively inhibiting KRAS in a subject, comprising administering to a subject in need thereof an effective amount of a cyclic compound as described in any one of [1] to [4-53], or a salt thereof, or a solvent thereof.

[37] The method as described in any one of

[34] to

[36] , wherein the subject is a human. [Effects of the Invention]. According to the present invention, novel cyclic compounds having selective KRAS inhibitory activity can be provided. (Abbreviations) The abbreviations used in the present invention are as follows: AA: Ammonium acetate Boc: Tertiary butyloxycarbonyl CSA: (+)-10-camphorsulfonic acid CPME: Cyclopentyl methyl ether DAST: (Diethylamino)sulfur trifluoride DBU: 1,8-diazabicyclo[5.4.0]-7-undecene DCM: Dichloromethane DCE: 1,2-Dichloroethane DEAD: Diethyl azodicarboxylate DEPBT: 3-(diethoxyphosphino)-1,2,3-benzotriazol-4(3H)-one DIAD: Diisopropyl azodicarboxylate DIC: N,N'-Diisopropylcarbodiimide DIPEA: N,N-diisopropylethylamine DHP: 3,4-dihydro-2H-pyran DMA: N,N-dimethylacetamide DMAP: N,N-dimethyl-4-aminopyridine DMF: N,N-dimethylformamide dtbbpy: 4,4'-di-tert-butyl-2,2'-bipyridyl EDTA: ethylenediaminetetraacetic acid FA: formic acid Fmoc: 9-fluorenylmethyloxycarbonyl NMP: N-methyl-2-pyrrolidone TBME: tert-butyl methyl ether TES: triethylsilane TFA: trifluoroacetic acid TFE: 2,2,2-trifluoroethanol THF: Tetrahydrofuran THP: Tetrahydropyranyl TMSCl: Trimethylsilyl chloride HFIP: 1,1,1,3,3,3-hexafluoroisopropanol HOAt: 1-hydroxy-7-azabenzotriazole HOBt: 1-hydroxybenzotriazole HOOBt: 3,4-dihydro-3-hydroxy-4-oxo-1,2,3-benzotriazolium IPAC: Isopropyl acetate Oxyma: Ethyl cyano(hydroxyimino)acetate PPTS: Pyridinium p-toluenesulfonate Pis: 2-phenylisopropyl WSCI・HCl, WSCDI: 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride TIPS: triisopropylsilane TfOH: trifluoromethanesulfonic acid HATU: O-(7-aza-1H-benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate DMSO: dimethylsulfoxide Fmoc-Cl: chlorine (9H-Fluoren-9-yl)methyl formate; Fmoc-OSu: N-succinimidyl-9-fluoren-1,2-dimethylformate; Ns: o-nitrobenzenesulfonyl; Trt: trityl; 9-BBN: 9-boronobicyclo[3.3.1]nonane; HMDS: 1,1,1,3,3,3-hexamethyldisilazane; LDA: lithium diisopropylamide; TMSOTf: trimethylsilyl trifluoromethanesulfonate; PPA: polyphosphoric acid. In this specification, when the term “about” is used in combination with a numerical value, it means a range of values ​​from +10% to -10% of the numerical value. In this specification, "to" indicating a range includes both ends of the value. For example, "A to B" indicates a range of not less than A and not more than B. The unit of molecular weight in this specification is "g / mol" (hereinafter, in this specification, the unit of molecular weight may be omitted). The use of the articles "a," "an," and "the" in this specification and the claims is to be construed as including both the singular and the plural unless otherwise indicated in the specification or clearly denied by the context. (Definition of Functional Group, etc.) Examples of the "halogen atom" in this specification include F, Cl, Br, and I. In this specification, "alkyl" refers to a monovalent group derived from an aliphatic hydrocarbon by removing one arbitrary hydrogen atom, and the skeleton does not contain heteroatoms (atoms other than carbon and hydrogen atoms) or unsaturated carbon-carbon bonds, and has a partial collection of hydrocarbon or hydrocarbon structures containing hydrogen and carbon atoms. Alkyl groups include not only straight chains but also branched chains. Specific examples of alkyl groups include those with 1 to 20 carbon atoms (C 1~C 20 , the following "C p ~C q " represents an alkyl group with p to q carbon atoms, preferably C 1~C 10 Alkyl, more preferably C 1~C Specific examples of the alkyl group include methyl, ethyl, n-propyl, isopropyl, n-butyl, secondary butyl, tertiary butyl, isobutyl (2-methylpropyl), n-pentyl, secondary pentyl (1-methylbutyl), tertiary pentyl (1,1-dimethylpropyl), neopentyl (2,2-dimethylpropyl), isopentyl (3-methylbutyl), 3-pentyl (1-ethylpropyl), 1,2-dimethylpropyl, 2-methylbutyl, n-hexyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1,1,2,2-tetramethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, 3,3-dimethylbutyl, 1-ethylbutyl, and 2-ethylbutyl. In this specification, "alkenyl" refers to a group having at least one double bond (two adjacent SP 2The double bond geometry may be in the trans (E) or cis (Z) configuration, or in the trans or cis configuration, depending on the configuration of the double bond and the substituent (if any). Alkenyl groups may be linear or branched. Preferred examples of alkenyl groups include C 2~C 10 Alkenyl, more preferably C 2~C 7 alkenyl, C 2~C Specific examples of the 6-alkenyl group include vinyl, allyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl (including cis and trans forms), 3-butenyl, pentenyl, 3-methyl-2-butenyl, hexenyl, and 6-heptenyl. In this specification, "alkynyl" refers to a monovalent group having at least one triple bond (two adjacent SP carbon atoms). Alkyl groups include not only straight-chain ones but also branched ones. Preferred examples of alkynyl groups include C 2~C 10 Alkynyl, more preferably C 2~C Specific examples of the 6-alkynyl group include ethynyl, 1-propynyl, propargyl, 3-butynyl, pentynyl, hexynyl, 3-phenyl-2-propynyl, 3-(2'-fluorophenyl)-2-propynyl, 2-hydroxy-2-propynyl, 3-(3-fluorophenyl)-2-propynyl, and 3-methyl-(5-phenyl)-4-pentynyl. In this specification, "cycloalkyl" refers to a saturated or partially saturated cyclic monovalent aliphatic hydrocarbon group, including monocyclic, bicyclic, and spirocyclic rings. Preferred examples of cycloalkyl include C 3~C Specific examples of the cycloalkyl group include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, bicyclo[2.2.1]heptyl, and spiro[3.3]heptyl. The term "aryl" in this specification refers to a monovalent aromatic hydrocarbon ring, preferably C 6~C 10 Aryl. Specific examples of aryl groups include phenyl and naphthyl (e.g., 1-naphthyl and 2-naphthyl). In this specification, aryl groups include bicyclic aryl groups in which the aforementioned aromatic hydrocarbon ring is condensed with another saturated or unsaturated ring. For example, aryl groups include condensed ring structures in which the aromatic hydrocarbon ring is a benzene ring and the saturated ring is a 5-, 6-, or 7-membered saturated hydrocarbon ring or a saturated heterocyclic ring. Specific examples include indanyl, 1,2,3,4-tetrahydronaphthyl, and 2,3-dihydrobenzofuran. As used herein, "heterocyclic group" refers to a non-aromatic, cyclic, monovalent group containing 1 to 5 heteroatoms in addition to carbon atoms. Heterocyclic groups may have double and / or triple bonds within the ring, and carbon atoms within the ring may be oxidized to form a carbonyl group. The ring may be monocyclic or condensed. The number of atoms constituting the ring is preferably 3-10 (for 3- to 10-membered heterocyclic groups), or 4-10 (for 4- to 10-membered heterocyclic groups), more preferably 3-7 (for 3- to 7-membered heterocyclic groups), or 4-7 (for 4- to 7-membered heterocyclic groups). Specific examples of the heterocyclic group include azetidinyl, oxiranyl, oxetanyl, azetidinyl, dihydrofuranyl, tetrahydrofuranyl, dihydropyranyl, tetrahydropyranyl, tetrahydropyridinyl, tetrahydropyrimidinyl, morpholinyl, thiomorpholinyl, pyrrolidinyl, piperidyl, piperazinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, oxazolidinyl, isoxazolidinyl, tetrahydrothiazolyl, 1,2-thiazinane, thiadiazolidinyl, azetidinyl, oxazolidone, benzodioxanyl, benzoxazolyl, dioxolanyl, dioxanyl, tetrahydropyrrolo[1,2-c]imidazole, thietanyl, 3,6-diazabicyclo[3.1.1]heptyl, 2,5-diazabicyclo[2.2.1]heptyl, 3-oxa-8-azabicyclo[3.2.1]octyl, sultam, 2-oxaspiro[3.3]heptyl, etc. As used herein, a "protected heterocyclic group" refers to a group in which one or more functional groups (e.g., an amino group) included in the "heterocyclic group" defined above are protected by any protecting group. Preferred examples include protected 4- to 7-membered heterocyclic groups. Specific examples of protecting groups include Boc, Fmoc, Cbz, Troc, and Alloc. Specific examples of protected heterocyclic groups include Boc-protected azetidine. In this specification, "heterocycloalkylidene" refers to a divalent group in which the free valences of the atoms generated by removing two hydrogen atoms from one carbon atom of the "heterocyclic group" defined above become part of a double bond. Preferred examples of heterocycloalkylidene include 4- to 7-membered heterocycloalkylidene groups, and specific examples include tetrahydropyran-4-ylidene and azetidine-3-ylidene. As used herein, a "protected heterocycloalkylene group" refers to a group in which one or more functional groups (e.g., an amino group) included in the above-defined "heterocycloalkylene group" are protected by any protecting group. Preferred examples include protected 4- to 7-membered heterocycloalkylene groups. Specific examples of protecting groups include Boc, Fmoc, Cbz, Troc, and Alloc. Specific examples of protected heterocycloalkylene groups include Boc-protected azetidin-3-ylidene groups. As used herein, "heteroaryl" refers to an aromatic cyclic monovalent group containing 1 to 5 heteroatoms in addition to carbon atoms. The ring may be monocyclic, condensed with other rings, or partially saturated. The number of atoms constituting the ring is preferably 5 to 10 (5- to 10-membered heteroaryl), more preferably 5 to 7 (5- to 7-membered heteroaryl). Specific examples of the heteroaryl group include furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadizolyl, thiadizolyl, triazolyl, tetrazolyl, pyridyl, pyrimidyl, pyridazinyl, pyrazinyl, triazinyl, benzofuranyl, benzothiophene, and the like. ienyl), benzothiadiazolyl, benzothiazolyl, benzoxazolyl, benzoxadiazolyl, benzoimidazolyl, indolyl, isoindolyl, indazolyl, quinolyl, isoquinolyl, cinnolinyl, quinazolinyl, quinoxalinyl, benzodioxolyl, indolizinyl, imidazopyridyl, and the like. In this specification, "alkoxy" refers to an oxy group bonded to the "alkyl" defined above, and preferably C 1~C Specific examples of the alkoxy group include methoxy, ethoxy, 1-propoxy, 2-propoxy, n-butoxy, isobutoxy, secondary butoxy, tertiary butoxy, pentyloxy, and 3-methylbutoxy. The "alkylthio group" in this specification refers to a thiol group bonded to the "alkyl group" defined above, and preferably C 1~C Specific examples of the alkylthio group include methylthio, ethylthio, 1-propylthio, 2-propylthio, n-butylthio, isobutylthio, secondary butylthio, and tertiary butylthio. In this specification, "alkenyloxy" refers to an oxy group bonded to the "alkenyl" defined above, and preferably C 2~C Specific examples of the alkenyloxy group include vinyloxy, allyloxy, 1-propenyloxy, 2-propenyloxy, 1-butenyloxy, 2-butenyloxy (including cis and trans forms), 3-butenyloxy, pentenyloxy, and hexenyloxy. In the present specification, "cycloalkoxy" refers to an oxy group bonded to the "cycloalkyl" defined above, and preferably C 3~C 8. Cycloalkoxy. Specific examples of the cycloalkoxy include cyclopropyloxy, cyclobutyloxy, and cyclopentyloxy. In this specification, "aryloxy" refers to an oxy group bonded to the above-defined "aryl", and preferably C 6~C 10 Aryloxy groups: Specific examples of the aryloxy groups include phenoxy, 1-naphthyloxy, and 2-naphthyloxy groups. In this specification, the term "amino group" refers to -NH 2, broadly represents -NRR', where R and R' are independently selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl, or heteroaryl, or R and R' together with the nitrogen atom to which they are bonded form a ring. Preferred examples of amino groups include -NH 2. Single C 1~C 6-alkylamino, di-C 1~C 6-alkylamino, 4- to 8-membered cyclic amino, etc. In this specification, the "monoalkylamino group" means an "amino group" defined above in which R is hydrogen and R' is an "alkyl group" defined above, preferably a mono-C 1~C Specific examples of the monoalkylamino group include a methylamino group, an ethylamino group, an n-propylamino group, an isopropylamino group, an n-butylamino group, a secondary butylamino group, and a tertiary butylamino group. In the present specification, "dialkylamino" refers to an "amino" defined above in which R and R' are independently "alkyl" as defined above. Preferred examples include dialkylamino. 1~C Specific examples of the dialkylamino group include a dimethylamino group and a diethylamino group. In this specification, a "cyclic amino group" refers to an "amino group" defined above in which R and R' together with the nitrogen atom to which they are bonded form a ring. Preferred examples include 4- to 8-membered cyclic amino groups. Specific examples of cyclic amino groups include 1-azetidyl, 1-pyrrolidyl, 1-piperidyl, 1-piperidinyl, 4-morpholinyl, 3-oxazolidinyl, 1,1-dioxidethiomorpholinyl-4-yl, and 3-oxa-8-azabicyclo[3.2.1]octan-8-yl. In the present specification, a "protected amine group" refers to an amine group protected by any protecting group. Specific examples of protected amine groups include amine groups protected by protecting groups such as Boc, Fmoc, Cbz, Troc, and Alloc. The "alkylcarbonyl group" in this specification refers to a carbonyl group bonded to the "alkyl group" defined above, and preferably C 1~C 6 alkylcarbonyl. Specific examples of alkylcarbonyl include acetyl, propionyl, butyryl, etc. The carbon number indicated in the above definition indicates the carbon number of the alkyl part. For example, "C 1~C 6-alkylcarbonyl" in "C 1~C 6" means that the alkyl portion has 1 to 6 carbon atoms. The "aminocarbonyl group" in this specification refers to a carbonyl group bonded to the "amino group" defined above, preferably -CONH 2. Single C 1~C 6-alkylaminocarbonyl, di-C 1~C 6-alkylaminocarbonyl, 4- to 8-membered cyclic aminocarbonyl. Specific examples of the aminocarbonyl group include -CONH 2. dimethylaminocarbonyl, 1-azetidinylcarbonyl, 1-pyrrolidinylcarbonyl, 1-piperidinylcarbonyl, 1-piperidinylcarbonyl, 4-morpholinylcarbonyl, 3-oxazolidinylcarbonyl, 1,1-dioxidothiomorpholin-4-ylcarbonyl, 3-oxa-8-azabicyclo[3.2.1]octan-8-ylcarbonyl, etc. In the present specification, "alkenyloxycarbonyl" refers to a carbonyl group to which the above-defined "alkenyloxy" is bonded, and preferably C 2~C Specific examples of the alkenyloxycarbonyl group include vinyloxycarbonyl, allyloxycarbonyl, 1-propenyloxycarbonyl, 2-propenyloxycarbonyl, 1-butenyloxycarbonyl, 2-butenyloxycarbonyl (including cis and trans forms), 3-butenyloxycarbonyl, pentenyloxycarbonyl, and hexenyloxycarbonyl. The "alkylsulfonyl group" in this specification refers to a sulfonyl group bonded to the "alkyl group" defined above, and preferably C 1~C 6. Alkylsulfonyl group. Specific examples of the alkylsulfonyl group include methylsulfonyl group and the like. The "hydroxyalkyl" in this specification refers to a group in which one or more hydrogen atoms of the "alkyl" defined above are replaced by hydroxyl groups, and preferably C 1~C Specific examples of the hydroxyalkyl group include hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, 2-hydroxy-2-methylpropyl, and 5-hydroxypentyl. In the present specification, "haloalkyl" refers to an "alkyl" defined above in which one or more hydrogen atoms are replaced by halogen. Preferred examples include C 1~C 6 haloalkyl, more preferably C 1~C Specific examples of the haloalkyl group include difluoromethyl, trifluoromethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 3,3-difluoropropyl, 4,4-difluorobutyl, 5,5-difluoropentyl, and 1,1-difluoroethyl. The "cyanoalkyl" in this specification refers to an "alkyl" defined above in which one or more hydrogen atoms are replaced by a cyano group, preferably C 1~C Specific examples of the cyanoalkyl group include cyanomethyl and 2-cyanoethyl. In this specification, "aminoalkyl" refers to a group in which one or more hydrogen atoms of the above-defined "alkyl" are replaced by the above-defined "amino" group, preferably C 1~C Specific examples of the aminoalkyl group include 1-pyridylmethyl, 2-(1-piperidyl)ethyl, 3-(1-piperidyl)propyl, 4-aminobutyl, and 2-aminoethyl. The term "carboxyalkyl" in this specification refers to an "alkyl" defined above in which one or more hydrogen atoms are replaced by carboxyl groups, preferably C 1~C 6-carboxyalkyl, C 2~C 6 carboxyalkyl. Specific examples of carboxyalkyl include carboxymethyl. The carbon number indicated in the above definition indicates the carbon number of the alkyl portion. For example, "C 1~C 6 carboxyalkyl" in "C 1~C 6" means that the alkyl portion has 1 to 6 carbon atoms. In this specification, "alkenyloxycarbonylalkyl" refers to a group in which one or more hydrogen atoms of the above-defined "alkyl" are replaced by the above-defined "alkenyloxycarbonyl" group, preferably C 2~C 6-Alkenyloxycarbonyl C 1~C 6 alkyl, more preferably C 2~C 6-Alkenyloxycarbonyl C 1~C Specific examples of the alkenyloxycarbonylalkyl group include allyloxycarbonylmethyl and 2-(allyloxycarbonyl)ethyl. In this specification, "alkoxyalkyl" refers to a group in which one or more hydrogen atoms of the above-defined "alkyl" are replaced by the above-defined "alkoxy" group, preferably C 1~C 6 Alkoxy C 1~C 6 alkyl, more preferably C 1~C 6 Alkoxy C 1~C Specific examples of the alkoxyalkyl group include methoxymethyl, ethoxymethyl, 1-propoxymethyl, 2-propoxymethyl, n-butoxymethyl, isobutoxymethyl, secondary butoxymethyl, tertiary butoxymethyl, pentyloxymethyl, 3-methylbutoxymethyl, 1-methoxyethyl, 2-methoxyethyl, 2-ethoxyethyl, 1-ethoxyethyl, and 1-n-propoxyethyl. The term "alkylthioalkyl" in this specification refers to a group in which one or more hydrogen atoms of the above-defined "alkyl" are replaced by the above-defined "alkylthio" group, preferably C 1~C 6-alkylthio C 1~C 6 alkyl, more preferably C 1~C 6-alkylthio C 1~C Specific examples of the alkylthioalkyl group include methylthiomethyl, ethylthiomethyl, 1-propylthiomethyl, 2-propylthiomethyl, n-butylthiomethyl, isobutylthiomethyl, secondary butylthiomethyl, and tertiary butylthiomethyl. In this specification, "alkenyloxyalkyl" refers to a group in which one or more hydrogen atoms of the above-defined "alkyl" are replaced by "alkenyloxy" groups as defined above, preferably C 2~C 6-Alkenyloxy C 1~C 6 alkyl, more preferably C 1~C 6-Alkenyloxy C 1~C Specific examples of the alkenyloxyalkyl group include vinyloxymethyl and allyloxymethyl. The term "cycloalkylalkyl" in this specification refers to a group in which one or more hydrogen atoms of the above-defined "alkyl" are replaced by the above-defined "cycloalkyl" group, preferably C 3~C 8-cycloalkyl C 1~C 6 alkyl, more preferably C 3~C 6-cycloalkyl C 1~C Specific examples of the cycloalkylalkyl group include cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, and cyclohexylmethyl. The "cycloalkoxyalkyl" in this specification refers to a group in which one or more hydrogen atoms of the "alkyl" defined above are replaced by the "cycloalkoxy" defined above, preferably C 3~C 8-cycloalkoxy C 1~C 6 alkyl, more preferably C 3~C 6-cycloalkoxy C 1~C Specific examples of the cycloalkoxyalkyl group include cyclopropyloxymethyl and cyclobutyloxymethyl. The term "heterocyclylalkyl" in this specification refers to an "alkyl" defined above in which one or more hydrogen atoms are replaced by a "heterocyclyl" defined above, preferably a 4- to 7-membered heterocyclyl C 1~C 6-membered alkyl, more preferably 4-7 membered heterocyclic C 1~C Specific examples of the heterocyclic alkyl group include 2-(tetrahydro-2H-pyran-4-yl)ethyl and 2-(azetidin-3-yl)ethyl. In the present specification, "alkylsulfonylalkyl" refers to a group in which one or more hydrogen atoms of the above-defined "alkyl" are replaced by the above-defined "alkylsulfonyl" group, preferably C 1~C 6-Alkylsulfonyl C 1~C 6 alkyl, more preferably C 1~C 6-Alkylsulfonyl C 1~C Specific examples of the alkylsulfonylalkyl group include methylsulfonylmethyl and 2-(methylsulfonyl)ethyl. In this specification, "aminocarbonylalkyl" refers to a group in which one or more hydrogen atoms of the above-defined "alkyl" are replaced by the above-defined "aminocarbonyl" group, preferably aminocarbonyl C 1~C 6 alkyl, more preferably aminocarbonyl C 1~C Specific examples of the aminocarbonylalkyl group include methylaminocarbonylmethyl, dimethylaminocarbonylmethyl, tertiary butylaminocarbonylmethyl, 1-azetidinylcarbonylmethyl, 1-pyrrolidinylcarbonylmethyl, 1-piperidinylcarbonylmethyl, 4-morpholinylcarbonylmethyl, 2-(methylaminocarbonyl)ethyl, 2-(dimethylaminocarbonyl)ethyl, 2-(1-azetidinylcarbonyl)ethyl, 2-(1-pyrrolidinylcarbonyl)ethyl, 2-(4-morpholinylcarbonyl)ethyl, 3-(dimethylaminocarbonyl)propyl, and 4-(dimethylaminocarbonyl)butyl. The term "aryloxyalkyl" in this specification refers to a group in which one or more hydrogen atoms of the above-defined "alkyl" are replaced by the above-defined "aryloxy" group, preferably C 6~C 10 Aryloxy C 1~C 6 alkyl, more preferably C 6~C 10 Aryloxy C 1~C Specific examples of the aryloxyalkyl group include phenoxymethyl and 2-phenoxyethyl. In this specification, "aralkyl (arylalkyl)" means a group in which at least one hydrogen atom of the above-defined "alkyl" is replaced by the above-defined "aryl" group, preferably C 7~C 14 Arylalkyl, more preferably C 7~C 10 Aralkyl group: Specific examples of the aralkyl group include benzyl, phenethyl, and 3-phenylpropyl. In this specification, "aralkyloxy" refers to an oxy group bonded to the "aralkyl" defined above, preferably C 7~C 14 Aralkyloxy, more preferably C 7~C 10 Aralkyloxy groups: Specific examples of the aralkyloxy groups include benzyloxy, phenethyloxy, and 3-phenylpropoxy. In this specification, "aralkyloxyalkyl" refers to a group in which one or more hydrogen atoms of the above-defined "alkyl" are replaced by the above-defined "aralkyloxy" groups, preferably C 7~C 14 Aralkyloxy C 1~C 6 alkyl, more preferably C 7~C 14 Aralkyloxy C 1~C Specific examples of the aralkyloxyalkyl group include benzyloxymethyl and 1-(benzyloxy)ethyl. The term "heteroarylalkyl" in this specification refers to a group in which at least one hydrogen atom of the above-defined "alkyl" is replaced by a "heteroaryl" as defined above, preferably a 5- to 10-membered heteroaryl C 1~C 6-membered alkyl, more preferably 5-10 membered heteroaryl C 1~C Specific examples of the heteroarylalkyl group include 3-thienylmethyl, 4-thiazolylmethyl, 2-pyridylmethyl, 3-pyridylmethyl, 4-pyridylmethyl, 2-(2-pyridyl)ethyl, 2-(3-pyridyl)ethyl, 2-(4-pyridyl)ethyl, 2-(6-quinolyl)ethyl, 2-(7-quinolyl)ethyl, 2-(6-indolyl)ethyl, 2-(5-indolyl)ethyl, and 2-(5-benzofuranyl)ethyl. The "heteroarylalkoxy" in this specification refers to an oxy group bonded to the "heteroarylalkyl" defined above, preferably a 5-10 membered heteroaryl C 1~C 6-membered alkoxy, more preferably 5-10 membered heteroaryl C 1~C Specific examples of the heteroarylalkoxy group include 3-thienylmethoxy and 3-pyridylmethoxy. The term "heteroarylalkoxyalkyl" in this specification refers to a group in which one or more hydrogen atoms of the above-defined "alkyl" are replaced by the above-defined "heteroarylalkoxy" group, preferably a 5- to 10-membered heteroaryl C 1~C 6 Alkoxy C 1~C 6-membered alkyl, more preferably 5-10 membered heteroaryl C 1~C 2 Alkoxy C 1~C Specific examples of the heteroarylalkoxyalkyl group include 3-pyridylmethoxymethyl and the like. In this specification, "heterocycloalkylenealkyl" means a group in which one or more hydrogen atoms of the above-defined "alkyl" are replaced by the above-defined "heterocycloalkylene" groups, preferably a 4-7 membered heterocycloalkylene group C 1~C 6-membered alkyl, more preferably 4-7 membered heterocyclic alkylene C 1~C Specific examples of the heterocycloalkylenealkyl group include tetrahydro-4H-pyran-4-ylidenemethyl and azetidin-3-ylidenemethyl. In this specification, "alkoxyalkenyl" refers to a group in which one or more hydrogen atoms of the above-defined "alkenyl" are replaced by the above-defined "alkoxy" group, preferably C 1~C 6 Alkoxy C 2~C Specific examples of the alkoxyalkenyl group include (E)-4-methoxybut-2-en-1-yl and the like. The "aminocarbonylalkenyl" in this specification refers to a group in which one or more hydrogen atoms of the "alkenyl" defined above are replaced by the "aminocarbonyl" defined above, preferably aminocarbonyl C 2~C Specific examples of the aminocarbonylalkenyl group include (E)-3-(dimethylaminocarbonylcarbonyl)-prop-2-en-1-yl and the like. The term "haloalkoxy" in this specification refers to an "alkoxy" defined above in which one or more hydrogen atoms are replaced by halogen. 1~C 6-Haloalkoxy. Specific examples of the haloalkoxy include difluoromethoxy, trifluoromethoxy, 2,2-difluoroethoxy, and 2,2,2-trifluoroethoxy. In this specification, "alkylene" refers to a divalent group derived from the above-mentioned "alkyl" by removing one arbitrary hydrogen atom, preferably C 4~C 8 alkylene. Specific examples of the alkylene include -CH 2-、-(CH 2) 2-、-(CH 2) 3-、-CH(CH 3) CH 2-、-C(CH 3) 2-、-(CH 2) 4-、-CH(CH 3) CH 2CH 2-、-C(CH 3) 2CH 2-、-CH 2CH(CH 3) CH 2-、-CH 2C(CH 3) 2-、-CH 2CH 2CH(CH 3)-、-(CH 2) 5-、-(CH 2) 6-、-(CH 2) 7-、-(CH 2) 8- etc. In this specification, "cycloalkylene" refers to a divalent group derived from the above-mentioned "cycloalkyl" by removing one arbitrary hydrogen atom, preferably C 3~C 8. Cycloalkylene. Specific examples of the cycloalkylene include cyclopropane-1,2-diyl, cyclobutane-1,2-diyl, cyclopentane-1,2-diyl, and cyclohexane-1,2-diyl. In this specification, a "heterocyclic group" refers to a divalent group derived from a "heterocyclic group" described above by removing one arbitrary hydrogen atom, and is preferably a 3- to 7-membered heterocyclic group. Specific examples of the heterocyclic group include oxirane-2,3-diyl, oxetane-2,3-diyl, tetrahydrofuran-2,5-diyl, and tetrahydropyran-2,6-diyl. In this specification, "alkenyl" refers to a divalent group derived from the above-mentioned "alkenyl" by removing one arbitrary hydrogen atom. Depending on the configuration of the double bond and the substituent (if any), the double bond geometry can be in the trans (E) or cis (Z) configuration, or in the cis or trans configuration. Alkenyl includes straight or branched chains, preferably C 2~C 10 Alkenyl, more preferably C 2~C 6-alkenyl. In this specification, "alkynylene" refers to a divalent group derived from the above-mentioned "alkynyl" by removing one arbitrary hydrogen atom. Alkyne groups include straight-chain or branched chains, preferably C 2~C 10 Alkyne, more preferably C 2~C 6 alkynyl. In this specification, "arylene" refers to a divalent group derived from the aforementioned "aryl" by removing one arbitrary hydrogen atom. An arylene group may be a single ring or a condensed ring. The number of atoms constituting the ring is not particularly limited, but is preferably 6 to 10 (C6-10 arylene). Specific examples of arylene groups include 1,2-phenylene, 1,3-phenylene, 1,4-phenylene, 1,2-naphthylene, 1,3-naphthylene, and 1,4-naphthylene. In the present specification, "spirocycloalkyl" refers to a group formed by sharing one carbon atom constituting a cycloalkane ring with a carbon atom in a group to which the group is bound. Preferred examples of the spirocycloalkyl group include C 3~C Specific examples of the spirocycloalkyl group include spirocyclopropyl, spirocyclobutyl, spirocyclopentyl, spirocyclohexyl, spirocycloheptyl, and spirocyclooctyl. In the present specification, a "spiroheterocyclic group" refers to a group in which one or more carbon atoms in the aforementioned "spirocycloalkyl group" are substituted with heteroatoms. Preferred examples of the spiroheterocyclic group include 4- to 10-membered spiroheterocyclic groups. As used herein, "alicyclic ring" refers to a non-aromatic hydrocarbon ring. An alicyclic ring may have an unsaturated bond within the ring or may be a polycyclic ring having two or more rings. Furthermore, carbon atoms constituting the ring may be oxidized to form a carbonyl group. Preferred examples of the alicyclic ring include 3- to 8-membered alicyclic rings, specifically cyclopropane rings, cyclobutane rings, cyclopentane rings, cyclohexane rings, cycloheptane rings, cyclooctane rings, and bicyclo[2.2.1]heptane rings. As used herein, a "saturated heterocycle" refers to a non-aromatic heterocycle containing 1 to 5 heteroatoms in addition to carbon atoms and containing no double and / or triple bonds. A saturated heterocycle may be a single ring or may form a condensed ring with another ring, such as a benzene ring, or an aromatic ring. Preferred saturated heterocyclic rings include 4- to 7-membered saturated heterocyclic rings, and specific examples include azetidine ring, oxetane ring, tetrahydrofuran ring, tetrahydropyran ring, morpholine ring, thiomorpholine ring, pyrrolidine ring, 4-oxopyrrolidine ring, piperidine ring, 4-oxopiperidine ring, piperidine ring, pyrazolidine ring, imidazolidinyl ring, oxazolidinyl ring, isoxazolidinyl ring, tetrahydrothiazolidine ring, isothiazolidine ring, thiadiazolidine ring, oxazolidinone ring, dioxolane ring, dioxane ring, thietane ring, octahydroindole ring, indoline ring, and azepane ring. In this specification, a "peptide chain" refers to a peptide chain comprising one, two, three, four, or more natural and / or non-natural amino acids linked via amide and / or ester bonds. A peptide chain preferably comprises one to four amino acid residues, and more preferably comprises one to four amino acid residues. In the present specification, "may also be substituted" means that a certain group may also be substituted by an arbitrary substituent. In the present specification, "may also be protected" means that a certain group may also be protected by an arbitrary protecting group. In this specification, "one or more" means one or more than two. When "one or more" is used in connection with a substituent of a group, it refers to a number from one to the maximum number of substituents permitted for the group. Specific examples of "one or more" include 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, and / or numbers greater than these. The wavy lines in the structural formulas herein indicate that any stereochemistry is permitted. For example, when an asymmetric center has a wavy line, the stereochemistry of the asymmetric center can be either S or R. Furthermore, when a double bond has a wavy line, the stereochemistry of the double bond can be either E or Z. In this manual, “PPn 1 n 2 n 3 n 4 (Here, n 1 、n 2 、n 3 , and n 4 Each independently represents an integer from 0 to 9)" (e.g., PP1574, PP1640, etc.) represents a compound number. The compound of the present invention may be a salt thereof, preferably a chemically or pharmaceutically acceptable salt thereof. In addition, the compound of the present invention or its salt may be a solvent complex thereof, preferably a chemically or pharmaceutically acceptable solvent complex thereof. Salts of the compound of the present invention include, for example, hydrochloride; hydrobromide; hydroiodide; phosphate; phosphonate; sulfate; sulfonate such as methanesulfonate and p-toluenesulfonate; carboxylate such as acetate, citrate, malate, tartrate, succinate, salicylate; or alkali metal salt such as sodium salt and potassium salt; alkaline earth metal salt such as magnesium salt and calcium salt; ammonium salt such as ammonium salt, alkylammonium salt, dialkylammonium salt, trialkylammonium salt, tetraalkylammonium salt, etc. Such salts are produced, for example, by contacting the compound with an acid or base that can be used in the manufacture of pharmaceuticals. In the present invention, a solvent complex of a compound refers to a compound and a solvent that together form a molecular group. If the solvent is water, it is called a hydrate. The solvent complexes of the compounds of the present invention are preferably hydrates. Specific examples of such hydrates include 1-10 hydrates, preferably 1-5 hydrates, and more preferably 1-3 hydrates. The solvent complexes of the compounds of the present invention include not only solvent complexes with a single solvent such as water, alcohols (e.g., methanol, ethanol, 1-propanol, 2-propanol, etc.), or dimethylformamide, but also solvent complexes with multiple solvents. The "amino acid" in this specification includes natural amino acids and non-natural amino acids. The "natural amino acid" in this specification refers to Gly, Ala, Ser, Thr, Val, Leu, Ile, Phe, Tyr, Trp, His, Glu, Asp, Gln, Asn, Cys, Met, Lys, Arg, and Pro. Non-natural amino acids are not particularly limited, and examples include β-amino acids, γ-amino acids, D-type amino acids, N-substituted amino acids, α,α-disubstituted amino acids, amino acids with side chains different from those of natural ones, hydroxycarboxylic acids, and the like. The amino acids in this specification are allowed to have any stereo configuration. There is no particular restriction on the choice of the side chain of the amino acid. In addition to hydrogen atoms, for example, it can be freely selected from alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, and cycloalkyl groups. One or two non-adjacent methyl groups in these groups can also be replaced by oxygen atoms, carbonyl groups (-CO-), or sulfonyl groups (-SO-). 2-). Each may also be given a substituent, which is not limited, such as independently and freely selecting one or more from any substituent comprising a halogen atom, an O atom, an S atom, a N atom, a B atom, a Si atom, or a P atom. That is, for example, an alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, cycloalkyl, etc. which may also be substituted. In a non-limiting aspect, the amino acid in this specification may be a compound having a carboxyl group and an amino group in the same molecule (even in this case, imidic acids such as proline and hydroxyproline are also included in the amino acid). The main chain amino group of the amino acid can be unsubstituted (NH 2-yl), which may also be substituted (i.e., -NHR group: R represents an alkyl group, alkenyl group, alkynyl group, aryl group, heteroaryl group, aralkyl group, or cycloalkyl group which may have a substituent, and one or two non-adjacent methyl groups in such groups may be replaced by an oxygen atom, a carbonyl group (-CO-), or a sulfonyl group (-SO- 2-), and it is also possible to form a ring between the carbon chain bonded to the N atom and the carbon atom at the α position, such as proline). The substituents of the above R are selected in the same manner as the substituents of the above amino acid side chains. In the case where the main chain amino group is substituted, the above R is included in the "side chain of the amino acid" in this specification. The amino acid in which the main chain amino group is substituted is referred to as "N-substituted amino acid" in this specification. Preferred "N-substituted amino acids" in this specification include N-alkylamino acids, NC 1~C 6-alkyl amino acid, NC 1~C 4-alkyl amino acids, N-methyl amino acids, but not limited thereto. In this specification, the "amino acid" constituting the peptide compound includes all corresponding isotopes. An isotope of an "amino acid" is a compound in which at least one atom is replaced by an atom with the same atomic number (number of protons) but a different mass number (the sum of the number of protons and neutrons). Examples of isotopes included in the "amino acid" constituting the peptide compound of the present invention include hydrogen atoms, carbon atoms, nitrogen atoms, oxygen atoms, phosphorus atoms, sulfur atoms, fluorine atoms, chlorine atoms, etc., respectively. 2 H. 3 H. 13 C. 14 C. 15 N. 17 O. 18 O. 31 P. 32 P. 35 S. 18 F. 36 Cl et al. Examples of the substituent containing a halogen atom in the present specification include alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, and aralkyl groups each having a halogen as a substituent, and more specifically, fluoroalkyl, difluoroalkyl, and trifluoroalkyl groups. Examples of the substituent containing an O atom include a hydroxyl group (-OH), an oxy group (-OR), a carbonyl group (-C(=O)-R), a carboxyl group (-CO 2H), oxycarbonyl (-C(=O)-OR), carbonyloxy (-OC(=O)-R), thiocarbonyl (-C(=O)-SR), carbonylthio (-SC(=O)-R), aminocarbonyl (-C(=O)-NHR), carbonylamino (-NH-C(=O)-R), oxycarbonylamino (-NH-C(=O)-OR), sulfonylamino (-NH-SO 2-R), aminosulfonyl (-SO 2-NHR), sulfonylamine (-NH-SO 2-NHR), thiocarboxyl (-C(=O)-SH), carboxylcarbonyl (-C(=O)-CO 2H) and the like. Examples of the oxy group (-OR) include alkoxy, cycloalkoxy, alkenyloxy, alkynyloxy, aryloxy, heteroaryloxy, and aralkyloxy. Preferably, the alkoxy group is C 1~C 4 alkoxy, C 1~C 2 alkoxy groups, particularly preferably methoxy or ethoxy groups. Examples of the carbonyl group (—C(═O)—R) include a formyl group (—C(═O)—H), an alkylcarbonyl group, a cycloalkylcarbonyl group, an alkenylcarbonyl group, an alkynylcarbonyl group, an arylcarbonyl group, a heteroarylcarbonyl group, and an aralkylcarbonyl group. Examples of the oxycarbonyl group (—C(═O)—OR) include an alkyloxycarbonyl group, a cycloalkyloxycarbonyl group, an alkenyloxycarbonyl group, an alkynyloxycarbonyl group, an aryloxycarbonyl group, a heteroaryloxycarbonyl group, and an aralkyloxycarbonyl group. Examples of the carbonyloxy group (—OC(═O)—R) include an alkylcarbonyloxy group, a cycloalkylcarbonyloxy group, an alkenylcarbonyloxy group, an alkynylcarbonyloxy group, an arylcarbonyloxy group, a heteroarylcarbonyloxy group, and an aralkylcarbonyloxy group. Examples of the thiocarbonyl group (—C(═O)—SR) include an alkylthiocarbonyl group, a cycloalkylthiocarbonyl group, an alkenylthiocarbonyl group, an alkynylthiocarbonyl group, an arylthiocarbonyl group, a heteroarylthiocarbonyl group, and an aralkylthiocarbonyl group. Examples of the carbonylthio group (—SC(═O)—R) include an alkylcarbonylthio group, a cycloalkylcarbonylthio group, an alkenylcarbonylthio group, an alkynylcarbonylthio group, an arylcarbonylthio group, a heteroarylcarbonylthio group, and an aralkylcarbonylthio group. Examples of aminocarbonyl groups (-C(=O)-NHR) include alkylaminocarbonyl groups (e.g., C 1~C 6 or C 1~C In some embodiments, the present invention includes an aminocarbonyl group (e.g., an alkylaminocarbonyl group, particularly exemplified by an ethylaminocarbonyl group, a methylaminocarbonyl group, etc.), a cycloalkylaminocarbonyl group, an alkenylaminocarbonyl group, an alkynylaminocarbonyl group, an arylaminocarbonyl group, a heteroarylaminocarbonyl group, an aralkylaminocarbonyl group, etc. In addition to these, examples include compounds in which the H atom bonded to the N atom in -C(=O)-NHR is further substituted with an alkyl group, a cycloalkyl group, an alkenyl group, an alkynyl group, an aryl group, a heteroaryl group, or an aralkyl group. Examples of the carbonylamino group (-NH-C(=O)-R) include alkylcarbonylamino, cycloalkylcarbonylamino, alkenylcarbonylamino, alkynylcarbonylamino, arylcarbonylamino, heteroarylcarbonylamino, and aralkylcarbonylamino. In addition to these, compounds in which the H atom bonded to the nitrogen atom in -NH-C(=O)-R is further substituted with an alkyl group, cycloalkyl group, alkenyl group, alkynyl group, aryl group, heteroaryl group, or aralkyl group can be mentioned. Examples of the oxycarbonylamino group (-NH-C(=O)-OR) include alkoxycarbonylamino, cycloalkoxycarbonylamino, alkenyloxycarbonylamino, alkynyloxycarbonylamino, aryloxycarbonylamino, heteroaryloxycarbonylamino, and aralkyloxycarbonylamino. In addition to these, examples include compounds in which the H atom bonded to the N atom in -NH-C(=O)-OR is further substituted with an alkyl group, cycloalkyl group, alkenyl group, alkynyl group, aryl group, heteroaryl group, or aralkyl group. As a sulfonylamino group (-NH-SO Examples of 2-R) include alkylsulfonylamino, cycloalkylsulfonylamino, alkenylsulfonylamino, alkynylsulfonylamino, arylsulfonylamino, heteroarylsulfonylamino, and aralkylsulfonylamino. In addition to these, examples include -NH-SO Compounds in which the H atom bonded to the N atom in 2-R is further substituted by an alkyl group, a cycloalkyl group, an alkenyl group, an alkynyl group, an aryl group, a heteroaryl group, or an aralkyl group. As an aminosulfonyl group (-SO Examples of -SO-2-NHR) include alkylaminosulfonyl, cycloalkylaminosulfonyl, alkenylaminosulfonyl, alkynylaminosulfonyl, arylaminosulfonyl, heteroarylaminosulfonyl, and aralkylaminosulfonyl. In addition to these, examples thereof include -SO- Compounds in which the H atom bonded to the N atom in 2-NHR is further substituted by an alkyl group, cycloalkyl group, alkenyl group, alkynyl group, aryl group, heteroaryl group, or aralkyl group. As sulfonylamine (-NH-SO Examples of -NH-SO include alkylaminesulfonylamino, cycloalkylaminesulfonylamino, alkenylaminesulfonylamino, alkynylaminesulfonylamino, arylaminesulfonylamino, heteroarylaminesulfonylamino, and aralkylaminesulfonylamino. The two H atoms bonded to the N atom in 2-NHR may be substituted by a substituent independently selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, and aralkyl groups, and these two substituents may form a ring. Examples of the substituent containing a S atom include a mercapto group (—SH), a thio group (—SR), a sulfinyl group (—S(═O)—R), a sulfonyl group (—SO 2-R), sulfonic acid (-SO 3H) and the like. Examples of the thio group (—SR) include alkylthio, cycloalkylthio, alkenylthio, alkynylthio, arylthio, heteroarylthio, and aralkylthio. As a sulfonyl group (-SO Examples of 2-R) include alkylsulfonyl, cycloalkylsulfonyl, alkenylsulfonyl, alkynylsulfonyl, arylsulfonyl, heteroarylsulfonyl, and aralkylsulfonyl. Examples of the substituent containing a nitrogen atom include azide (-N 3, also known as "azido"), cyano (-CN), primary amine (-NH 2), secondary amine group (-NH-R, also known as monosubstituted amine group), tertiary amine group (-NR(R'), also known as disubstituted amine group), amidino group (-C(=NH)-NH 2), substituted amidino (-C(=NR)-NR'R"), guanidino (-NH-C(=NH)-NH 2) substituted guanidine (-NR-C(=NR'")-NR'R"), aminocarbonylamino (-NR-CO-NR'R"), pyridyl, piperidyl, morpholinyl, azetidinyl and the like. Examples of the secondary amino group (—NH—R; monosubstituted amino group) include an alkylamino group, a cycloalkylamino group, an alkenylamino group, an alkynylamino group, an arylamino group, a heteroarylamino group, and an aralkylamino group. Examples of tertiary amino groups (-NR(R'); disubstituted amino groups) include alkyl (aralkyl) amino groups, and amino groups having any two substituents independently selected from alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, and aralkyl groups. These two substituents may form a ring. Specific examples include dialkylamino groups, especially C 1-C 6 dialkylamino, C 1-C 4 dialkylamino, dimethylamino, diethylamino, etc. In this specification, "C p -C q "Dialkylamino" refers to an amino group replaced by two C p -C q Alkyl-substituted group, two C p -C q The alkyl groups may be the same or different. Examples of substituted amidino groups (-C(=NR)-NR'R") include three substituents R, R', and R" on the N atom, each independently selected from an alkyl group, a cycloalkyl group, an alkenyl group, an alkynyl group, an aryl group, a heteroaryl group, and an aralkyl group, such as an alkyl (aralkyl) (aryl) amidino group. Examples of substituted guanidine groups (-NR-C(=NR'")-NR'R") include groups wherein R, R', R", and R'" are independently selected from alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, and aralkyl groups, or groups forming a ring thereof. Examples of aminocarbonylamino groups (-NR-CO-NR'R") include groups in which R, R', and R" are independently selected from hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, and aralkyl groups, or groups forming a ring thereof. In this specification, the "peptide residue" and "amino acid residue" constituting the peptide compound may be abbreviated as "peptide" and "amino acid," respectively. In this specification, the term "and / or" includes all appropriate combinations of "and" and "or." For example, "A, B, and / or C" includes the following seven variations: (i) A, (ii) B, (iii) C, (iv) A and B, (v) A and C, (vi) B and C, and (vii) A, B, and C. In some aspects, the present invention relates to a cyclic compound represented by the following formula (1), or a salt thereof or a solvent thereof. [Chemical 11] The cyclic compound of formula (1) is composed of 11 amino acid residues. 1. Q 1. R 1. and L The amino acid residues of 1 are called core 1, which has P 2. Q 2. and R The amino acid residues of 2 are called core 2, which has P 3. Q 3. and R The amino acid residues of 3 are called core 3, which has P 4. Q 4. and R The amino acid residues of 4 are called core 4, which has P 5. Q 5. and R The amino acid residue of 5 is called core 5, which has P 6. Q 6. and R The amino acid residue of 6 is called core 6, which has P 7. Q 7. and R The amino acid residue of 7 is called core 7, which has P 8. Q 8. and R The amino acid residue of 8 is called core 8, which has P 9. Q 9. and R The amino acid residue at 9 is called core 9 and has P 10 , Q 10 , and R 10 The amino acid residue is called core 10, with P 11 , Q 11 、R 11 , and L 11 The amino acid residues of are called the amino acid residues of core 11. In some aspects, in formula (1), L 1 is a single bond. In some aspects, in formula (1), R 1 is C 1~C 7-alkyl, preferably 2-methylpropyl or n-propyl. In some cases, R 1 and R 5 together form a divalent group. In this case, the partial structure of the cyclic compound represented by formula (1): *-CR 1Q 1-L 1-CO-NP 2-CR 2Q 2-CO-NP 3-CR 3Q 3-CO-NP 4- CR 4Q 4- CO-NP 5-CR 5Q 5-* is represented by the following formula: [Chemical 12] Where: X 2 is -L 1-CO-NP 2-CR 2Q 2-CO-NP 3-CR 3Q 3-CO-NP 4- CR 4Q 4- CO-NP 5-, [Chemistry 13] is a single bond or a double bond, n is 0, 1 or 2, m is 0, 1, 2, 3 or 4, and * represents the bonding point with the adjacent atom. Indicates

[15] In the case of a double bond, the stereochemistry may be either E or Z. As the above formula, the formula: [Chemical 16] Better. In some cases, P 1 is C 1~C 6-alkyl, preferably methyl. In some cases, Q 1 is hydrogen. In addition to the side chain of core 1 (R 1) with the side chain of core 5 (R 5) Except for the case where they form a divalent group together, specific examples of the amino acid residues of the core 1 include MeLeu and MeNva. 1) with the side chain of core 5 (R 5) The case of forming a divalent group together corresponds to R of MeAhpe(2), MeAocte(2), and MeAhxe(2) 1 and the side chain corresponding to core 5 (R 5) is linked using the method described in the "General Preparation Method" section below. In some aspects, in formula (1), R 2 for C 1~C 6-alkyl, preferably 1-methylpropyl. In some cases, P 2 is hydrogen. In some cases, Q 2 is hydrogen. Specific examples of the amino acid residue of core 2 include Ile. In some aspects, in formula (1), R 3 is hydrogen. In some cases, R 3 and P 3. R 3-bonded carbon atoms, and P The three bonded nitrogen atoms together form a 4- to 7-membered saturated heterocyclic ring. Specific examples of the 4- to 7-membered saturated heterocyclic ring include a pyrrolidine ring. In some cases, P 3 for C 1~C 6 alkyl, or C 3~C 8-cycloalkyl, preferably methyl or cyclopropyl. In some cases, Q 3 is hydrogen. Specific examples of the amino acid residue of core 3 include MeGly, Pro, and cPrGly. In some cases, R 4 and P 5 together form a divalent group. In this case, the partial structure *-CR in the cyclic compound represented by formula (1) 4Q 4- CO-NP 5-* is represented by the following formula: [Chemical 17] . In some cases, P 4 for C 1~C 6-alkyl, preferably methyl. In some cases, Q 4 is hydrogen. Furthermore, the side chain of core 4 (R 4) with the N substituent (P 5) When forming a divalent group together, preferably, R corresponding to MeAlgly 4 and the N substituent corresponding to the core 5 (P 5) is connected by, for example, the method described in the "General Preparation Methods" section below. In some aspects, in formula (1), R 5 can be independently selected from C 1~C 6 alkyl, C 1~C 6 haloalkyl, and C 3~C The benzyl group substituted by one or more groups selected from the group consisting of 8-cycloalkyl groups is preferably 4-cyclopropylbenzyl, 4-(trifluoromethyl)benzyl, 4-methylbenzyl or 4-ethylbenzyl. In some aspects, in formula (1), R 5 and R 1 together form a divalent group. The details of this group are as described above. In some cases, P 5 and R 4 together form a divalent group. The details of this group are as described above. In some cases, Q 5 is hydrogen. The side chain of core 5 (R 5) with the side chain of core 1 (R 1) together form a divalent group, and the N substituent of core 5 (P 5) with the side chain of core 4 (R 4) When forming a divalent group together, for example, R corresponding to ButenylPhe (4-CH=CH2) 5 and P The group at position 5 and the side chain corresponding to core 1 (R 1) and the side chain of core 4 (R 4) is connected using, for example, the method described in the "General Preparation Method" section below. 5) with the side chain of core 1 (R 1) does not form a divalent group, and the N substituent of core 5 (P 5) with the side chain of core 4 (R 4) When a divalent group is formed, for example, P corresponding to ButenylPhe(4-Et), ButenylPhe(4-cPr), or AllylPhe(4-CF3) The group at position 5 and the side chain corresponding to core 4 (R 4) The group at the position of is connected, for example, by the method described in the "General Preparation Method" section below. In some aspects, in formula (1), R 6 is hydrogen. In some cases, P 6 for C 1~C 6-alkyl, preferably methyl. In some cases, Q 6 is hydrogen. Specific examples of the amino acid residue of core 6 include MeGly. In some aspects, in formula (1), the 1~C 6 haloalkyl, and C 1~C The phenethyl group substituted by one or more groups selected from the group consisting of 6-alkoxy groups is preferably 3,5-difluoro-4-(trifluoromethyl)phenethyl, 3,4-dichlorophenethyl, or 3-methoxy-4-(trifluoromethyl)phenethyl. In some cases, P 7 is hydrogen. In some cases, Q 7 is hydrogen. Specific examples of the amino acid residue of core 7 include Hph(4-CF3-35-F2), Hph(34-Cl2), and Hph(4-CF3-3-OMe). In some aspects, in formula (1), R 8 and P 8. R 8-bonded carbon atoms, and P The 8-bonded nitrogen atoms can form a 4-7 membered saturated heterocyclic ring. 1~C The 6-membered saturated heterocyclic ring is preferably substituted by an alkoxy group, preferably an ethoxy group or an n-propoxy group. Specific examples of the 4- to 7-membered saturated heterocyclic ring include a pyrrolidine ring. In some cases, Q 8 is hydrogen. Specific examples of the amino acid residue of the core 8 include Hyp(Et) and Hyp(nPr). In some aspects, in formula (1), R 9 and Q 9. and R 9 and Q 9 bonded carbon atoms together form a 3 to 8 membered alicyclic ring. The 3 to 8 membered alicyclic ring can be formed through one or more C 1~C 6-membered alkyl, for example, 2 methyl groups. Specific examples of the 3- to 8-membered alicyclic ring include a cyclobutane ring and a cyclopentane ring. In some cases, P 9 is hydrogen or C 1~C 6-alkyl, preferably hydrogen or methyl. Specific examples of the amino acid residue of core 9 include cLeu, cVal, cVal(3-Me2), and MecVal. In some aspects, in formula (1), R 10 C 1~C 6 alkyl, or C 3~C 8-cycloalkyl, preferably pentan-3-yl or cyclopentyl. In some cases, P 10 C 1~C 6-alkyl, preferably methyl. In some cases, Q 10 For hydrogen. Specific examples of the amino acid residue of the core 10 include MeGly(cPent) and MeNva(3-Et). In some aspects, in formula (1), L 11 -CH 2-. In some aspects, in formula (1), R 11 For two C 1~C 6-membered alkylaminocarbonyl or 4- to 8-membered cyclic aminocarbonyl, preferably dimethylaminocarbonyl, N-ethyl-N-methylaminocarbonyl, pyrrolidinylcarbonyl or piperidinylcarbonyl. In some cases, P 11 C 1~C 6-alkyl, preferably methyl. In some cases, Q 11 For hydrogen. In some aspects, the compound of the present invention may be one or more selected from the group consisting of the following, or a salt thereof or a solvent thereof: PP1574: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-N-ethyl-27-isobutyl-N,4,19,22,26,32,35-heptamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecacyclo-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 ]Tetradec-38-ene-17,1'-cyclopentane]-23-carboxamide, PP1650: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-27-isobutyl-N,N,3',3',4,19,22,26,32,35-decamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecacyclo-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14]tetradec-38-ene-17,1'-cyclobutane]-23-carboxamide, PP1827: (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z,47E)-19-cyclopentyl-7-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-11-ethoxy-N-ethyl-N,3,18,21,25,31,34-heptamethyl-29-[(1S)-1-methylpropyl]-2,5,8,14,17,20,24,27,30,33,55-undecacyclo-spiro[3,6,9,15,18,21,25,28,31,34,41-undecaazapentacyclo[24.15.11.2 43,46 .1 35,41 .0 9,13 ]pentacarbonyl-37,43(54),44,46(53),47-pentaene-16,1'-cyclobutane]-22-carboxamide, PP1830: (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z,47E)-19-cyclopentyl-11-ethoxy-N-ethyl-7-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-N,3,3',3',18,21,25,31,34-nonamethyl-29-[(1S)-1-methylpropyl]-2,5,8,14,17,20,24,27,30,33,55-undecacyclo-spiro[3,6,9,15,18,21,25,28,31,34,41-undecacyclopentacyclo[24,15,11,2 43,46 .1 35,41 .0 9,13]pentacarbonyl-37,43(54),44,46(53),47-pentaene-16,1'-cyclobutane]-22-carboxamide, PP2093: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-32-cyclopropyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-N,N,3',3',4,19,22,26,35-nonamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecacyclo-27-propyl-2-(p-tolylmethyl)spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 ]tetradec-38-ene-17,1'-cyclobutane]-23-carboxamide, PP2260: (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z)-19-cyclopentyl-11-ethoxy-N-ethyl-7-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-N,3,3',3',18,21,25,31,34-nonamethyl-29-[(1S)-1-methylpropyl]-2,5,8,14,17,20,24,27,30,33,55-undecacyclo-spiro[3,6,9,15,18,21,25,28,31,34,41-undecaazapentacyclo[24.15.11.2 43,46 .1 35,41 .0 9,13 ]pentacarbonyl-37,43(54),44,46(53)-tetraene-16,1'-cyclobutane]-22-carboxamide, PP2316: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-32-cyclopropyl-12-ethoxy-8-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-N,N,4,16,19,22,26,35-octamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecacyclo-27-propyl-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14]tetradec-38-ene-17,1'-cyclobutane]-23-carboxamide, PP2320: (1S,4S,10S,13S,17S,20S,26S,28R,32S,38S,42Z)-20-cyclopentyl-28-ethoxy-32-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-N,N,2,14,18,21,24,36-octamethyl-10-[(1S)-1-methylpropyl]-3,9,12,15,19,22,25,31,34,37,45-undecacyclo-13-propyl-38-[[4-(trifluoromethyl)phenyl]methyl]spiro[2,8,11,14,18,21,24,30,33,36,39-undecaazatetracyclo[37.5.1.0 4,8 .0 26,30 ]pentadec-42-ene-23,1'-cyclobutane]-17-carboxamide, PP2328: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-32-cyclopropyl-12-ethoxy-8-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-N,N,4,16,19,22,26,35-octamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecacyclo-27-propyl-2-(p-tolylmethyl)spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 ]tetradec-38-ene-17,1'-cyclobutane]-23-carboxamide, PP2574: (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z,47E)-19-cyclopentyl-7-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-11-ethoxy-3,3',3',18,21,25,31,34-octamethyl-29-[(1S)-1-methylpropyl]-22-(pyrrolidine-1-carbonyl)spiro[3,6,9,15,18,21,25,28,31,34,41-undecaazapentacyclo[24.15.10.2 43,46 .1 35,41 .0 9,13]pentacontan-37,43(53),44,46(52),47-pentaene-16,1'-cyclobutane]-2,5,8,14,17,20,24,27,30,33,54-undecanone, PP2576: (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z,47E)-7-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-11-ethoxy-19-(1-ethylpropyl)-3,3',3',18,21,25,31,34-octamethyl-29-[(1S)-1-methylpropyl]-22-(pyrrolidine-1-carbonyl)spiro[3,6,9,15,18,21,25,28,31,34,41-undecaazapentacyclo[24.15.10.2 43,46 .1 35,41 .0 9,13 ]pentacontan-37,43(53),44,46(52),47-pentaene-16,1'-cyclobutane]-2,5,8,14,17,20,24,27,30,33,54-undecanone, PP2583: (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z,47E)-19-cyclopentyl-31-cyclopropyl-7-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-11-ethoxy-3,3',3',18,21,25,34-heptamethyl-29-[(1S)-1-methylpropyl]-22-(pyrrolidine-1-carbonyl)spiro[3,6,9,15,18,21,25,28,31,34,41-undecaazapentacyclo[24.15.10.2 43,46 .1 35,41 .0 9,13]pentacontan-37,43(53),44,46(52),47-pentaene-16,1'-cyclobutane]-2,5,8,14,17,20,24,27,30,33,54-undecanone, PP2687: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-12-ethoxy-2-[(4-ethylphenyl)methyl]-27-isobutyl-8-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-N,N,3',3',4,19,22,26,32,35-decamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecacyclo-1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 ]tetradec-38-ene-17,1'-cyclobutane]-23-carboxamide, PP2691: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-2-[(4-cyclopropylphenyl)methyl]-12-ethoxy-27-isobutyl-8-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-N,N,3',3',4,19,22,26,32,35-decamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecacyclo ... 10,14 ]tetradec-38-ene-17,1'-cyclobutane]-23-carboxamide, PP2957: (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z,47E)-31-cyclopropyl-7-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-11-ethoxy-19-(1-ethylpropyl)-3,18,21,25,34-pentamethyl-29-[(1S)-1-methylpropyl]-22-(pyrrolidine-1-carbonyl)spiro[3,6,9,15,18,21,25,28,31,34,41-undecaazapentacyclo[24.15.10.2 43,46 .1 35,41 .0 9,13]pentacontan-37,43(53),44,46(52),47-pentaene-16,1'-cyclobutane]-2,5,8,14,17,20,24,27,30,33,54-undecanone, PP3033: (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z)-19-cyclopentyl-11-ethoxy-7-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-3,18,21,25,31,34-hexamethyl-29-[(1S)-1-methylpropyl]-22-(piperidine-1-carbonyl)spiro[3,6,9,15,18,21,25,28,31,34,41-undecaazapentacyclo[24.15.11.2 43,46 .1 35,41 .0 9,13 ]pentacarbonyl-37,43(54),44,46(53)-tetraene-16,1'-cyclobutane]-2,5,8,14,17,20,24,27,30,33,55-undecanone, PP3034: (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z)-19-cyclopentyl-11-ethoxy-7-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-3,3',3',18,21,25,31,34-octamethyl-29-[(1S)-1-methylpropyl]-22-(pyrrolidine-1-carbonyl)spiro[3,6,9,15,18,21,25,28,31,34,41-undecaazapentacyclo[24,15,11,2 43,46 .1 35,41 .0 9,13 ]pentacarbonyl-37,43(54),44,46(53)-tetraene-16,1'-cyclobutane]-2,5,8,14,17,20,24,27,30,33,55-undecanone, PP3036: (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z)-19-cyclopentyl-11-ethoxy-7-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-3,3',3',18,21,25,31,34-octamethyl-29-[(1S)-1-methylpropyl]-22-(piperidine-1-carbonyl)spiro[3,6,9,15,18,21,25,28,31,34,41-undecaazapentacyclo[24.15.10.2 43,46 .1 35,41 .0 9,13 ]54-tetradecanoic acid-37,43(53),44,46(52)-tetraene-16,1'-cyclobutane]-2,5,8,14,17,20,24,27,30,33,54-undecanone, PP3037: (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z)-19-cyclopentyl-11-ethoxy-7-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-3,3',3',18,21,25,31,34-octamethyl-29-[(1S)-1-methylpropyl]-22-(pyrrolidine-1-carbonyl)spiro[3,6,9,15,18,21,25,28,31,34,41-undecaazapentacyclo[24.15.10.2 43,46 .1 35,41 .0 9,13 ]54-tetradecanoic acid-37,43(53),44,46(52)-tetraene-16,1'-cyclobutane]-2,5,8,14,17,20,24,27,30,33,54-undecanone, PP3047: (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z,47E)-7-[2-(3,4-dichlorophenyl)ethyl]-11-ethoxy-19-(1-ethylpropyl)-3,18,21,25,31,34-hexamethyl-29-[(1S)-1-methylpropyl]-22-(pyrrolidine-1-carbonyl)spiro[3,6,9,15,18,21,25,28,31,34,41-undecaazapentacyclo[24.15.11.2 43,46 .1 35,41 .0 9,13]pentacarbonyl-37,43(54),44,46(53),47-pentaene-16,1'-cyclobutane]-2,5,8,14,17,20,24,27,30,33,55-undecanone, PP3093: (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z)-19-cyclopentyl-11-ethoxy-7-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-3,3',3',18,21,25,31,34-octamethyl-29-[(1S)-1-methylpropyl]-22-(piperidine-1-carbonyl)spiro[3,6,9,15,18,21,25,28,31,34,41-undecaazapentacyclo[24.15.9.2 43,46 .1 35,41 .0 9,13 ]Fifty-three carbon-37,43(52),44,46(51)-tetraene-16,1'-cyclobutane]-2,5,8,14,17,20,24,27,30,33,53-undecanone, PP3094: (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z)-19-cyclopentyl-7-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-3,3',3',18,21,25,31,34-octamethyl-29-[(1S)-1-methylpropyl]-11-propoxy-22-(pyrrolidine-1-carbonyl)spiro[3,6,9,15,18,21,25,28,31,34,41-undecaazapentacyclo[24,15,9,2 43,46 .1 35,41 .0 9,13]Fifty-three carbon-37,43(52),44,46(51)-tetraene-16,1'-cyclobutane]-2,5,8,14,17,20,24,27,30,33,53-undecanone, PP3095: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-32-cyclopropyl-12-ethoxy-8-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-4,16,19,22,26,35-hexamethyl-30-[(1S)-1-methylpropyl]-23-(piperidine-1-carbonyl)-27-propyl-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 ]tetradec-38-ene-17,1'-cyclobutane]-3,6,9,15,18,21,25,28,31,34,42-undecanone, PP3096: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-32-cyclopropyl-12-ethoxy-8-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-4,16,19,22,26,35-hexamethyl-30-[(1S)-1-methylpropyl]-23-(piperidine-1-carbonyl)-27-propyl-2-(p-tolylmethyl)spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 ]tetradec-38-ene-17,1'-cyclobutane]-3,6,9,15,18,21,25,28,31,34,42-undecanone, PP3097: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-32-cyclopropyl-12-ethoxy-8-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-4,16,19,22,26,35-hexamethyl-30-[(1S)-1-methylpropyl]-27-propyl-23-(pyrrolidine-1-carbonyl)-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14]tetradec-38-ene-17,1'-cyclobutane]-3,6,9,15,18,21,25,28,31,34,42-undecanone, PP3098: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-32-cyclopropyl-12-ethoxy-8-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-4,16,19,22,26,35-hexamethyl-30-[(1S)-1-methylpropyl]-27-propyl-2-(p-tolylmethyl)-23-(pyrrolidine-1-carbonyl)spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 ]tetradec-38-ene-17,1'-cyclobutane]-3,6,9,15,18,21,25,28,31,34,42-undecanone, PP3099: (1S,4S,10S,13S,17S,20S,26S,28R,32S,38S,42Z)-20-cyclopentyl-28-ethoxy-32-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-2,14,18,21,24,36-hexamethyl-10-[(1S)-1-methylpropyl]-17-(piperidine-1-carbonyl)-13-propyl-38-[[4-(trifluoromethyl)phenyl]methyl]spiro[2,8,11,14,18,21,24,30,33,36,39-undecaazatetracyclo[37.5.1.0 4,8 .0 26,30 ]pentacontan-42-ene-23,1'-cyclobutane]-3,9,12,15,19,22,25,31,34,37,45-undecanone, PP3100: (1S,4S,10S,13S,17S,20S,26S,28R,32S,38S,42Z)-20-cyclopentyl-28-ethoxy-32-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-2,14,18,21,24,36-hexamethyl-10-[(1S)-1-methylpropyl]-17-(piperidine-1-carbonyl)-13-propyl-38-(p-tolylmethyl)spiro[2,8,11,14,18,21,24,30,33,36,39-undecaazatetracyclo[37.5.1.0 4,8 .0 26,30]pentadec-42-ene-23,1'-cyclobutane]-3,9,12,15,19,22,25,31,34,37,45-undecanone, PP3101: (1S,4S,10S,13S,17S,20S,26S,28R,32S,38S,42Z)-20-cyclopentyl-28-ethoxy-32-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-2,14,18,21,24,36-hexamethyl-10-[(1S)-1-methylpropyl]-13-propyl-17-(pyrrolidine-1-carbonyl)-38-[[4-(trifluoromethyl)phenyl]methyl]spiro[2,8,11,14,18,21,24,30,33,36,39-undecaazatetracyclo[37.5.1.0 4,8 .0 26,30 ]pentadec-42-ene-23,1'-cyclobutane]-3,9,12,15,19,22,25,31,34,37,45-undecanone, PP3102: (1S,4S,10S,13S,17S,20S,26S,28R,32S,38S,42Z)-20-cyclopentyl-28-ethoxy-32-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-2,14,18,21,24,36-hexamethyl-10-[(1S)-1-methylpropyl]-13-propyl-38-(p-tolylmethyl)-17-(pyrrolidine-1-carbonyl)spiro[2,8,11,14,18,21,24,30,33,36,39-undecaazatetracyclo[37.5.1.0 4,8 .0 26,30 ]pentadec-42-ene-23,1'-cyclobutane]-3,9,12,15,19,22,25,31,34,37,45-undecanone, PP3103: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-12-ethoxy-8-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-4,16,19,22,26,32,35-heptamethyl-30-[(1S)-1-methylpropyl]-23-(piperidine-1-carbonyl)-27-propyl-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14]tetradec-38-ene-17,1'-cyclobutane]-3,6,9,15,18,21,25,28,31,34,42-undecanone, PP3104: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-12-ethoxy-8-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-4,16,19,22,26,32,35-heptamethyl-30-[(1S)-1-methylpropyl]-23-(piperidine-1-carbonyl)-27-propyl-2-(p-tolylmethyl)spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 ]tetradec-38-ene-17,1'-cyclobutane]-3,6,9,15,18,21,25,28,31,34,42-undecanone, PP3105: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-12-ethoxy-8-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-4,16,19,22,26,32,35-heptamethyl-30-[(1S)-1-methylpropyl]-27-propyl-23-(pyrrolidine-1-carbonyl)-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 ]tetradec-38-ene-17,1'-cyclobutane]-3,6,9,15,18,21,25,28,31,34,42-undecanone, PP3106: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-12-ethoxy-8-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-4,16,19,22,26,32,35-heptamethyl-30-[(1S)-1-methylpropyl]-27-propyl-2-(p-tolylmethyl)-23-(pyrrolidine-1-carbonyl)spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14]tetradec-38-ene-17,1'-cyclobutane]-3,6,9,15,18,21,25,28,31,34,42-undecanone, PP3110: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-32-cyclopropyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-4,16,19,22,26,35-hexamethyl-30-[(1S)-1-methylpropyl]-23-(piperidine-1-carbonyl)-27-propyl-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 ]tetradec-38-ene-17,1'-cyclobutane]-3,6,9,15,18,21,25,28,31,34,42-undecanone, PP3111: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-32-cyclopropyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-4,16,19,22,26,35-hexamethyl-30-[(1S)-1-methylpropyl]-23-(piperidine-1-carbonyl)-27-propyl-2-(p-tolylmethyl)spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 ]tetradec-38-ene-17,1'-cyclobutane]-3,6,9,15,18,21,25,28,31,34,42-undecanone, PP3112: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-32-cyclopropyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-4,16,19,22,26,35-hexamethyl-30-[(1S)-1-methylpropyl]-27-propyl-23-(pyrrolidine-1-carbonyl)-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14]tetradec-38-ene-17,1'-cyclobutane]-3,6,9,15,18,21,25,28,31,34,42-undecanone, PP3113: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-32-cyclopropyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-4,16,19,22,26,35-hexamethyl-30-[(1S)-1-methylpropyl]-27-propyl-2-(p-tolylmethyl)-23-(pyrrolidine-1-carbonyl)spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 ]tetradec-38-ene-17,1'-cyclobutane]-3,6,9,15,18,21,25,28,31,34,42-undecanone, PP3114: (1S,4S,10S,13S,17S,20S,26S,28R,32S,38S,42Z)-20-cyclopentyl-32-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-28-ethoxy-2,14,18,21,24,36-hexamethyl-10-[(1S)-1-methylpropyl]-17-(piperidine-1-carbonyl)-13-propyl-38-[[4-(trifluoromethyl)phenyl]methyl]spiro[2,8,11,14,18,21,24,30,33,36,39-undecaazatetracyclo[37.5.1.0 4,8 .0 26,30 ]pentacontan-42-ene-23,1'-cyclobutane]-3,9,12,15,19,22,25,31,34,37,45-undecanone, PP3115: (1S,4S,10S,13S,17S,20S,26S,28R,32S,38S,42Z)-20-cyclopentyl-32-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-28-ethoxy-2,14,18,21,24,36-hexamethyl-10-[(1S)-1-methylpropyl]-17-(piperidine-1-carbonyl)-13-propyl-38-(p-tolylmethyl)spiro[2,8,11,14,18,21,24,30,33,36,39-undecaazatetracyclo[37.5.1.0 4,8 .0 26,30]pentacontan-42-ene-23,1'-cyclobutane]-3,9,12,15,19,22,25,31,34,37,45-undecanone, PP3116: (1S,4S,10S,13S,17S,20S,26S,28R,32S,38S,42Z)-20-cyclopentyl-32-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-28-ethoxy-2,14,18,21,24,36-hexamethyl-10-[(1S)-1-methylpropyl]-13-propyl-17-(pyrrolidine-1-carbonyl)-38-[[4-(trifluoromethyl)phenyl]methyl]spiro[2,8,11,14,18,21,24,30,33,36,39-undecaazatetracyclo[37.5.1.0 4,8 .0 26,30 ]pentacontan-42-ene-23,1'-cyclobutane]-3,9,12,15,19,22,25,31,34,37,45-undecanone, PP3117: (1S,4S,10S,13S,17S,20S,26S,28R,32S,38S,42Z)-20-cyclopentyl-32-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-28-ethoxy-2,14,18,21,24,36-hexamethyl-10-[(1S)-1-methylpropyl]-13-propyl-38-(p-tolylmethyl)-17-(pyrrolidine-1-carbonyl)spiro[2,8,11,14,18,21,24,30,33,36,39-undecaazatetracyclo[37.5.1.0 4,8 .0 26,30 ]pentacontan-42-ene-23,1'-cyclobutane]-3,9,12,15,19,22,25,31,34,37,45-undecanone, PP3118: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-4,16,19,22,26,32,35-heptamethyl-30-[(1S)-1-methylpropyl]-23-(piperidine-1-carbonyl)-27-propyl-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14]tetradec-38-ene-17,1'-cyclobutane]-3,6,9,15,18,21,25,28,31,34,42-undecanone, PP3119: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-4,16,19,22,26,32,35-heptamethyl-30-[(1S)-1-methylpropyl]-23-(piperidine-1-carbonyl)-27-propyl-2-(p-tolylmethyl)spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 ]tetradec-38-ene-17,1'-cyclobutane]-3,6,9,15,18,21,25,28,31,34,42-undecanone, PP3120: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-4,16,19,22,26,32,35-heptamethyl-30-[(1S)-1-methylpropyl]-27-propyl-23-(pyrrolidine-1-carbonyl)-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 ]tetradec-38-ene-17,1'-cyclobutane]-3,6,9,15,18,21,25,28,31,34,42-undecanone, PP3121: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-4,16,19,22,26,32,35-heptamethyl-30-[(1S)-1-methylpropyl]-27-propyl-2-(p-tolylmethyl)-23-(pyrrolidine-1-carbonyl)spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14]Tetradodec-38-ene-17,1'-cyclobutane]-3,6,9,15,18,21,25,28,31,34,42-undecanone, (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z,47Z)-19-cyclopentyl-7-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-11-ethoxy-N-ethyl-N,3,18,21,25,31,34-heptamethyl-29-[(1S)-1-methylpropyl]-2,5,8,14,17,20,24,27,30,33,55-undecacyclo-spiro[3,6,9,15,18,21,25,28,31,34,41-undecacyclopentacyclo[24,15,11,25,31,34-heptamethyl-29-[(1S)-1-methylpropyl] 43,46 .1 35,41 .0 9,13 ]pentacarbonyl-37,43(54),44,46(53),47-pentaene-16,1'-cyclobutane]-22-carboxamide, (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z,47Z)-19-cyclopentyl-11-ethoxy-N-ethyl-7-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-N,3,3',3',18,21,25,31,34-nonamethyl-29-[(1S)-1-methylpropyl]-2,5,8,14,17,20,24,27,30,33,55-undecacyclo-spiro[3,6,9,15,18,21,25,28,31,34,41-undecacyclopentacyclo[24,15,11,2 43,46 .1 35,41 .0 9,13 ]pentacarbonyl-37,43(54),44,46(53),47-pentaene-16,1'-cyclobutane]-22-carboxamide, (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z,47Z)-19-cyclopentyl-7-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-11-ethoxy-3,3',3',18,21,25,31,34-octamethyl-29-[(1S)-1-methylpropyl]-22-(pyrrolidine-1-carbonyl)spiro[3,6,9,15,18,21,25,28,31,34,41-undecaazapentacyclo[24.15.10.2 43,46 .1 35,41 .0 9,13 ]54-tetradecanoic acid-37,43(53),44,46(52),47-pentaene-16,1'-cyclobutane]-2,5,8,14,17,20,24,27,30,33,54-undecanone, (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z,47Z)-7-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-11-ethoxy-19-(1-ethylpropyl)-3,3',3',18,21,25,31,34-octamethyl-29-[(1S)-1-methylpropyl]-22-(pyrrolidine-1-carbonyl)spiro[3,6,9,15,18,21,25,28,31,34,41-undecaazapentacyclo[24.15.10.2 43,46 .1 35,41 .0 9,13 ]54-tetradecanoic acid-37,43(53),44,46(52),47-pentaene-16,1'-cyclobutane]-2,5,8,14,17,20,24,27,30,33,54-undecanone, (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z,47Z)-19-cyclopentyl-31-cyclopropyl-7-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-11-ethoxy-3,3',3',18,21,25,34-heptamethyl-29-[(1S)-1-methylpropyl]-22-(pyrrolidine-1-carbonyl)spiro[3,6,9,15,18,21,25,28,31,34,41-undecaazapentacyclo[24.15.10.2 43,46 .1 35,41 .0 9,13]54-tetradecanoic acid-37,43(53),44,46(52),47-pentaene-16,1'-cyclobutane]-2,5,8,14,17,20,24,27,30,33,54-undecanone, (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z,47Z)-31-cyclopropyl-7-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-11-ethoxy-19-(1-ethylpropyl)-3,18,21,25,34-pentamethyl-29-[(1S)-1-methylpropyl]-22-(pyrrolidine-1-carbonyl)spiro[3,6,9,15,18,21,25,28,31,34,41-undecaazapentacyclo[24,15,10.2 43,46 .1 35,41 .0 9,13 ]penta-37,43(53),44,46(52),47-penta-16,1'-cyclobutane]-2,5,8,14,17,20,24,27,30,33,54-undecanone, and (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z,47Z)-7-[2-(3 ,4-dichlorophenyl)ethyl]-11-ethoxy-19-(1-ethylpropyl)-3,18,21,25,31,34-hexamethyl-29-[(1S)-1-methylpropyl]-22-(pyrrolidine-1-carbonyl)spiro[3,6,9,15,18,21,25,28,31,34,41-undecazapentacyclo[24.15.11.2 43,46 .1 35,41 .0 9,13 ]pentacarbonyl-37,43(54),44,46(53),47-pentaene-16,1'-cyclobutane]-2,5,8,14,17,20,24,27,30,33,55-undecanone. These compounds may be included in the formula represented by the aforementioned formula (1). In some aspects, the compound of the present invention is preferably a compound represented by formula (2): [Chemical 18] In the formula,

[19] n、m、P 1. R 2. R 3. P 3. P 4. P 6. R 7. R 8. P 8. R 9. P 9. Q 9. R 10 、P 10 、R 11 , and P 11 The meanings are the same as those in the aforementioned formula (1). For example, compounds PP1827, PP1830, PP2260, PP2574, PP2576, PP2583, PP2957, PP3033, PP3034, PP3036, PP3037, PP3047, PP3093, and PP3094, as well as the following compounds, may be included in formula (2). (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z,47Z)-19-cyclopentyl-7-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-11-ethoxy-N-ethyl-N,3,18,21,25,31,34-heptamethyl-29-[(1S)-1-methylpropyl]-2,5,8,14,17,20,24,27,30,33,55-undecacyclo-spiro[3,6,9,15,18,21,25,28,31,34,41-undecacyclopentacyclo[24,15,11,25,31,34-heptamethyl-29-[(1S)-1-methylpropyl] 43,46 .1 35,41 .0 9,13 ]pentacarbonyl-37,43(54),44,46(53),47-pentaene-16,1'-cyclobutane]-22-carboxamide, (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z,47Z)-19-cyclopentyl-11-ethoxy-N-ethyl-7-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-N,3,3',3',18,21,25,31,34-nonamethyl-29-[(1S)-1-methylpropyl]-2,5,8,14,17,20,24,27,30,33,55-undecacyclo-spiro[3,6,9,15,18,21,25,28,31,34,41-undecacyclopentacyclo[24,15,11,2 43,46 .1 35,41 .0 9,13 ]pentacarbonyl-37,43(54),44,46(53),47-pentaene-16,1'-cyclobutane]-22-carboxamide, (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z,47Z)-19-cyclopentyl-7-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-11-ethoxy-3,3',3',18,21,25,31,34-octamethyl-29-[(1S)-1-methylpropyl]-22-(pyrrolidine-1-carbonyl)spiro[3,6,9,15,18,21,25,28,31,34,41-undecaazapentacyclo[24.15.10.2 43,46 .1 35,41 .0 9,13 ]54-tetradecanoic acid-37,43(53),44,46(52),47-pentaene-16,1'-cyclobutane]-2,5,8,14,17,20,24,27,30,33,54-undecanone, (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z,47Z)-7-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-11-ethoxy-19-(1-ethylpropyl)-3,3',3',18,21,25,31,34-octamethyl-29-[(1S)-1-methylpropyl]-22-(pyrrolidine-1-carbonyl)spiro[3,6,9,15,18,21,25,28,31,34,41-undecaazapentacyclo[24.15.10.2 43,46 .1 35,41 .0 9,13]54-tetradecanoic acid-37,43(53),44,46(52),47-pentaene-16,1'-cyclobutane]-2,5,8,14,17,20,24,27,30,33,54-undecanone, (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z,47Z)-19-cyclopentyl-31-cyclopropyl-7-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-11-ethoxy-3,3',3',18,21,25,34-heptamethyl-29-[(1S)-1-methylpropyl]-22-(pyrrolidine-1-carbonyl)spiro[3,6,9,15,18,21,25,28,31,34,41-undecaazapentacyclo[24.15.10.2 43,46 .1 35,41 .0 9,13 ]54-tetradecanoic acid-37,43(53),44,46(52),47-pentaene-16,1'-cyclobutane]-2,5,8,14,17,20,24,27,30,33,54-undecanone, (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z,47Z)-31-cyclopropyl-7-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-11-ethoxy-19-(1-ethylpropyl)-3,18,21,25,34-pentamethyl-29-[(1S)-1-methylpropyl]-22-(pyrrolidine-1-carbonyl)spiro[3,6,9,15,18,21,25,28,31,34,41-undecaazapentacyclo[24,15,10.2 43,46 .1 35,41 .0 9,13 ]penta-37,43(53),44,46(52),47-penta-16,1'-cyclobutane]-2,5,8,14,17,20,24,27,30,33,54-undecanone, and (1S,7S,11R,13S,19S,22S,26S,29S,35S,37Z,47Z)-7-[2-(3 ,4-dichlorophenyl)ethyl]-11-ethoxy-19-(1-ethylpropyl)-3,18,21,25,31,34-hexamethyl-29-[(1S)-1-methylpropyl]-22-(pyrrolidine-1-carbonyl)spiro[3,6,9,15,18,21,25,28,31,34,41-undecazapentacyclo[24.15.11.2 43,46 .1 35,41 .0 9,13 ]pentacarbonyl-37,43(54),44,46(53),47-pentaene-16,1'-cyclobutane]-2,5,8,14,17,20,24,27,30,33,55-undecanone In some aspects, the compound of the present invention is preferably a compound represented by formula (3): [Chemical 20] In formula (3), R 1 is C 1~C 7-alkyl; R 5 is available through the selection of C 1~C 6 alkyl, C 1~C 6 haloalkyl, and C 3~C Benzyl substituted by one or more groups selected from the group consisting of 8-cycloalkyl; [Chemical 21] n、m、P 1. R 2. R 3. P 3. P 4. P 6. R 7. R 8. P 8. R 9. P 9. Q 9. R 10 、P 10 、R 11 , and P 11The meanings are the same as those in formula (1). For example, the compounds PP1574, PP1650, PP2093, PP2316, PP2320, PP2328, PP2687, PP2691, PP3095, PP3096, PP3097, PP3098, PP3099, PP3100, PP3101, PP3102, PP3103, PP3104, PP3105, PP3106, PP3110, PP3111, PP3112, PP3113, PP3114, PP3115, PP3116, PP3117, PP3118, PP3119, PP3120, and PP3121 may be included in formula (3). In some aspects, the cyclic compounds of the present invention have high selectivity for KRAS. In some aspects, the cyclic compounds of the present invention selectively inhibit KRAS. Although not bound by a particular theory, R 4 and P The bivalent group formed by these two compounds interacts with His95 of KRAS, achieving high selectivity for KRAS. While there are three known RAS isoforms: HRAS, KRAS, and NRAS, His95 is unique to KRAS. Therefore, compounds that specifically interact with His95 of KRAS can inhibit KRAS with high selectivity over NRAS and / or HRAS. In the present invention, the sources of NRAS, HRAS, and KRAS are not particularly limited and can be derived from a variety of animals, including humans, mice, rats, rabbits, dogs, cats, cows, horses, pigs, goats, rhesus macaques, cynomolgus macaques, chimpanzees, and chickens. Human HRAS, KRAS, and NRAS are preferred. The amino acid sequence of human NRAS is shown in SEQ ID NO: 1, the amino acid sequence of human HRAS is shown in SEQ ID NO: 2, and the amino acid sequence of human KRAS is shown in SEQ ID NO: 3. In some aspects, the KRAS inhibitory activity of the cyclic compounds of the present invention is 3-fold greater than the NRAS inhibitory activity and / or HRAS inhibitory activity. In some aspects, the KRAS binding activity of the cyclic compounds of the present invention is 3-fold greater than the NRAS binding activity and / or HRAS binding activity. In some aspects, the KRAS inhibitory activity of the cyclic compounds of the present invention is 5-fold, 7-fold, 10-fold, 15-fold, or 20-fold greater than the NRAS inhibitory activity and / or HRAS inhibitory activity. In some aspects, the KRAS binding activity of the cyclic compounds of the present invention is 5-fold, 7-fold, 10-fold, 15-fold, or 20-fold greater than the NRAS binding activity and / or HRAS binding activity. In the present invention, the KRAS inhibitory activity relative to the NRAS inhibitory activity and / or HRAS inhibitory activity can be obtained from the ratio of the NRAS inhibitory activity and / or HRAS inhibitory activity of the cyclic compound of the present invention to the KRAS inhibitory activity of the cyclic compound of the present invention. As an example, the ratio is defined as [IC of the cyclic compound of the present invention against NRAS and / or HRAS] 50 value] divided by [IC value of the cyclic compound of the present invention for KRAS 50 value], when the value is large, it means that the KRAS inhibitory activity is large relative to the NRAS inhibitory activity and / or HRAS inhibitory activity, that is, the selective inhibitory activity of KRAS via the cyclic compound of the present invention is large. Conversely, when the value is small, it means that the KRAS inhibitory activity is small relative to the NRAS inhibitory activity and / or HRAS inhibitory activity, that is, the selective inhibitory activity of KRAS via the cyclic compound of the present invention is small. Furthermore, in the present invention, the binding activity against KRAS relative to the binding activity against NRAS and / or HRAS can be determined from the ratio of the binding activity against NRAS and / or HRAS of the cyclic compound of the present invention to the binding activity against KRAS. For example, if this ratio is defined as [KD value for NRAS and HRAS] divided by [KD for KRAS], a larger value indicates that the binding activity against KRAS is greater than the binding activity against NRAS and / or HRAS, i.e., the binding selectivity for KRAS relative to NRAS and / or HRAS is greater. Conversely, a smaller value indicates that the binding activity against KRAS is smaller than the binding activity against NRAS and / or HRAS, i.e., the binding selectivity for KRAS relative to NRAS and / or HRAS is smaller. In the present invention, "interaction" refers to non-covalent interactions such as electrostatic interactions (including ionic bonds, hydrogen bonds, and dipole interactions) and van der Waals interactions (including hydrophobic interactions). Examples include CH-π interactions, NH-π interactions, S-π interactions, cation-π interactions, and halogen-π interactions. The interactions described in the present invention may be permeable to other molecules such as water molecules or impermeable to other molecules such as water molecules, but impermeable to other molecules such as water molecules is preferred. In the present invention, whether the histidine residue at amino acid residue position 95 (denoted as His95 or H95) in the wild-type human KRAS protein interacts with the cyclic compound can be determined based on the interatomic distance between the non-hydrogen atoms of both parties (in the case of a bond through another molecule such as a water molecule, the interatomic distance between the non-hydrogen atoms of both parties in the other molecule is ignored). When the interatomic distance is 5.1 angstroms (Å) or less, the non-hydrogen atoms of both parties can be determined to be interacting. In some aspects, the interatomic distance between the two interacting non-hydrogen atoms can be, for example, 5.1 Å or less, 4.8 Å or less, 4.5 Å or less, 4.3 Å or less, 4.2 Å or less, 4.1 Å or less, 4.0 Å or less, 3.9 Å or less, or 3.7 Å or less. Alternatively, the interatomic distance can be 2.0 Å or more, 2.1 Å or more, or 2.5 Å or more. In the present invention, atomic distances can be measured, for example, by analyzing the three-dimensional structure of a complex of wild-type human KRAS protein and the cyclic compound of the present invention. Specifically, a crystal of the complex of wild-type human KRAS protein and the cyclic compound of the present invention is prepared. X-ray diffraction of the crystal is performed to obtain X-ray diffraction intensity data, such as space group and unit lattice. If the obtained X-ray diffraction intensity data is applied to programs for determining preliminary or refined structures known to those skilled in the art, such as Coot (Emsley, P. et al., 2010), Phenix (Adams, PD et al., 2010), Phaser (J. Appl. Cryst. 40: 658-674 (2007)), Refmac5 (Acta Cryst. D67: 355-467 (2011)), and ARP / wARP (Cohen, SX et al., 2008), the three-dimensional structure of the complex of wild-type human KRAS protein and the cyclic compound of the present invention can be determined. Once the three-dimensional structure of the complex of the wild-type human KRAS protein and the cyclic compound of the present invention can be identified, those skilled in the art can measure the interatomic distances using conventional methods. For example, molecular modeling or molecular simulation software programs such as Discovery Studio 2020 Client, MOE (Molecular Operating Environment), and Maestro can be used to read the structural information of the complex of the cyclic compound of the present invention and the wild-type human KRAS protein. The interatomic distances can be measured using a function imported into the software program (e.g., the Distance Monitor function in the case of Discovery Studio 2020 Client). In addition, the details of the conditions or criteria used by the software to determine whether there is an interaction can be confirmed in the manual, specification sheet, etc. included with the software (for example, when using Discovery studio 2020 Client, you can confirm the details of the conditions or criteria used to determine whether there is an interaction by opening the specification sheet webpage from the Help button, selecting "Receptor-Ligand Interactions tools", then selecting "Theory-Receptor-Ligand Interactions", and then selecting "Non-bond Interactions"). Crystals of a complex of human KRAS wild-type protein and the cyclic compound of the present invention can also be obtained by methods known to those skilled in the art. For example, a solution containing the cyclic compound of the present invention and a solution containing the human KRAS wild-type protein are mixed to obtain a complex of the human KRAS wild-type protein and the cyclic compound of the present invention. Crystals of the complex of human KRAS wild-type protein and the cyclic compound of the present invention can be prepared by subjecting the resulting complex to a crystallization method known to those skilled in the art, such as vapor diffusion, batch (macrobatch, microbatch), dialysis, or interdiffusion. Known vapor diffusion methods include the sitting drop method, the hanging drop method, and the sandwich drop method. Furthermore, wild-type human KRAS protein can also be obtained by methods known to those skilled in the art. For example, wild-type human KRAS protein can be produced using recombinant polypeptide expression methods using cells, but is not limited thereto. In one aspect, a nucleic acid encoding the wild-type human KRAS protein of the present invention is inserted into an appropriate expression vector, the vector is introduced into appropriate cells, the transformed cells are cultured, and the expressed protein is isolated and purified. Such a protein can also be expressed as a fusion protein with other proteins for purposes such as ease of purification. For example, methods for producing a protein as a fusion protein with maltose binding protein (Vector pMAL series sold by New England BioLabs, USA), as a fusion protein with glutathione S-transferase (GST) (Vector pGEX series sold by Amersham Pharmacia Biotech), as a histidine tag (pET series sold by Novagen), or as a HAT tag can be used. As host cells, as long as they are cells suitable for recombinant protein expression, there are no particular restrictions. In addition to the above-mentioned Escherichia coli, for example, yeast, a variety of plant and animal cells, insect cells, etc. can be used. Regarding the vector introduction of host cells, various methods known to those skilled in the art can be used. For example, the introduction of Escherichia coli can use an introduction method utilizing calcium ions (Mandel, M., Higa, A. (1970) Journal of Molecular Biology, 53, 158-162, Hanahan, D. (1983) Journal of Molecular Biology, 166, 557-580). The protein expressed in the host cell can be purified and collected from the host cell or its cell culture or culture supernatant via methods known to those skilled in the art. When the protein is expressed as a fusion protein with the above-mentioned maltose binding protein or HAT tag, affinity purification or gel filtration chromatography (size separation chromatography, SEC) purification can be easily performed. For affinity chromatography purification and SEC purification, an AKTAxpress (trademark) apparatus (GE Healthcare), an NGC (trademark) chromatography system (Bio-Rad), or a BioLogic DuoFlow (trademark) chromatography system (Bio-Rad) can be used. The energy between atoms can also be measured by methods commonly known to those skilled in the art. For example, a molecular simulation program commonly known to those skilled in the art, such as Discovery studio 2020 Client, MOE (Molecular Operating Environment), or Maestro, reads the three-dimensional structure of the substance being measured. According to the program's instructions, the force field used for the calculation (such as Amber, CHARM, etc.) and the atoms to be used for energy calculation can be easily calculated. For example, when using Discovery studio 2020 Client, the Calculate Interaction Energy function can be used to calculate the energy between atoms. In a non-limiting aspect, in the complex of the cyclic compound of the present invention and the human KRAS wild-type protein, the cyclic compound of the present invention interacts with His95 in the human KRAS wild-type protein. While not being bound by a particular theory, the fact that the cyclic compounds of the present invention form a complex with the wild-type human KRAS protein in this manner is presumably related to the contribution of the cyclic compounds of the present invention to the strong binding activity for the wild-type human KRAS protein and their binding selectivity relative to HRAS and NRAS. The present invention also relates to non-natural amino acids used to produce the cyclic compounds of the present invention. In some aspects, the non-natural amino acids of the present invention are N-protected non-natural amino acids used to produce peptide compounds using solid-phase synthesis methods. In other aspects, the non-natural amino acids of the present invention are non-natural amino acids having a free amino group obtained by removing the protecting group from the N-protected non-natural amino acid. Examples of N-protected non-natural amino acids include Fmoc, Boc, Cbz, Alloc, o-nitrobenzenesulfonyl (nosyl), dinitro-o-nitrobenzenesulfonyl, t-Bu, mesityl, and cumyl. Among these, Fmoc, Boc, Cbz, and Alloc are preferred, with Fmoc being more preferred. In some aspects, the N-protected non-natural amino acid having an Fmoc group as a protecting group of the present invention includes, for example, the following amino acids listed in Table 4, or salts thereof, or solvent complexes thereof. aa004: (2S)-2-[9H-fluoren-9-ylmethoxycarbonyl(methyl)amino]octanoic acid, aa013: (2R)-2-[9H-fluoren-9-ylmethoxycarbonyl(methyl)amino]-3-methylsulfhydryl-propionic acid, aa019: (2S)-2-[9H-fluoren-9-ylmethoxycarbonyl(methyl)amino]-4,4-difluoro-butanoic acid, aa023: (2S)-2-[9H-fluoren-9-ylmethoxycarbonyl(methyl)amino]-3-(3-thienyl)propionic acid, aa028: (2S)-3-(3,4-dichlorophenyl)-2-[9H-fluoren-9-ylmethoxycarbonyl(methyl)amino]propionic acid, aa043: (2S)-5,5-dichloro-2-[9H-fluoren-9-ylmethoxycarbonyl(methyl)amino]pentanoic acid, aa056: (2R)-3-[9H-fluoren-9-ylmethoxycarbonyl(methyl)amino]-2-methyl-propionic acid, aa098: (2S,3S)-1-(9H-fluoren-9-ylmethoxycarbonyl)-3-methyl-azetidine-2-carboxylic acid, aa099: (2S,3R)-1-(9H-fluoren-9-ylmethoxycarbonyl)-3-methyl-azetidine-2-carboxylic acid, aa100: (2S)-1-(9H-fluoren-9-ylmethoxycarbonyl)-3,3-dimethyl-azetidine-2-carboxylic acid, aa111: (2R)-3-allyloxy-2-[9H-fluoren-9-ylmethoxycarbonyl(methyl)amino]propanoic acid, aa136: (2S)-2-[9H-fluoren-9-ylmethoxycarbonyl(propyl)amino]-3-[4-(trifluoromethyl)phenyl]propanoic acid, aa174: (2S)-2-[9H-fluoren-9-ylmethoxycarbonyl(propyl)amino]-3-(p-tolyl)propanoic acid, aa210: (2S)-2-cyclopentyl-2-[ethyl(9H-fluoren-9-ylmethoxycarbonyl)amino]acetic acid, aa220: (2S)-4-(4-chloro-3,5-difluoro-phenyl)-2-(9H-fluoren-9-ylmethoxycarbonylamino)butanoic acid, aa229: (2S)-4-(Benzothiophene-5-yl)-2-(9H-fluoren-9-ylmethoxycarbonylamino)butanoic acid, aa233: (2S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-4-[3-methyl-4-(trifluoromethyl)phenyl]butanoic acid, aa235: (2S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-4-[3-methoxy-4-(trifluoromethyl)phenyl]butanoic acid, aa239: (2S,4S)-1-(9H-fluoren-9-ylmethoxycarbonyl)-4-methyl-pyrrolidine-2-carboxylic acid, aa244: (2S)-2-[9H-fluoren-9-ylmethoxycarbonyl(methyl)amino]-5,5-difluoro-pentanoic acid, aa246: (2S,4R)-1-(9H-fluoren-9-ylmethoxycarbonyl)-4-propoxy-pyrrolidine-2-carboxylic acid, aa250: (2R)-2-[9H-fluoren-9-ylmethoxycarbonyl(methyl)amino]-3-propoxy-propionic acid, aa264: (2S,3R)-1-(9H-fluoren-9-ylmethoxycarbonyl)-3-hydroxy-pyrrolidine-2-carboxylic acid, aa265: (2S,3S)-1-(9H-fluoren-9-ylmethoxycarbonyl)-3-hydroxy-pyrrolidine-2-carboxylic acid, aa268: (1S,2S,5R)-3-(9H-fluoren-9-ylmethoxycarbonyl)-3-azabicyclo[3.1.0]hexane-2-carboxylic acid, aa279: (2S,4R)-1-(9H-fluoren-9-ylmethoxycarbonyl)-4-tetrahydropyran-2-yloxy-pyrrolidine-2-carboxylic acid, aa281: (2S,4R)-1-(9H-fluoren-9-ylmethoxycarbonyl)-4-methoxy-pyrrolidine-2-carboxylic acid, aa331: (2S)-3-ethyl-2-[9H-fluoren-9-ylmethoxycarbonyl(methyl)amino]pentanoic acid. aa389: (2S)-2-[9H-fluoren-9-ylmethoxycarbonyl(propyl)amino]-4-methyl-pentanoic acid, aa391: (2S,3R)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-3-propoxy-butanoic acid, aa397: (2S)-2-[9H-fluoren-9-ylmethoxycarbonyl(propyl)amino]-3-isopentyloxy-propionic acid, aa398: (2S)-3-(cyclobutyloxy)-2-[9H-fluoren-9-ylmethoxycarbonyl(propyl)amino]propionic acid, aa399: (2S)-4-(7-chloro-1-methyl-indol-5-yl)-2-(9H-fluoren-9-ylmethoxycarbonylamino)butanoic acid, aa400: (2S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-4-(2-fluoro-3-methyl-benzothiophen-5-yl)butanoic acid, aa401: (2S)-4-(7-chlorobenzothiophen-5-yl)-2-(9H-fluoren-9-ylmethoxycarbonylamino)butanoic acid, aa402: (2S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-4-(1-methylindol-6-yl)butanoic acid, aa403: (2S)-4-(1,3-dimethylindol-6-yl)-2-(9H-fluoren-9-ylmethoxycarbonylamino)butanoic acid, aa404: (2S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-4-(1,2,3-trimethylindol-6-yl)butanoic acid, aa405: (2S)-4-(2,3-dimethylbenzothiophen-5-yl)-2-(9H-fluoren-9-ylmethoxycarbonylamino)butanoic acid, aa406: (2S)-4-(3-chloro-4-ethyl-phenyl)-2-(9H-fluoren-9-ylmethoxycarbonylamino)butanoic acid, aa407: (2S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-4-[4-(methoxymethyl)-3,5-dimethyl-phenyl]butanoic acid, aa408: (2S)-4-(4-chloro-3-methoxy-phenyl)-2-(9H-fluoren-9-ylmethoxycarbonylamino)butanoic acid, aa409: (2S)-4-[4-chloro-3-(trifluoromethyl)phenyl]-2-(9H-fluoren-9-ylmethoxycarbonylamino)butanoic acid, aa410: (2S)-4-[4-(difluoromethyl)-3,5-difluoro-phenyl]-2-(9H-fluoren-9-ylmethoxycarbonylamino)butanoic acid, aa411: (2S)-4-(4-chloro-3,5-dimethyl-phenyl)-2-(9H-fluoren-9-ylmethoxycarbonylamino)butanoic acid, aa414: (2S,4R)-4-(cyclopentyloxy)-1-(9H-fluoren-9-ylmethoxycarbonyl)pyrrolidine-2-carboxylic acid, aa415: (2S,4R)-4-(cyclobutoxy)-1-(9H-fluoren-9-ylmethoxycarbonyl)pyrrolidine-2-carboxylic acid, aa423: (3S)-3-cyclobutyl-3-[9H-fluoren-9-ylmethoxycarbonyl(methyl)amino]propanoic acid, aa424: (3R)-3-[9H-fluoren-9-ylmethoxycarbonyl(methyl)amino]pentanoic acid, aa425: (3S)-3-[9H-fluoren-9-ylmethoxycarbonyl(methyl)amino]-4-methyl-pentanoic acid, aa426: (3S)-3-cyclohexyl-3-[9H-fluoren-9-ylmethoxycarbonyl(methyl)amino]propanoic acid, and aa443: (2S)-2-[But-3-enyl(9H-fluoren-9-ylmethoxycarbonyl)amino]-3-(p-tolyl)propanoic acid. (General Preparation Methods) This section describes general methods for preparing the cyclic compounds of the present invention, as well as the oligopeptide compounds and unnatural amino acids used to prepare these compounds. In this specification, cyclic compounds may also be referred to as "cyclic peptide compounds." In this specification, the "cyclic portion" of a peptide compound refers to a cyclic portion formed by linking two or more amino acid residues. Chemical synthesis methods for peptide compounds or cyclic compounds described herein include, for example, liquid phase synthesis, solid phase synthesis using Fmoc synthesis or Boc synthesis, and combinations thereof. Fmoc synthesis involves protecting the main chain amino group with an Fmoc group, optionally protecting the side chain functional groups with a protecting group that is not cleaved by alkaline agents such as piperidine, such as t-Bu, THP, or Trt, and using an amino acid whose main chain carboxylic acid is not protected as the basic unit. Furthermore, the basic unit is not particularly limited as long as it comprises a combination of an Fmoc-protected amino group and a carboxyl group. For example, a dipeptide or tripeptide can be used as the basic unit, and the substituents on the nitrogen atoms contained in the dipeptide or tripeptide and / or the substituents with the side chains can form a cyclic structure. The basic unit located at the N-terminus can also be an amino acid other than an Fmoc amino acid. For example, it can be a Boc amino acid, a Tfa group, an Ns group, or a carboxylic acid analog without an amino group. The main-chain carboxyl group, or the side-chain carboxyl group of an amino acid with a carboxyl group protected by an appropriate protecting group, is supported on the solid phase through a chemical reaction with the functional groups of the solid support. The Fmoc group is then deprotected using a base such as piperidine or DBU, allowing a condensation reaction between the newly generated amine group and the protected amino acid with a carboxyl group of the subsequently added base unit to form a peptide bond. The condensation reaction can be performed using various combinations of carboxyl group activators, such as DIC and HOBt, DIC and HOAt, or HATU and DIPEA. By repeating the Fmoc group removal and subsequent peptide bond formation reactions, the desired peptide sequence can be generated. After obtaining the desired sequence, excision from the solid phase and deprotection of the protective groups of the side-chain functional groups, if necessary, are performed. Furthermore, prior to excision from the solid phase, the peptide can undergo structural transformation or cyclization. The cleavage from the solid phase and the deprotection can be carried out under the same conditions, for example, with 90:10 TFA / H Deprotection can be performed using 2O, and other deprotection conditions can be used as needed. If cleavage from the solid phase is also possible with weak acids such as 1% TFA, deprotection-capable protecting groups can be used with Pd catalysts, taking advantage of the orthogonality of the chemical reactions. Cyclization and other steps can also be performed between these steps or at the end. For example, a side chain carboxylic acid can be condensed with an amine group on the N-terminal main chain, or a side chain amine group can be condensed with a carboxylic acid group on the C-terminal main chain. Alternatively, an olefin can be introduced at two or more positions on the side chain and / or nitrogen atom substituents, and cyclization can be achieved via metathesis. Furthermore, the double bond generated by cyclization can be reduced to a single bond. Alternatively, the double bond generated by cyclization can be converted to a cyclopropane ring using conditions such as diiodomethane-diethylzinc. Furthermore, these cyclization, reduction, and conversion to a cyclopropane ring steps can also be performed during the steps of synthesizing the basic units of di- or tripeptides. Furthermore, orthogonality is essential between the carboxylic acid on the C-terminal side and the side chain carboxylic acid that is cyclized, between the main chain amine group or hydroxyl group on the N-terminal side and the side chain amine group that is cyclized, or between the olefin of the side chain and / or nitrogen atom substituent and the olefin that is cyclized. As described above, the orthogonality of the protecting group should be considered when selecting the protecting group. Alternatively, a chloroacetyl group can be added to the N-terminus to allow cyclization with the sulfhydryl group on the side chain of a cysteine ​​residue. The resulting reactant can be purified using a reverse phase column or molecular sieve column. Detailed descriptions of these are described, for example, in the Solid Phase Synthesis Handbook published by Merck Co., Ltd. on May 1, 2001. Commercially available resins for solid phase synthesis can be used, such as CTC resin, Wang resin, or SASRIN resin. The following is a general method for synthesizing amino acid-supported resins used in peptide synthesis using a peptide synthesizer. The loading of Fmoc amino acid on the resin can be carried out according to the method described in WO2013 / 100132 or WO2018 / 225864. Specifically, 2-chlorotrityl chloride resin and a solvent (e.g., dehydrated dichloromethane) are added to a reaction vessel equipped with a filter to swell the resin. Next, the solvent and the resin are separated, and then a mixture of the resin, the C-terminal free Fmoc amino acid dissolved in the solvent (e.g., dehydrated dichloromethane), the solvent (e.g., dehydrated methanol), and the base (e.g., diisopropylethylamine) is added to the reaction vessel and mixed to load the Fmoc amino acid on the resin. After separating the resin and the reaction solution, the resin is mixed with one or more solvents and a mixture of a base (e.g., a mixture of dehydrated dichloromethane, dehydrated methanol, and diisopropylethylamine), and the resin is washed. After washing the resin multiple times with a solvent (e.g., dichloromethane) as needed, the resin and the reaction solution are separated. The obtained resin is dried under reduced pressure overnight to obtain a resin loaded with Fmoc amino acid. [Chemical 22] (where n represents an integer from 1 to 11, P 1~P 11 , Q 1~Q 11 、R 1~R 11 Respectively represent P defined in this specification 1~P 11 , Q 1~Q 11 、R 1~R 11 , L 1 and L 11 Respectively represent L defined in this specification 1 and L 11 , L 2~L 10 ( ) represents a single bond, and 0 represents a resin site. ) Furthermore, the above structure shows that in Fmoc-amino acid, the 2-chlorotrityl group on the resin is bonded to the carboxylic acid of the Fmoc amino acid via an ester bond. In the manufacture of the compounds described in this specification, when the defined groups are subjected to undesirable chemical conversion under the conditions of the implementation method, the compound can be manufactured by using means such as protection and deprotection of functional groups. The selection of protecting groups and the decoupling operation here can be exemplified by the methods described in "Greene's, "Protective Groups in Organic Synthesis" (5th edition, John Wiley & Sons 2014)", which can be used appropriately depending on the reaction conditions. In addition, the order of reaction steps such as introduction of substituents can be changed as needed. For example, the protecting groups of amino groups are exemplified by Fmoc, Boc, Cbz, or Alloc groups. These carbamate groups can be introduced by reacting the amino groups in the presence of a carbamate-forming agent and an alkaline catalyst. Carbamate-forming agents can be exemplified by Boc 2O, BocOPh, FmocOSu, FmocCl, CbzCl, AllocCl, etc. Examples of alkaline catalysts include lithium carbonate, sodium carbonate, sodium bicarbonate, potassium carbonate, potassium bicarbonate, cesium carbonate, cesium bicarbonate, lithium hydroxide, sodium hydroxide, potassium hydroxide, cesium hydroxide, sodium phosphate, potassium phosphate, N-methylmorpholine, triethylamine, diisopropylethylamine, and N,N-dimethylaminopyridine. Carbamate groups, which serve as protecting groups for amino groups, can be removed under alkaline conditions, acidic conditions, or hydrolysis reaction conditions. (Synthesis of Cyclic Compounds by Cyclization of Peptide Compounds) The method for converting a linear peptide compound into a cyclic compound can be carried out by performing a bond-forming reaction within the molecule according to the method described in Comprehensive Organic Transformations, A Guide to Functional Group Preparations, 3rd Edition, by RC Larock, or March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 7th Edition, by MB March. After the bond-forming reaction, a functional group conversion reaction may be further performed. Examples of bond-forming reactions include the formation of a C(O)-N bond by carboxylic acid and an amine; a C(O)-C bond, a C(O)-O bond, and a C(S)-O bond using an oxygen atom; and a C(O)-S bond, a C(S)-S bond, a CSSC bond, a CSC bond, a CS(O)-C bond, and a CS(O)-S bond using a sulfur atom. 2) -C bond; CNC bond, C=NC bond, NC(O)-N bond, NC(S)N bond, C(S)-N bond, etc. utilizing nitrogen atoms. Furthermore, C-C bond formation reactions catalyzed by transition metals such as Suzuki reaction, Heck reaction, Sonogashira reaction, and metathesis reaction can be cited. As functional group conversion reactions carried out after the bond formation reaction, oxidation reactions or reduction reactions are exemplified. Specifically, a reaction in which a sulfur atom is oxidized to convert it into a sulfonyl group or a sulfonic acid group is exemplified. Another example is a reduction reaction in which a triple bond or double bond in a carbon-carbon bond is reduced to convert it into a double bond or a single bond. When two amino acids are bonded to the main chain of the amino acid, a closed ring structure is formed due to the peptide bond, but a covalent bond can also be formed between the two amino acids through bonds between the side chains of the two amino acids or between the side chains and the main chain. The black circles or black squares below represent amino acid residues, and connected black circles or black squares represent peptide chains connected by amide bonds. The number of amino acid residues constituting a peptide chain is not particularly limited, and the number of amino acid residues is not limited to the number of black circles or black squares shown below. (General Preparation Method 1 of Cyclic Compounds) [Chemical 23] The cyclic portion of the cyclic compound having a linear portion can be activated by activating the amino group at the N-terminus and the carboxyl group of the side chain at the C-terminus (for example, in the case of aspartic acid or its derivatives, L = -CH 2-, in the case of glutamate or its derivatives, L = -CH 2CH 2-) After activation or conversion to an active ester, an intramolecular condensation reaction occurs to form a C(O)-N bond and cyclize. (General Preparation Method 2 of Cyclic Compounds) [Chemical 24] In the cyclic compound described in the general preparation method 1 for cyclic compounds, the amino group at the N-terminus and the carboxyl group of the side chain at the C-terminus (for example, in the case of aspartic acid or its derivatives, L=-CH 2-, in the case of glutamate or its derivatives, L=-CH 2CH 2-) After activation or conversion to an active ester, an intramolecular condensation reaction can form a C(O)-N bond and cyclize. (General Preparation Method 3 of Cyclic Compounds) (Method of Cyclization with Haloalkyl and SH Groups) [Chemical 25] The cyclic portion of the cyclic compound having a straight-chain portion can be cyclized by reacting the haloalkyl group of the amino acid residue and the sulfhydryl group of the amino acid residue within the molecule to form a CSC bond. Similar to the cyclic compound in which the straight-chain portion described in the general preparation method 1 of the cyclic compound becomes a C-term, it can be cyclized by reacting the haloalkyl group of the amino acid residue and the sulfhydryl group of the amino acid residue within the molecule to form a CSC bond. Furthermore, the sulfur atom can also be oxidized to convert it into sulfone or sulfonic acid to form a CS(O)-C bond, ... 2)-C bond. (Method of cyclization of vinyl and SH groups) [Chemical 26] The cyclic portion of the cyclic compound having a straight chain portion can be cyclized by reacting the vinyl group of the amino acid residue and the sulfhydryl group of the amino acid residue in the molecule to form a CSC bond. The same as the cyclic compound in which the straight chain portion described in the general preparation method 1 of the cyclic compound becomes a C-term, the vinyl group of the amino acid residue and the sulfhydryl group of the amino acid residue can be cyclized by reacting in the molecule to form a CSC bond. Furthermore, the sulfur atom can also be oxidized to convert it into sulfone or sulfonic acid to form a CS(O)-C bond, ... 2)-C bond. (Method of cyclization with ethynyl and SH groups) [Chemical 27] The cyclic portion of the cyclic compound having a straight chain portion can be cyclized by reacting the acetylene group of the amino acid residue and the sulfhydryl group of the amino acid residue within the molecule to form a CSC bond. The same as the cyclic compound in which the straight chain portion described in the general preparation method 1 of the cyclic compound becomes a C-term, the acetylene group of the amino acid residue and the sulfhydryl group of the amino acid residue can be cyclized by reacting the acetylene group of the amino acid residue and the sulfhydryl group of the amino acid residue within the molecule to form a CSC bond. Furthermore, the sulfur atom can also be oxidized and converted into sulfone or sulfonic acid to form a CS(O)-C bond, ... 2) -C bond. Double bonds can also be reduced to single bonds. (Vinyl-vinyl cyclization method) [Chemical 28] The cyclic portion of a cyclic compound having a linear portion can be cyclized by reacting different vinyl groups of an amino acid residue intramolecularly to form a C-C bond. Similar to the cyclic compound having a linear portion as a C-terminal described in General Preparation Method 1 for Cyclic Compounds, cyclization can be achieved by reacting different vinyl groups of an amino acid residue intramolecularly to form a C-C bond. (Method of cyclization by forming a triazole ring with an azide group and an ethynyl group) [Chemical 29] The cyclic portion of a cyclic compound having a linear portion can be cyclized by reacting the azide group of an amino acid residue with the acetylene group of an amino acid residue intramolecularly to form a triazole ring. Similar to the cyclic compound described in General Preparation Method 1 for Cyclic Compounds in which the linear portion serves as the C-terminus, cyclization can be achieved by reacting the azide group of an amino acid residue with the acetylene group of an amino acid residue intramolecularly to form a triazole ring. The following shows the general preparation method of peptide compounds modified by peptides. n represents a substituent of a nitrogen atom, R n and Q n represents the side chain of an amino acid, black circles represent amino acid residues, connected black circles represent peptide chains connected by amide bonds, and m represents the number of amino acid residues and can be any integer greater than 1. (Method for Producing N-Alkylamino Acid-Containing Peptides) In addition to using Fmoc-protected N-alkylamino acids as starting materials and synthesizing them according to the general peptide synthesis method described in this example, peptides containing N-alkylamino acids can also be produced by alkylating the nitrogen at the N-terminus of the resin as shown in the following method. Specifically, the nitrogen at the N-terminus of the resin-supported peptide, Tfa amide (trifluoroacetamide), is reacted with an alkyl halide under alkaline conditions, followed by treatment with a reducing agent, as described in Organic Letters, 2008, 10, 4815-4818, to produce the target peptide having an N-alkylamino acid at its N-terminus. Furthermore, the general peptide synthesis method described in this example can be followed by peptide extension, excision from the resin, cyclization, deprotection, and purification to produce a cyclic compound. [Chemistry 30] The nitrogen at the N-terminus is introduced into the nAlternatively, the method described in Nature Protocols, 2012, 7, 432-444 as shown below can be used. Specifically, the amine at the N-terminus of the peptide supported on the resin is induced to be an Ns substituted product, and P is introduced into the peptide through the Mitsunobu reaction. n Then, the Ns group is deprotected to obtain the target with P at the N-terminus. n Furthermore, according to the general peptide synthesis method described in this example, a cyclic peptide compound can be produced by carrying out peptide elongation and cleavage from the resin, cyclization, deprotection, and purification. [Chemistry 31] As a nitrogen atom containing P n The peptide synthesis method of glycine, except for the use of Fmoc-protected nitrogen atom to introduce P n In addition to the method of synthesizing the peptide according to the general peptide synthesis method described in this example, the peptide can be produced by the displacement reaction of the N-terminal halogenated carbon and amine as shown in the following method. Specifically, with reference to Organic Letters, 2010, 12, 4928-4931, etc., the target peptide having a P-terminal nitrogen atom introduced therein can be obtained by reacting iodoacetic acid with an amine at the N-terminal. n Furthermore, according to the general peptide synthesis method described in this example, a cyclic peptide compound can be produced by carrying out peptide elongation and cleavage from the resin, cyclization, deprotection, and purification. [Chemistry 32] (Method for Producing Peptides Containing Aryloxy or Heteroaryloxy Groups in Side Chains) In addition to using an Fmoc amino acid containing the desired aryloxy or heteroaryloxy group in its side chain as a starting material and following the general peptide synthesis method described in this example, peptides containing an alcohol group in its side chain can be produced using the following method as a precursor, as described in Organic Letters, 2014, 16, 4944-4947 or Tetrahedron Letters, 2003, 44, 3863-3865. Specifically, a peptide containing an alcohol group in its side chain is reacted with a triarylboroxane-pyridine complex in the presence of copper(II) acetate to produce a peptide containing an aryloxy or heteroaryloxy group in its side chain. [Chemistry 33] Peptides having ether groups other than aryloxy or heteroaryloxy groups in their side chains can be produced using the general peptide synthesis method described in this example using an Fmoc amino acid having the target ether group in its side chain as a starting material. Alternatively, peptides having an alcohol in their side chain as a precursor can be produced using the method described in the following method, with reference to the method described in Journal of Medicinal Chemistry, 2011, 54, 4815-4830, or the method described in Journal of Medicinal Chemistry, 2014, 57, 159-170. Specifically, peptides having the target ether group in their side chains can be produced by reacting an alcohol-containing peptide with an alkyl halide in the presence of silver (I) oxide, or by reacting an alkyl halide with an aqueous sodium hydroxide base in the presence of a phase transfer catalyst, such as a tetraalkylammonium salt. [Chemistry 34] (Method for producing peptides containing aryl or heteroaryl groups on the side chain) In addition to using an Fmoc amino acid having the target aryl or heteroaryl group on the side chain as a raw material and following the general peptide synthesis method described in this example, peptides containing carboxylic acid on the side chain can be produced using the following method as a precursor, as described in J. Am. Chem. Soc., 2016, 138, 5016-5019. Specifically, a peptide containing carboxylic acid on the side chain is activated with N-hydroxyphthalimide and reacted with any aryl halide or heteroaryl halide to produce a peptide containing the target aryl or heteroaryl group on the side chain. [Chemistry 35] Furthermore, peptide compounds with cross-linked peptide backbones can be produced using peptides having nitrogen substituents and / or carboxylic acid side chains, or having other nitrogen substituents and / or aryl halides or heteroaryl halides on their side chains. Specifically, peptides with carboxylic acid are activated with N-hydroxyphthalimide and cross-linked by reaction with aryl halides or heteroaryl halides within the molecule, thereby producing cross-linked compounds. [Chemistry 36] As another method for producing peptides with aryl or heteroaryl side chains, a peptide with a boronic acid side chain can be synthesized using the Suzuki coupling reaction as a precursor, as shown in the following method. Specifically, a precursor peptide is synthesized using an Fmoc amino acid with a boronic acid side chain as a raw material, and then reacted with an arbitrary aryl halide in the presence of a palladium catalyst to produce the target peptide with an aromatic ring on the side chain. [Chemistry 37] Furthermore, peptide compounds with cross-linked peptide backbones can be produced by using peptides with nitrogen substituents and / or boronic acid side chains, or with substituents on other nitrogen atoms within the molecule and / or aryl halides on the side chains. Specifically, cross-linking can be achieved by reacting the boronic acid-containing peptide with an intramolecular aryl halide in the presence of a palladium catalyst. [Chemical 38] Furthermore, peptides having nitrogen atom substituents and / or olefins on their side chains, substituents on other nitrogen atoms within the molecule, and / or aryl halides on their side chains can be used to produce peptide compounds cross-linked with arylene-containing alkylene groups. Specifically, cross-linking can be produced by converting the olefin into a boron compound through a hydroboration reaction, followed by a reaction with an aryl halide within the molecule in the presence of a palladium catalyst. [Chemistry 39] (Method for producing peptides containing an amide group on the side chain) In addition to synthesizing peptides containing an amide group on the side chain using an Fmoc amino acid containing the target amide group on the side chain as a raw material, peptides containing a carboxylic acid on the side chain can also be synthesized by amidation using a peptide containing a carboxylic acid on the side chain as a precursor as shown in the following method. Specifically, a peptide containing a protected carboxylic acid on the side chain is deprotected to synthesize a precursor peptide containing a carboxylic acid on the side chain. This is then condensed with an arbitrary amine using HATU or the like as a condensing agent to obtain a peptide containing an amide group on the side chain. [Chemistry 40] Furthermore, peptide compounds with cross-linked peptide backbones can be produced using peptides having substituents on nitrogen atoms and / or carboxylic acid on their side chains, and substituents on other nitrogen atoms within the molecule and / or amine groups on their side chains. Specifically, deprotection is performed to synthesize a precursor peptide having carboxylic acid and amine groups, which is then condensed using a condensing agent such as HATU to form cross-linked peptides via an intramolecular amidation reaction. [Chemical 41] (Synthesis of highly substituted peptides containing side chains that may contain double bonds) In addition to using Fmoc amino acids containing double bonds in the target side chains as starting materials, peptides containing highly substituted peptides can also be produced by functionalizing terminal olefins. Specifically, according to the general peptide synthesis method described in this example, a peptide containing a terminal olefin in the side chain is synthesized and then coupled with a substrate containing any terminal olefin through olefin metathesis to convert it into a side chain containing a highly substituted olefin. Further reduction of the olefin through hydrogenation can also convert it into the corresponding side chain. [Chemistry 42] Furthermore, peptide compounds with cross-linked peptide backbones can be produced using peptides with nitrogen atom substituents and / or side chains having multiple double bonds. Specifically, peptides with nitrogen atom substituents and / or olefins at two positions on the side chains can be synthesized according to the general peptide synthesis method described in this example. The olefins at two positions can then be cross-linked via an olefin metathesis reaction, as described in Nature Protocols, 2011, 6, 761-771, to produce cross-linked compounds. Furthermore, compounds cross-linked via saturated alkylene groups can be produced by reducing the olefins via hydrogenation. [Chemical 43] Furthermore, as the cross-linked compound, a peptide containing a nitrogen atom substituent and / or an aryl group with an olefin-containing substituent on the side chain can be used to produce a cross-linked peptide compound via a divalent group containing an aryl group and a double bond. Specifically, according to the general peptide synthesis method described in this example, a peptide containing an olefin and / or an aryl group with an olefin on the side chain is synthesized, and the olefins at two positions are cross-linked through an olefin metathesis reaction to produce a cross-linked compound. The olefin is then reduced through a hydrogenation reaction to produce a compound cross-linked through an alkylene group containing an aryl group. [Chemical 44] (Synthesis of Peptides Containing a Triazole Group on the Side Chain) Peptides containing a triazole group on the side chain can be produced through a click reaction with an azide group. Specifically, a peptide containing an azide group on the side chain is synthesized according to the general peptide synthesis method described in this example. Furthermore, referring to Bioorganic & Medicinal Chemistry Letters, 2009, 19, 4130-4133, a peptide compound containing an azide group on the side chain can be produced by coupling with any acetylene in the presence of copper (I) iodide. [Chemistry 45] Furthermore, peptide compounds with cross-linked peptide backbones can be produced using peptides having nitrogen substituents and / or azide groups on their side chains, substituents on other nitrogen atoms within the molecule, and / or acetylene groups on their side chains. Specifically, cross-linking can be achieved by reacting the azide-containing peptide with acetylene within the molecule in the presence of a palladium catalyst. [Chemical 46] (Synthesis of Peptides Containing Alkynyl-Substituted Aryl Groups on the Side Chain) Peptides containing alkynyl-substituted aryl groups on the side chain can be synthesized via a Sonogashira coupling reaction with halogenated aryl groups. Specifically, a peptide containing iodinated aryl groups on the side chain is synthesized according to the general peptide synthesis method described in this example. This peptide is then coupled with any acetylene in the presence of copper (I) iodide to convert it into a peptide compound containing alkynyl-substituted aryl groups on the side chain. [Chemistry 47] Furthermore, peptide compounds with cross-linked peptide backbones can be produced using peptides having nitrogen atom substituents and / or halogenated aryl groups on their side chains, or having substituents on other nitrogen atoms within the molecule and / or acetylene groups on their side chains. Specifically, cross-linking can be achieved by coupling a peptide having an iodinated aryl group with an acetylene group within the molecule in the presence of copper (I) iodide. [Chemical 48] (General Preparation Method of Oligopeptide Compounds) The following is a general preparation method of oligopeptides in which the substituents on the nitrogen atom form a cyclic structure with the side chain. 1 and PG 1' represents the protecting group of nitrogen atom, PG 2 and PG 2' represents a protective group for oxygen atoms, R n-1 、R n 、R n+1 , Q n Represents the side chain of amino acid, P n-1 、P n 、P n+1 represents a substituent of a nitrogen atom, Y 1 and Y 2 represents hydrogen, halogen or alkyl. The manufacturing method of amino acid shown below has the situation that chemical reaction occurs outside the target functional group. In such a case, by introducing a protecting group in a non-target functional group, only the desired reaction can be carried out. The debonding reaction of such a protecting group can be cited by the method recorded in "Greene's, " Protective Groups in Organic Synthesis" (5th edition, John Wiley & Sons 2014)". The transformation reaction of the functional group of the compound can refer to Larock's Comprehensive Organic Transformations: A Guide to Functional Group Preparations (5th edition), Smith's March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure (8th edition) and the like. Oligopeptide compounds in which the substituents on the nitrogen atom of an amino acid form a cyclic structure with the side chains of other amino acids can be synthesized using the following method. For protected amino acids, an alkylating agent having an alkene can be allowed to act in the presence of a base to introduce an alkyl group having an alkene. Subsequently, by condensing any amino acid with a C-terminal protection, any amino acid can be extended on the C-terminal side. The condensation reaction can use various combinations such as a combination of DIC and HOBt, a combination of DIC and HOAt, and a combination of HATU and DIPEA as a carboxyl group activator. Next, after deprotecting the protecting group on the nitrogen atom, the protected amino acid having an alkene side chain can be extended. Subsequently, the alkene in the molecule can be cyclized through a metathesis reaction. Subsequently, by deprotecting the protecting group on the C-terminal, a C-terminal free oligopeptide compound can be produced, which forms a cyclic structure having a double bond between the substituent on the nitrogen atom and the side chain. [Chemistry 49] Furthermore, oligopeptide compounds having a cyclic structure containing a double bond can be used to produce oligopeptide compounds having a cyclic structure in which the double bond is converted to a single bond. Specifically, by reducing the C-terminal protected compound having a cyclic structure containing a double bond through a hydrogenation reaction, and then deprotecting the C-terminal protecting group, an oligopeptide compound can be produced in which the C-terminal is free and the cyclic structure is formed between the nitrogen atom substituent and the side chain via an alkylene group. [Chemistry 50] Furthermore, using oligopeptide compounds that form a cyclic structure containing a double bond, oligopeptide compounds having a cross-linked structure in which the double bond is converted to a cyclopropane ring can be produced. Specifically, the C-terminal protected compound that forms a cyclic structure containing a double bond can be converted to a cyclopropane ring under conditions such as diiodomethane-diethylzinc. Subsequently, by deprotecting the C-terminal protecting group, an oligopeptide compound having a cross-linked structure in which the double bond is converted to a cyclopropane ring can be produced. [Chemistry 51] Oligopeptide compounds in which the substituents on the nitrogen atom of an amino acid form a cyclic structure with the side chains of other amino acids can also be synthesized using the following method. For protected amino acids, oxazolidinone compounds with introduced cyclic protective groups can be obtained by reacting them with aldehydes according to the method of Freidinger et al. (J. Org. Chem., 1983, 48(1), 77-81). Subsequently, an alkyl group with an alkene can be introduced onto the nitrogen atom by a ring-opening reaction using a silicon compound with an alkene according to the method of Nguyen et al. (Synthesis, 2009, 12, 1991). Subsequently, any amino acid with a protected C-terminus can be extended by condensing it. Subsequently, the protected amino acid with an alkene in its side chain can be extended by deprotecting the nitrogen atom's protecting group. Subsequently, the alkene in the molecule can be cyclized by a metathesis reaction. Then, by deprotecting the C-terminal protecting group, a C-terminal free oligopeptide compound can be produced, which forms a cyclic structure containing a double bond between the substituent group on the nitrogen atom and the side chain. [Chemistry 52] Oligopeptides containing an aryl group substituted with an alkenyl group (y = 0-2) on the side chain can be synthesized via a Suzuki coupling reaction with a boron compound containing a halogenated aryl group and an alkenyl group. Specifically, according to the general oligopeptide synthesis method described in this example, a peptide containing an iodinated aryl group on the side chain is synthesized and then coupled with a boron compound containing any alkenyl group in the presence of a palladium catalyst to convert it into an oligopeptide compound containing an aryl group substituted with an alkenyl group (y = 0-2) on the side chain. [Chemistry 53] Oligopeptide compounds in which the substituents on the nitrogen atom of an amino acid and the side chains of other amino acids form a cyclic structure via an amide bond can be synthesized using the following method. Specifically, according to the general synthesis method described in this example, a peptide with a protected C-terminus is synthesized, the N-terminus is deprotected, and then a reductive amination reaction with an aldehyde compound containing an amino group with a protected group can be performed to introduce an amino group with a protected group on the N substituent. Subsequently, after condensation with a protected amino acid containing a carboxyl group with a protected group on the side chain, the protecting groups of the carboxyl and amino groups are removed, and then condensation is carried out intramolecularly. By deprotecting the C-terminus, the peptide is converted into an oligopeptide compound in which the substituents on the nitrogen atom of the amino acid and the side chains of other amino acids form a cyclic structure via an amide bond. [Chemistry 54] (Cyclization method of peptide compounds on resin) In addition to being cyclized according to the method described in this example, cyclic compounds and oligopeptide compounds having a cyclic structure can be cyclized via a metathesis reaction on a resin as shown below. Specifically, according to the general peptide synthesis method described in this example, a peptide having a nitrogen atom substituent and / or an olefin at two positions in the side chain is synthesized, and as a peptide supported on a resin, the olefin at the two positions is cyclized via a metathesis reaction to produce a compound having a cyclic structure. Furthermore, according to the general peptide synthesis method described in this example, the peptide is extended and cut from the resin, cyclized, deprotected, and purified to produce cyclic compounds and oligopeptide compounds having a cyclic structure. [Chemistry 55] (General preparation of non-natural amino acids) The following shows a general preparation of non-natural amino acids with protected C-terminal amino acids. 1 and PG 1' represents the protecting group of nitrogen atom, PG 2 and PG 2' represents the protective group of oxygen atom, PG 3 and PG 4 represents the protecting group of the amino acid side chain, R n and Q n Represents the side chain of amino acid, P n represents a substituent of a nitrogen atom, P' represents C 1-C 5 alkyl, R, R', R'', R''' respectively represent a substituent of hydrogen or an amino group. In the manufacturing method of the amino acid shown below, there is a case where a chemical reaction occurs outside the target functional group. In such a case, it is possible to introduce a protecting group into a non-target functional group and only carry out the desired reaction. The debonding reaction of such a protecting group can be cited, for example, by the method described in "Greene's, "Protective Groups in Organic Synthesis" (5th edition, John Wiley & Sons 2014)". The conversion reaction of the functional group of the compound can be referred to in Larock's Comprehensive Organic Transformations: A Guide to Functional Group Preparations (5th edition) or Smith's March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure (8th edition). Regarding the introduction of protective groups (PG 1) The following method can be used to produce the non-natural amino acid. The target C-terminal free non-natural amino acid can be produced by performing a protecting group introduction reaction and, if necessary, a deprotection reaction on the N-terminal free amino acid purchased from a commercial supplier according to a standard. [Chemistry 56] Regarding the introduction of protective groups (PG The following method can be used to produce non-natural amino acids. A protective group (PG 1) amino acid, according to the established rules, deprotection reaction and protecting group introduction reaction can produce the target C-terminal free non-natural amino acid. [Chemistry 57] The substituents on the nitrogen atoms of amino acids (P n ) can be produced by the following method. A bromoacetate derivative available from a commercial supplier is reacted with an amine alcohol according to the method of King et al. (Tetrahedron Letters, 2002, 43(11), 1987-1990), and then a protecting group (PG) is introduced at the nitrogen atom. 1). After oxidation of the hydroxyl group according to the method of Dess et al. (J. Org. Chem., 1983, 48(22), 4155-4156), a reductive amination reaction is performed on the aldehyde group according to the method of Borch et al. (J. Org. Chem. 1972, 37(10), 1673-1674) to introduce an amino group. Subsequently, by deprotecting the protective group of the oxygen atom, the target C-terminal free unnatural amino acid can be produced. [Chemistry 58] N-substituted amino acids can also be synthesized by introducing a substituent (P n ) is prepared by the following scheme. In the presence of a base, a bromoacetate derivative and an amine (P n NH 2) reaction, then introduce a protecting group (PG) on the nitrogen atom 1). Then, by deprotecting the oxygen atom's protecting group, the target C-terminal free non-natural amino acid can be produced. [Chemistry 59] Introducing -CH 2-P'-based unnatural amino acids can be produced according to the following scheme. According to the method of Freidinger et al. (J. Org. Chem., 1983, 48(1), 77-81), a C-terminal free amino acid available from a commercial supplier is reacted with an aldehyde to obtain an oxazolidinone compound with an introduced cyclic protecting group. Subsequently, a ring-opening reaction is performed to produce the desired C-terminal free unnatural amino acid. [Chemistry 60] Introducing P into the nitrogen atom of the amino acid n The non-natural amino acid of the present invention can be prepared according to the following scheme. By reacting a commercially available C-terminal free amino acid with an alkylating agent (P n -X) function, can import P n Then, according to the established rules, a deprotection reaction and a protecting group introduction reaction are carried out to produce a non-natural amino acid with a free C-terminus. [Chemistry 61] Unnatural amino acids with an amide group introduced into the side chain of an amino acid can be produced according to the following scheme. Commercially available protected amino acids (n = 1 or 2) are deprotected and the resulting carboxylic acid reacts with an amine (R''R'''NH) to introduce an amide group into the side chain. Subsequently, the C-terminal protecting group is deprotected to produce an unnatural amino acid with a free C-terminus. [Chemistry 62] Introducing an amide group into the side chain of an amino acid and -CH into the nitrogen atom of an amino acid 2-P'-based unnatural amino acids can be produced according to the following scheme. According to the method of Freidinger et al. (J. Org. Chem., 1983, 48(1), 77-81), a commercially available protected amino acid (n = 1 or 2) is reacted with an aldehyde to obtain an oxazolidinone compound with an introduced cyclic protective group. Subsequently, after deprotecting the side chain protective group, an amine (R''R'''NH) is reacted to obtain an amide compound. Subsequently, a ring-opening reaction is performed to produce the target C-terminal free unnatural amino acid. [Chemistry 63] Non-natural amino acids with an amino group introduced into the side chain of an amino acid can be produced according to the following scheme. An amide group can be introduced into the side chain by reacting the carboxyl group of a commercially available protected amino acid (n=1 or 2) with an amine (R''R'''NH). Subsequently, a reduction reaction is performed according to the method of Reeves et al. (Advanced Synthesis & Catalysis, 2013, 355(1), 47-52), and then the C-terminal protecting group is deprotected to produce a non-natural amino acid with a free C-terminus. [Chemistry 64] Introducing an amine group into the side chain of an amino acid and -CH into the nitrogen atom of an amino acid 2-P'-based unnatural amino acids can be produced according to the following scheme. The carboxyl group of an amino acid (n = 1 or 2) protected by a cyclic protecting group is reacted with an amine (R''R'''NH) to introduce an amide group into the side chain. Then, according to the method of Reeves et al. (Advanced Synthesis & Catalysis, 2013, 355(1), 47-52), a reduction reaction is carried out, followed by a ring-opening reaction, to produce the target unnatural amino acid with a free C-terminus. [Chemistry 65] Unnatural amino acids with a fluoroalkyl group introduced into the side chain of an amino acid can be produced according to the following scheme. The carboxyl group of a commercially available protected amino acid (n=1 or 2) is reduced according to a standard and converted into an aldehyde group. Subsequently, a fluorine atom is introduced according to a standard to convert the aldehyde group into a difluoromethyl group. Subsequently, the C-terminal protecting group is deprotected to produce an unnatural amino acid with a free C-terminus. [Chemistry 66] Production of alkyl halide introduced into the amino acid side chain and -CH The method for producing a 2-P'-based unnatural amino acid can be carried out according to the following scheme. The carboxyl group of an amino acid (n = 1 or 2) protected by a cyclic protective group is reduced according to a prescribed method to convert it into an aldehyde group. Then, a halogen atom is introduced according to a prescribed method to convert the aldehyde group into a dihalogenated methyl group. Subsequently, the cyclic protective group at the C-terminus is ring-opened to produce an unnatural amino acid with a free C-terminus. [Chemistry 67] Alternatively, a halogenated alkyl group may be introduced into the side chain of an amino acid, and a -CH group may be introduced into the nitrogen atom of the amino acid. A free non-natural amino acid at the C-terminus of the 2-P' group. [Chemistry 68] Non-natural amino acids that introduce an aryl or heteroaryl group (in the scheme, these groups are referred to as "Ar") into the side chain of an amino acid can be produced according to the following scheme. The carboxyl group of a protected amino acid (n = 1 or 2) is allowed to react with N-hydroxyphthalimide (NHPI) to introduce an NHPI group into the side chain. According to the method of Huihui et al. (J. Am. Chem. Soc., 2016, 138(15), 5016-5019), an aryl or heteroaryl group is introduced by reacting an aryl halide or heteroaryl halide to produce a non-natural amino acid having an arylalkyl or heteroarylalkyl group in the side chain. Subsequently, the protecting group at the C-terminus is deprotected to produce a non-natural amino acid with a free C-terminus. [Chemistry 69] An aryl or heteroaryl group (in the scheme, these groups are referred to as "Ar") is introduced into the side chain of the amino acid, and a -CH 2-P'-based non-natural amino acids can be produced according to the following scheme. The carboxyl group of an amino acid (n = 1 or 2) protected by a cyclic protective group is reacted with N-hydroxyphthalimide (NHPI) to introduce an NHPI group into the side chain. According to the method of Huihui et al. (J. Am. Chem. Soc., 2016, 138(15), 5016-5019), an aryl or heteroaryl group is introduced by reacting an aryl halide or heteroaryl halide to produce a non-natural amino acid with an arylalkyl or heteroarylalkyl group protected by a cyclic protective group in the side chain. Afterwards, a ring-opening reaction is performed to produce the target C-terminal free non-natural amino acid. [Chemistry 70] Non-natural amino acids that introduce an aryl or heteroaryl group (in the scheme, these groups are referred to as "Ar") into the side chain of an amino acid can be produced according to the following scheme. After introducing a protecting group into a commercially available protected amino acid (n = 0 or 1), an aryl or heteroaryl group is introduced by reacting an aryl halide or heteroaryl halide according to the method of He et al. (Org. Lett. 2014, 16(24), 6488-6491), thereby producing non-natural amino acids having an arylalkyl or heteroarylalkyl group in the side chain. Subsequently, a deprotection reaction and a protecting group introduction reaction are performed to produce the target C-terminal free non-natural amino acid. [Chemistry 71] [Chemistry 72] The non-natural amino acid in which a halogen atom is introduced into the aralkyl group of the amino acid side chain can be prepared according to the following scheme. According to the method of Ishiyama et al. (J. Am. Chem. Soc. 2002, 124(3), 390-391), a substituent (R a ) is introduced into the arylalkyl group of a boronic acid ester. Halogen atoms are introduced into the introduced boryl group using N-halogenated succinimide according to the method of Lindner et al. (Chem. Eur. J., 2016, 22, 13218-13235). The unnatural amino acid thus obtained can be optionally deprotected to produce the desired C-terminus free unnatural amino acid. [Chem. 73] A halogen atom is introduced into the aralkyl group of the amino acid side chain, and a -CH group is introduced into the nitrogen atom of the amino acid. The non-natural amino acid of 2-P' group can be prepared according to the following scheme. According to the method of Ishiyama et al. (J. Am. Chem. Soc. 2002, 124(3), 390-391), a substituent (R a) is introduced into the aryl group of an amino acid containing an arylalkyl group. A halogen atom is introduced into the introduced oxyboryl group using N-halogenated succinimide according to the method of Lindner et al. (Chem. Eur. J., 2016, 22, 13218-13235). The resulting unnatural amino acid can be optionally freed from an appropriate protecting group to produce the desired C-terminal unnatural amino acid. [Chem. 74] Preparation of amino acid side chain with substituted alkoxy or aralkyloxy (R b The method for preparing the non-natural amino acid of (O) can be carried out according to the following scheme. After the o-nitrobenzenesulfonyl (Ns) group is introduced into a commercially available serine derivative (n=1 or 2) according to the established method, a cyclized product can be obtained according to the method of Mitsunobu et al. (Synthesis, 1981, 1, 1-28). The cyclized product is then reacted with BF 3・OEt In the presence of a Lewis acid of the same order, an appropriate alcohol (R b OH) to obtain a serine ether. The unnatural amino acid thus obtained can be optionally deprotected by removing the appropriate protecting group to produce the desired C-terminal free unnatural amino acid. [Chemistry 75] Preparation of amino acid side chain with substituted alkoxy or aralkyloxy (R b The method for preparing the unnatural amino acid of (O) can be carried out according to the following scheme. A commercially available cyclic compound (n=1 or 2) is reacted with BF according to the specified method. 3・OEt In the presence of a Lewis acid of the same order, an appropriate alcohol (R b OH) to obtain a serine ether. The unnatural amino acid thus obtained can be optionally deprotected by removing an appropriate protecting group to produce the desired C-terminal free unnatural amino acid. [Chemistry 76] The amino acid side chain has an alkoxy group or an aralkyloxy group (-R b The method for preparing the non-natural amino acid of (O) can be prepared according to the following scheme. Commercially available serine derivatives (n = 1 or 2) are alkylated with an alkylating agent (R) in the presence of a suitable base according to the method of Williamson (Liebigs Ann. Chem. 1851, 77, 37-49). b -X) reaction, serine etherification can be obtained. bIn the case of functional groups that can be further converted, additional additions can be made to convert the functional groups. b The functional group is converted to the target functional group. Examples of additional functional group conversions include multiple bond reduction reactions. The unnatural amino acid thus obtained can then be subjected to a deprotection reaction to produce the target C-terminal free unnatural amino acid. [Chemistry 77] To produce amino acid side chains with substituted alkoxy or aralkyloxy groups (-R b O) unnatural amino acid, and the introduction of -CH The method for producing a 2-P'-based unnatural amino acid can be carried out according to the following scheme. A commercially available serine derivative or a serine derivative (n = 1 or 2) produced as described above is reacted with an aldehyde according to the method of Freidinger et al. (J. Org. Chem., 1983, 48(1), 77-81) to obtain an oxazolidinone compound having a cyclic protecting group introduced therein. Subsequently, a ring-opening reaction is performed to produce the desired unnatural amino acid with a free C-terminus. [Chemistry 78] The following scheme can be used to prepare non-natural amino acids with protected hydroxyl groups on their side chains. Commercially available serine derivatives or serine derivatives (n = 1 or 2) prepared as described above are subjected to appropriate deprotection reactions to produce the desired C-terminus free non-natural amino acid. [Chemistry 79] The amino acid side chain has a protected hydroxyl group, and the nitrogen atom of the amino acid is introduced into a -CH Unnatural amino acids with a 2-P' group can be produced according to the following scheme. Commercially available serine derivatives or serine derivatives produced as described above (n = 1 or 2) are reacted with an aldehyde according to the method of Freidinger et al. (J. Org. Chem., 1983, 48(1), 77-81) to obtain an oxazolidinone compound with a cyclic protective group introduced therein. Subsequently, a ring-opening reaction and a protective group introduction reaction are performed to produce the desired unnatural amino acid with a free C-terminus. [Chemistry 80] Substituents (R c ) can be prepared according to the following scheme. The commercially available cyclic amino acid can be converted into the target -OR by introducing an appropriate functional group into the cyclic amino acid. c The conversion reaction of the functional group is carried out according to the method of Williamson (Liebigs Ann. Chem. 1851, 77, 37-49), in which an alkylating agent (R c -X) can generate ether bond. c In the case of functional groups that can be further converted, additional functional group conversion can be performed. c The target functional group is converted into the target functional group. Then, a deprotection reaction is performed to produce the target C-terminal free non-natural amino acid. [Chemistry 81] Introducing a protective group (PG) on the hydroxyl group of the cyclic amino acid The cyclic non-natural amino acid of 3) can be produced according to the following scheme. The target C-terminal free non-natural amino acid can be produced by removing the appropriate protecting group from a commercially available cyclic amino acid. [Chemistry 82] Non-natural amino acids with boronic acid introduced into the side chain of an amino acid can be produced according to the following scheme. Commercially available glycine derivatives are reacted with an aldehyde according to the method of Lee et al. (Bioorg. Med. Chem. Lett., 2009, 19(17), 4887-5274) to obtain non-natural amino acids with boronic acid ester introduced. Subsequently, a suitable protecting group removal reaction is performed to produce the target C-terminal free non-natural amino acid. [Chemistry 83] (Synthesis of Fmoc non-natural amino acid with carboxyl group on the side chain 1) Fmoc non-natural amino acid with carboxyl group on the side chain can be produced according to the following scheme. The main chain carboxyl group of the protected starting material (n=1 or 2) can be converted into an amide group by condensing amine (R''R'''NH) in the presence of a condensing agent such as DIC. The deprotection reaction of 3 can produce the target Fmoc non-natural amino acid with a carboxyl group on the side chain. [Chemistry 84] (Synthesis of Fmoc non-natural amino acids with carboxyl groups on the side chains 2) The side chains have carboxyl groups and -CH The 2-P'-based Fmoc unnatural amino acid can be prepared according to the following scheme. The main chain carboxyl group of the protected starting material (n=1 or 2) can be converted into an amide group by condensing amine (R''R'''NH) in the presence of a condensing agent such as DIC. The deprotection reaction of 3 can produce the target Fmoc non-natural amino acid with a carboxyl group on the side chain. [Chemistry 85] (Synthesis of Fmoc Non-natural Amino Acids with Vinyl Halide Side Chains) Fmoc non-natural amino acids with vinyl halide side chains can be synthesized according to the following scheme based on the method of Shendage et al. (Eur. J. Org. Chem., 2005, 719-727). In the presence of a base, Boc-2-tert-butyl-3-methylimidazolidin-4-one, available from a commercial supplier, is reacted with an alkylating agent with vinyl halide side chains. The target Fmoc non-natural amino acid with vinyl halide side chains can be produced according to the method described in the literature. [Chemistry 86] Non-natural amino acids (n=1 or 2) containing a thioether group in the side chain can be produced according to the following scheme. The amino acid with a protected thiol group in the side chain is amidated with a carboxylic acid. After the thiol group is deprotected, the protected carboxylic acid is reacted with an acetic acid halide to form a thioether bond. Subsequently, the side chain carboxylic acid is deprotected to produce an amino acid with a thioether group in the side chain. [Chemistry 87] By using the above-mentioned amino acids having thioether groups in their side chains as raw materials, peptides containing thioether groups in their peptide backbones can be produced. Peptides can also be produced according to other methods such as the method of Roberts et al. (Tetrahedron Letters, 1998, 39, 8357-8360), which involves reacting N-terminal bromoacetamide with the side chain of cysteine, or the method of Robey et al. (Journal of Peptide Research, 2000, 56, 115-120), which involves reacting N-terminal chloroacetamide with the side chain of cysteine. Furthermore, the compounds of the present invention, their salts, or such solvent compositions include all stereoisomers of the target compound obtained through each of the above reaction steps (e.g., enantiomers, diastereomers (including cis- and trans-geometric isomers)), racemates of such isomers, and other mixtures. For example, the compounds of the present invention may have one or more asymmetric points, and the present invention includes racemic mixtures, diastereomer mixtures, and enantiomers of such compounds. When the compound of the present invention is obtained as a free substance, the compound can be converted into a salt, hydrate or solvate that the compound can form according to conventional methods. Furthermore, when the compound of the present invention is obtained as a salt, hydrate, or solvate of the compound, the compound can be converted into its free form according to conventional methods. <Pharmaceutical composition> The present invention provides a pharmaceutical composition containing the cyclic compound of the present invention. The pharmaceutical composition of the present invention, in addition to the compound of the present invention, its salt, or the solvent thereof, can be introduced into a pharmaceutically acceptable carrier and formulated by a known method. Regarding formulation, commonly used excipients, binders, lubricants, colorants, flavoring agents, or as needed, stabilizers, emulsifiers, absorption promoters, surfactants, pH adjusters, preservatives, antioxidants, etc. can be used to prepare ingredients used as raw materials for general pharmaceutical preparations, and formulation is carried out according to conventional methods. For example, regarding the manufacture of oral preparations, after adding the compound of the present invention or its salt and excipients, and further adding binders, disintegrants, lubricants, colorants, flavoring agents, etc. as needed, powders, fine granules, granules, tablets, coated tablets, capsules, etc. are prepared according to conventional methods. Examples of these ingredients include animal and vegetable oils such as soybean oil, beef tallow, and synthetic glycerides; hydrocarbons such as liquid paraffin, squalane, and solid paraffin; ester oils such as octyldodecyl myristate and isopropyl myristate; higher alcohols such as cetearyl alcohol and behenyl alcohol; silicone resins; silicone oils; surfactants such as polyoxyethylene fatty acid esters, sorbitan fatty acid esters, glycerol fatty acid esters, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene hydrogenated castor oil, and polyoxyethylene polyoxypropylene block copolymers; water-soluble polymers such as hydroxyethyl cellulose, polyacrylic acid, carboxyvinyl polymer, polyethylene glycol, polyvinyl pyrrolidone, and methylcellulose; lower alcohols such as ethanol and isopropyl alcohol; polyvalent alcohols such as glycerol, propylene glycol, dipropylene glycol, and sorbitol; sugars such as glucose and sucrose; inorganic powders such as anhydrous silicic acid, magnesium aluminum silicate, and aluminum silicate, and pure water. Examples of the excipient include lactose, corn starch, powdered sugar, glucose, mannitol, sorbitol, crystalline cellulose, and silicon dioxide. Examples of the binder include polyvinyl alcohol, polyvinyl ether, methylcellulose, ethylcellulose, gum arabic, tragacanth, gelatin, shellac, hydroxypropyl methylcellulose, hydroxypropyl cellulose, polyvinyl pyrrolidone, polypropylene glycol-polyoxyethylene-block polymer, and meglumine. Examples of disintegrants include starch, agar, gelatin powder, crystalline cellulose, calcium carbonate, sodium hydrogen carbonate, calcium citrate, dextrin, pectin, and carboxymethylcellulose calcium. Examples of the lubricant include magnesium stearate, talc, polyethylene glycol, silicon oxide, and hardened vegetable oil. Colorants are ingredients permitted to be added to pharmaceuticals, and flavoring agents include cocoa powder, menthol, aromatic powder, peppermint oil, borneol, and cinnamon powder. These tablets and granules can naturally be coated with sugar or other appropriate coatings as needed. Furthermore, when preparing liquid preparations such as syrups or injections, a pH adjuster, solubilizer, isotonicity agent, and the like can be added to the compound of the present invention or a pharmaceutically acceptable salt thereof. A solubility aid, stabilizer, and the like can also be added as needed to prepare the preparation according to conventional methods. For example, it can be used parenterally in the form of an injection of a sterile solution or suspension of a pharmaceutically acceptable liquid other than water. For example, a pharmaceutically acceptable carrier or solvent, such as sterile water or physiological saline, vegetable oil, emulsifier, suspending agent, surfactant, stabilizer, flavoring agent, excipient, vehicle, preservative, binder, etc., is appropriately combined and mixed in the unit dosage form required by generally recognized pharmaceutical practices to form a formulation. Specifically, light anhydrous silicic acid, lactose, crystalline cellulose, mannitol, starch, carboxymethylcellulose calcium, carboxymethylcellulose sodium, hydroxypropyl cellulose, hydroxypropyl methylcellulose, polyvinyl acetal diethylamino acetate, polyvinyl pyrrolidone, gelatin, medium-chain fatty acid triglycerides, polyoxyethylene hardened castor oil 60, powdered sugar, carboxymethyl cellulose, corn starch, inorganic salts, etc. can be cited as carriers. The amount of the active ingredient in these preparations is an appropriate amount to obtain the indicated range. Sterile compositions for injection can be prepared according to conventional preparation practices using a carrier such as distilled water for injection. Examples of aqueous solutions for injection include isotonic solutions containing physiological saline, glucose, or other auxiliary drugs, such as D-sorbitol, D-mannose, D-mannitol, and sodium chloride. Suitable dissolution aids may also be used in combination, such as alcohols, specifically ethanol, polyols such as propylene glycol and polyethylene glycol, and nonionic surfactants such as polysorbate 80 (registered trademark) and HCO-50. Examples of oily liquids include sesame oil and soybean oil. Benzyl benzoate and benzyl alcohol can also be used in combination as dissolution aids. Alternatively, the injection can be prepared with buffers such as phosphate buffer and sodium acetate buffer, soothing agents such as procaine hydrochloride, tranquilizers such as benzyl alcohol and phenol, and antioxidants. The prepared injection solution is typically filled into an appropriate ampoule. Administration is preferably oral, but the method of administration is not limited to oral. Specific examples of parenteral administration include injections, nasal administration, transpulmonary administration, and transdermal administration. Examples of injections include systemic or local administration via intravenous, intramuscular, intraperitoneal, and subcutaneous injections. Furthermore, an appropriate administration method can be selected based on the patient's age and symptoms. For example, the dosage of a pharmaceutical composition containing a peptide compound produced by the method of the present invention can be selected within the range of 0.0001 mg to 1000 mg per kg of body weight. Alternatively, the dosage can be selected within the range of 0.001 to 100,000 mg / body per patient, but is not necessarily limited to these values. The dosage and administration method vary depending on the patient's weight, age, symptoms, and the like, and can be appropriately selected by those skilled in the art. In some aspects, the cyclic compound of the present invention, or its salt or solvent complex thereof, or a pharmaceutical composition containing the cyclic compound of the present invention, or its salt or solvent complex thereof, can be used to bind to or selectively bind to KRAS in a subject, thereby selectively inhibiting KRAS. In some aspects, the cyclic compounds of the present invention, or salts or solvent compositions thereof, can be used in the manufacture of a medicament that can bind to or selectively bind to KRAS in a subject, thereby selectively inhibiting KRAS. In some aspects, the present invention relates to methods for binding or selectively binding a cyclic compound of the present invention to KRAS in a subject, or methods for selectively inhibiting KRAS in a subject, comprising the step of administering to a subject in need thereof an effective amount of a cyclic compound of the present invention, or a salt thereof, or a solvent thereof. The cyclic compound of the present invention, or a salt or a solvent thereof, has high selectivity for KRAS. For example, the cyclic compound of the present invention has a higher affinity than PP1820: (3S,9S,12S,17S,20S,23S,27S,30S,36S)-3-[2-[3-chloro-4-(trifluoromethyl)phenyl]ethyl]-30-cyclopentyl-23-isobutyl-9-(isopentyloxymethyl)-N,N,7,17​​,18,24,28,31-octamethyl-20-[(1S)-1-methylpropyl]-2,5,8,11,16,19,22,25,29,32,35-undecacyclo-10-propyl-spiro[1,4,7,10,15,18,21,24,28,31,34-undecaazatricyclo[343.0.0] 12,15 ] Nonatriacontane-3,3,1'-cyclobutane]-2,7-carboxamide has higher KRAS selectivity (selectivity of KRAS over NRAS and / or selectivity of KRAS over HRAS). In some aspects, the KRAS inhibitory activity of the pharmaceutical composition of the present invention is more than three times greater than the NRAS inhibitory activity and the HRAS inhibitory activity. In some aspects, the KRAS inhibitory activity of the pharmaceutical composition of the present invention is 5-fold, 7-fold, 10-fold, 15-fold, or 20-fold greater than the NRAS inhibitory activity and the HRAS inhibitory activity. In some aspects, the cyclic compounds of the present invention, or their salts or solvent compounds, or pharmaceutical compositions containing the cyclic compounds, or their salts or solvent compounds, can be used to treat and / or prevent cancer in a subject. In some aspects, the cyclic compounds of the present invention, or salts thereof, or solvent compositions thereof, can be used in the manufacture of a medicament for treating and / or preventing cancer in a subject. In some aspects, the method of the present invention for treating and / or preventing cancer in a subject comprises the step of administering to a subject in need thereof an effective amount of a cyclic compound of the present invention, or a salt thereof, or a solvent thereof. Specific examples of cancer include lung cancer. In this specification, the term "subject" includes mammals, preferably humans. Furthermore, all prior art documents cited in this specification are incorporated herein by reference. [Examples] The following examples and reference examples further illustrate the present invention, but the present invention is not limited thereto. Where no production methods are described, starting materials and reagents were purchased from commercial suppliers or synthesized using known methods. LC / MS analysis conditions are listed in Table 1. [Table 1] Example 1 Solid-Phase Synthesis of Peptide Compounds Peptide elongation was performed according to the Fmoc peptide synthesis method described in WO2013 / 100132 or WO2018 / 225864 using the following basic pathway (also referred to as the basic peptide synthesis method). Specifically, the five-step process involves: 1) the carboxylic acid of the Asp side chain or the peptide backbone carboxylic acid being supported on a 2-chlorotrityl resin, followed by peptide elongation from the N-terminus of the amino acid via the Fmoc method; 2) cleavage of the peptide from the 2-chlorotrityl resin; 3) cyclization of the amide resulting from the cleavage of the Asp side chain carboxylic acid or the peptide backbone carboxylic acid from the 2-chlorotrityl resin, which condenses with the amino group at the N-terminus (triangular unit) of the peptide chain; 4) optionally deprotecting the protective groups of the side chain functional groups contained in the peptide chain; and 5) purification of the compound by preparative high-performance liquid chromatography (HPLC). In this example, unless otherwise specified, the synthesis of peptide compounds was carried out based on this basic route. 1-1. Fmoc-Amino Acids Used in Peptide Synthesis Using a Peptide Synthesizer In the peptide syntheses described in this specification, the Fmoc-amino acids listed in Tables 2 to 4 were used for synthesis using a peptide synthesizer. The Fmoc-amino acids listed in Table 2 were synthesized according to the methods described in WO2018 / 225851 or WO2018 / 225864. The Fmoc-amino acids listed in Table 3 were purchased from commercial suppliers. The Fmoc-amino acids listed in Table 4 were synthesized according to the scheme shown below. [Table 2] [Table 3] [Table 4] Synthesis of Fmoc-amino acid Synthesis of compound aa004 [Chemical 89] Compound aa004-a (3.00 g, 7.86 mmol) was dissolved in toluene (79 mL), and paraformaldehyde (708 mg, 23.6 mmol) and CSA (91 mg, 0.393 mmol) were added, followed by stirring at 90°C for 5 hours. After cooling to room temperature, paraformaldehyde (236 mg, 7.86 mmol) and CSA (46 mg, 0.197 mmol) were added, and the mixture was stirred at 90°C for another 30 minutes. After cooling to room temperature, the mixture was filtered through celite, and the residue was washed with ethyl acetate (50 mL). The filtrate was washed twice with saturated sodium bicarbonate aqueous solution (50 mL) and then with 50% brine (50 mL). The mixture was dried over sodium sulfate, filtered, and the solvent was distilled off under reduced pressure to obtain compound aa004-b as a crude product. LCMS (ESI) m / z = 394 (M+H) + Retention time: 1.08 minutes (Analysis conditions SQDFA05) The crude product of compound aa004-b (7.86 mmol) was dissolved in DCM (39 mL), and boron trifluoride diethyl ether complex (BF 3・OEt 2) (2.96 mL, 23.6 mmol) with TES (1.95 mL, 23.6 mmol) and water (0.142 mL, 7.86 mmol) and stirred at room temperature for 1 hour. The reaction solution was washed with saturated ammonium chloride solution (40 mL), washed with 50% brine (40 mL), dried over sodium sulfate, filtered, and the solvent was distilled off under reduced pressure. The resulting residue was dissolved in acetonitrile (40 mL) and washed twice with n-hexane (40 mL). The solvent was distilled off under reduced pressure to obtain compound aa004 (3.04 g, 98%). LCMS (ESI) m / z = 396 (M+H) + Retention time: 1.00 minutes (analysis conditions SQDFA05) Synthesis of compound aa028 [Chemical 90] Using aa028-a as the starting material, aa028-b was obtained as a crude product (9.61 g, 94%) by the same method as the synthesis of compound aa004-b. Using aa028-b as the starting material, aa028 (8.10 g, 84%) was obtained using the same method as for compound aa004. LCMS (ESI) m / z = 470 (M+H)+ retention time: 0.99 min (analysis conditions SQDFA05) Synthesis of compound aa018 [Chemical 91] Compound aa018-a, ((2S)-2-[9H-fluoren-9-ylmethoxycarbonylamino]pent-4-ynoic acid, and Fmoc-PRA-OH) (3 g, 8.95 mmol) were used as starting materials in the same manner as for the synthesis of compound aa004-b to obtain aa018-b (2.71 g, 87%). LCMS (ESI) m / z = 348 (M+H) + Retention time: 0.87 min (Analysis conditions: SQDFA05). Compound aa018-b (989 mg, 2.85 mmol) was synthesized using the same method as compound aa004 to obtain compound aa018 (986 mg, 99%). LCMS (ESI) m / z = 350 (M+H) + retention time: 0.79 min (analysis conditions SQDFA05) Synthesis of compound aa049 [Chemical 92] Compound aa049-a, ((2S)-3-(2-chlorophenyl)-2-[9H-fluoren-9-ylmethoxycarbonylamino]propionic acid, and Fmoc-Phe(2-Cl)-OH) (5 g, 11.85 mmol) were used as starting materials and the same method as for the synthesis of compound aa004-b was used to obtain compound aa049-b (4.2 g, 82%). LCMS (ESI) m / z = 434 (M+H)+, retention time: 1.01 min (analysis conditions: SQDFA05). The obtained compound aa049-b (4.2 g) was used in the same manner as for the synthesis of compound aa004 to obtain compound aa049 (3.32 g, 79%). LCMS (ESI) m / z = 436 (M+H) + retention time: 0.94 min (analysis conditions SQDFA05) Synthesis of compound aa199 [Chemical 93] Compound aa199-a, ((2S)-2-[9H-fluoren-9-ylmethoxycarbonylamino]-3-[4-(trifluoromethyl)phenyl]propanoic acid, and Fmoc-Phe(4-CF3)-OH) (200 g, 439 mmol) were used as starting materials and the same method as for the synthesis of compound aa004-b was used to obtain compound aa199-b as a crude product (206.8 g). LCMS (ESI) m / z = 469 (M+H) + retention time: 3.30 minutes (analysis conditions: SMD method_03) Compound aa199-b (205 g) was synthesized using the same method as compound aa004 to obtain compound aa199 (195 g, 95% yield over two steps). LCMS (ESI) m / z = 470 (M+H) + retention time: 2.96 min (analysis conditions: SMD Method_03). Synthesis of compound aa013 [Chemical 94] Using aa013-a as the starting material, aa013-b was obtained as a crude product (5.29 g, 102%) using the same method as compound aa004-b. LCMS (ESI) m / z = 370 (M+H)+ retention time: 0.89 min (analysis conditions SQDFA05). Compound aa013-b (5.29 g, 14.3 mmol) was dissolved in DCM (125 mL), and TES (22.9 mL, 143 mmol) and TFA (36.4 mL, 473 mmol) were added, followed by stirring at 38°C for 8 hours. The solvent was distilled off under reduced pressure, the mixture was dissolved in TBME (100 mL), and washed with 1M dipotassium hydrogen phosphate aqueous solution (50 mL). The aqueous layer was extracted three times with TBME, the organic layers were combined, and the solvent was distilled off under reduced pressure. Acetonitrile / n-hexane = 1 / 2 (100 mL) was added, and the mixture was extracted with 5% potassium bicarbonate aqueous solution (100 mL). 6M hydrochloric acid was added to the aqueous layer to make it acidic, and the mixture was extracted twice with TBME (30 mL). The organic layer was dried over sodium sulfate, filtered, and the solvent was distilled off under reduced pressure. Acetonitrile (100 mL) was added, and the mixture was washed with n-hexane (50 mL). The solvent was distilled off under reduced pressure to obtain compound aa013 (4.06 g, 76%). LCMS (ESI) m / z = 372 (M+H) + Retention time: 0.83 min (Analysis conditions SQDFA05) Synthesis of compound aa030 [Chemical 95] Under a nitrogen atmosphere, polyoxymethylene (172 mg, 5.74 mmol) and TFA (1.326 mL, 17.22 mmol) were added to a toluene solution (5.7 mL) of (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(3-cyanophenyl)propanoic acid (aa030-a, Fmoc-Phe(3-CN)-OH) (789 mg, 1.913 mmol) and stirred at room temperature for 5 hours and 30 minutes. The reaction solution was concentrated under reduced pressure, diluted with DCM, washed with saturated aqueous sodium bicarbonate solution, dried over anhydrous magnesium sulfate, and filtered. The resulting solution was concentrated under reduced pressure to obtain the crude product compound aa030-b (859 mg). This was used in the next reaction without purification. Under a nitrogen atmosphere, TES (2.75 mL, 17.22 mmol) and TFA (3.98 mL, 51.7 mmol) were added to a solution of compound aa030-b (853 mg) in DCE (10 mL) at room temperature, and the mixture was stirred at 60°C for 5 hours. The reaction mixture was cooled to room temperature, and the solvent was distilled off under reduced pressure. The resulting crude product was added with tertiary butyl methyl ether / n-hexane = 1 / 1 and extracted five times with saturated sodium bicarbonate aqueous solution. The pH of the resulting aqueous layer was adjusted to acidic with concentrated hydrochloric acid, and then extracted three times with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, filtered, and the solvent was distilled off under reduced pressure to obtain compound aa030 (811 mg, 99% for 2 steps). The resulting compound aa060 was used for peptide synthesis without further purification. LCMS (ESI) m / z = 427 (M+H) + Retention time: 0.83 minutes (Analysis conditions SQDFA05) Synthesis of compound aa029 [Chemical 96] Using compound aa029-a, ((2S)-3-(4-cyanophenyl)-2-(9H-fluoren-9-ylmethoxycarbonylamino)propionic acid, and Fmoc-Phe(4-CN)-OH) (1 g, 2.425 mmol) as starting materials, compound aa029 was obtained as a crude product (1.14 g, 108% in 2 steps) using the same method as compound aa030. Compound aa029 was used for peptide synthesis without further purification. LCMS (ESI) m / z = 427 (M+H) + retention time: 0.82 min (analysis conditions SQDFA05). Synthesis of compound aa031 [Chemical 97] Compound aa031-a, ((2S)-3-(2-cyanophenyl)-2-(9H-fluoren-9-ylmethoxycarbonylamino)propionic acid, and Fmoc-Phe(2-CN)-OH) (1 g, 2.425 mmol) were used as starting materials and the same method as for the synthesis of compound aa030-b was used to obtain compound aa031-b as a crude product. The resulting compound aa031-b was purified by reverse phase column chromatography (0.1% aqueous formic acid / 0.1% formic acid in acetonitrile) to obtain compound aa031 (529 mg, 51% over 2 steps). LCMS (ESI) m / z = 427 (M+H) + Retention time: 0.85 min (Analysis conditions SQDFA05) Synthesis of compound aa050 [Chemical 98] Compound aa050-a, ((2S)-3-(3,4-difluorophenyl)-2-[9H-fluoren-9-ylmethoxycarbonyl(methyl)amino]propionic acid, and Fmoc-Phe(34-F2)-OH) (105 mg, 0.247 mmol) were used as starting materials and the same method as for the synthesis of compound aa004-b was used to obtain compound aa050-b as a crude product. Using aa050-b, the same method as for the synthesis of compound aa030 was used to obtain compound aa050 (74.4 mg, 69% over two steps). LCMS (ESI) m / z = 438 (M+H) + Retention time: 0.88 min (Analysis conditions: SQDFA05) Synthesis of compound aa019 [Chemical 99] Compound aa019-a (5.00 g, 13.8 mmol) was suspended in DCM (46 mL), and polyoxymethylene (2.08 g, 69 mmol) and magnesium sulfate (4.16 g, 34.6 mmol) were added. Boron trifluoride diethyl ether complex (BF 3・OEt 2) (2.10 mL, 16.6 mmol), stirred at room temperature for 1 hour. The solid was filtered off, and TES (5.51 mL, 34.6 mmol) and water (0.249 mL, 13.8 mmol) were added. BF was added dropwise at 0°C. 3・OEt 2 (2.63 mL, 20.8 mmol) was added and stirred at room temperature for 1 hour. TES (1.10 mL, 6.92 mmol) was added and stirred at room temperature for 40 minutes. BF 3・OEt 2 (0.877 mL, 6.92 mmol) was added and stirred at room temperature. The reaction solution was washed with a saturated sodium chloride aqueous solution (25 mL) and then with saturated brine (50 mL). The organic layer was dried over sodium sulfate, filtered, and the solvent was distilled off under reduced pressure. The resulting solid was crushed and washed three times with n-hexane (50 mL) to obtain compound aa019 (4.93 g, 95%). LCMS (ESI) m / z = 376 (M+H) + Retention time: 0.80 minutes (Analysis conditions SQDFA05) Synthesis of compound aa331 [Chemical 100] Using aa331-a as the starting material, aa331 (9.09 g, 86%) was obtained using the same method as for the synthesis of compound aa019. LCMS (ESI) m / z = 382 (M+H)+, retention time: 0.94 min (analysis conditions SQDFA05). Synthesis of compound aa020 [Chemical 101] To a mixed solution of chloroform (145 mL) and methanol (145 mL) was added (S)-methyl N-tritylaziridine-2-carboxylate (aa020-a, CAS No. 75154-68-6) (50 g, 146 mmol). TFA (33 mL, 3 eq) was added dropwise at 0°C under a nitrogen atmosphere, and the mixture was stirred for 7 hours. DIPEA (127 mL, 5 eq) was added to the reaction mixture at 0°C, followed by a solution of Fmoc-Cl (36 g, 139 mmol) in 1,4-dioxane (145 mL). The mixture was stirred at 0°C under a nitrogen atmosphere for 90 minutes. The reaction mixture was concentrated under reduced pressure, diluted with ethyl acetate, and then washed sequentially with water, aqueous ammonium chloride, aqueous sodium bicarbonate, and saturated brine. The organic layer was dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The resulting residue was purified by silica gel column chromatography (ethyl acetate / petroleum ether, 0 / 100 to 10 / 90) to obtain compound aa020-b, ((2S)-aziridine-1,2-dicarboxylic acid 1-O-(9H-fluoren-9-ylmethyl) 2-O-methyl ester) (40 g, 85%). LCMS (ESI) m / z = 324 (M+H) + Retention time: 2.631 min (Analysis conditions: SMD method_10). Under nitrogen atmosphere, compound aa020-b, ((2S)-aziridine-1,2-dicarboxylic acid 1-O-(9H-fluoren-9-ylmethyl) 2-O-methyl ester) (5 g, 15.46 mmol) was dissolved in DCM (30.9 mL), cyclopropanol (1.665 mL, 26.3 mmol) was added, and then boron trifluoride diethyl ether complex (BF 3・OEt 2) (0.291 mL, 2.319 mmol). After reacting for 2 hours under ice cooling, water and saturated aqueous sodium bicarbonate solution were added to the reaction solution to stop the reaction. The aqueous layer was removed through a phase separator, and the organic layer was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (n-hexane / ethyl acetate = 4 / 1) to obtain compound aa020-c (4.6 g, 78%). LCMS (ESI) m / z = 382 (M+H) + Retention time: 0.89 min (Analysis conditions SQDFA05) Calcium chloride (20.08 g, 181 mmol) was dissolved in water (50.2 mL), lithium hydroxide monohydrate (2.024 g, 48.2 mmol) was added, and the mixture was stirred at room temperature for 5 minutes to prepare aqueous solution A. Compound aa020-c (4.6 g, 12.06 mmol) was dissolved in isopropanol (201 mL) and THF (50.2 mL), and the previously prepared aqueous solution A was added and stirred at room temperature for 5 hours. After that, 1N hydrochloric acid (72 mL) was added to the reaction solution, and the isopropanol and THF were removed by vacuum concentration. The obtained aqueous layer was diluted with water (50.2 mL) and extracted 3 times with ethyl acetate (total 100 mL). The organic layer was washed with water and saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The resulting residue was washed with ethyl acetate / n-hexane (1 / 2, 20 v / w) to obtain aa020-d, ((2S)-3-cyclopropyloxy-2-(9H-fluoren-9-ylmethoxycarbonylamino)propionic acid, and Fmoc-Ser(cPr)-OH) (3.5 g, 79%). LCMS (ESI) m / z = 368 (M+H)+, retention time: 0.78 min (analysis conditions SQDFA05). Under nitrogen atmosphere, polyoxymethylene (1.815 g, 60.5 mmol), magnesium sulfate (2.36 g, 19.63 mmol), boron trifluoride diethyl ether complex (BF 3・OEt 2) (1.184 mL, 9.42 mmol) was added to a DCM (87 mL) solution of compound aa020-d, ((2S)-3-cyclopropyloxy-2-(9H-fluoren-9-ylmethoxycarbonylamino)propionic acid, Fmoc-Ser(cPr)-OH) (2.89 g, 7.85 mmol) and stirred at room temperature for 2 hours. Saturated aqueous sodium bicarbonate solution was added to the reaction solution to separate the organic layer from the aqueous layer. The aqueous layer was extracted twice with DCM, the combined organic layers were washed with saturated brine, dried over sodium sulfate, and the solvent was distilled off under reduced pressure to obtain compound aa020-e as a crude product (3.1 g, quant.). LCMS (ESI) m / z = 380 (M+H) + Retention time: 0.93 minutes (analysis conditions SQDFA05) Under ice cooling and nitrogen atmosphere, triethylsilane (3.13 mL, 19.64 mmol), water (0.141 mL, 7.85 mmol), boron trifluoride diethyl ether complex (BF 3・OEt 2) (2.49 mL, 19.6 mmol) was added to the obtained DCM (26.2 mL) solution of compound aa020-e (2.98 g, 7.85 mmol) and stirred for 2 hours. Saturated aqueous ammonium chloride solution was added to the reaction solution, and the organic layer was separated. After washing the organic layer with saturated aqueous ammonium chloride solution, it was washed with saturated brine and concentrated under reduced pressure to obtain a crude product. The obtained crude product was dissolved in acetonitrile, washed with n-hexane, and the acetonitrile layer was concentrated under reduced pressure to obtain compound aa020 (2.71 g, 90%). LCMS (ESI) m / z=382 (M+H)+ Retention time: 0.83 minutes (Analysis conditions SQDFA05) Synthesis of compound aa006 [Chemical 102] Compound aa006-a, ((2S)-3-cyclopentyl-2-[9H-fluoren-9-ylmethoxycarbonylamino]propionic acid, and Fmoc-Ala(cPent)-OH) (10 g, 26.4 mmol) were used as starting materials, and the same method as for the synthesis of compound aa020-e was used to obtain compound aa006-b (10.5 g) as a crude product. LCMS (ESI) m / z = 392 (M+H) + Retention time: 1.05 min (Analysis conditions: SQDFA05) Compound aa006-b (10.5 g) was reacted with the same method as for the synthesis of compound aa020. The crude product was purified by reverse-phase column chromatography (0.1% aqueous formic acid / 0.1% formic acid in acetonitrile) to obtain compound aa006 (10.11 g, 96% over two steps). LCMS (ESI) m / z = 394 (M+H) + retention time: 0.98 min (analysis conditions SQDFA05). Synthesis of compound aa010 [Chemical 103] Compound aa010-a, ((2S)-3-cyclobutyl-2-[9H-fluoren-9-ylmethoxycarbonylamino]propionic acid, and Fmoc-Ala(cBu)-OH) (3.36 g, 9.19 mmol) were used as starting materials, and the same method as for the synthesis of compound aa020-e was used to obtain compound aa010-b as a crude product (3.63 g). LCMS (ESI) m / z = 378 (M+H)+, retention time: 1.01 min (analysis conditions SQDFA05). Compound aa010-b (3.63 g) was reacted with the same method as for the synthesis of compound aa020. The crude product was purified by reverse-phase column chromatography (0.1% formic acid-water / 0.1% formic acid-acetonitrile) to obtain compound aa010 (3.18 g, 91% over two steps). LCMS (ESI) m / z = 380 (M+H) + retention time: 0.94 min (analysis conditions SQDFA05). Synthesis of compound aa047 [Chemical 104] Using compound aa047-a, ((2S)-2-[9H-fluoren-9-ylmethoxycarbonylamino]-3-(2-methylphenyl)propionic acid, and Fmoc-Phe(2-Me)-OH) (2 g, 4.98 mmol) as starting materials, a saturated aqueous sodium bicarbonate solution was added to the reaction solution obtained by the same method as for the synthesis of compound aa020-e. The mixture was injected onto a silica gel column (2 v / w) and eluted with DCM to obtain compound aa047-b as a crude product (1.45 g). Using the obtained compound aa047-b, compound aa047 (1.21 g, 58% over 2 steps) was obtained by the same method as for the synthesis of compound aa020. LCMS (ESI) m / z = 416 (M+H) + retention time: 0.94 min (analysis conditions SQDFA05) Synthesis of compound aa060 [Chemical 105] Compound aa060-a, (2S)-2-cyclobutyl-2-[9H-fluoren-9-ylmethoxycarbonylamino]acetic acid, and Fmoc-Gly(cBu)-OH (2.5 g, 7.11 mmol) were used as starting materials, and the same method as for the synthesis of compound aa020-e was used to obtain compound aa075-b as a crude product. LCMS (ESI) m / z = 364 (M+H) + Retention time: 0.97 min (Analysis conditions: SQDFA05) The entire amount of compound aa060-b obtained above was reacted using the same method as for the synthesis of compound aa020. The resulting crude product was purified by reverse-phase column chromatography (0.1% aqueous formic acid / 0.1% formic acid in acetonitrile) to obtain compound aa060 (2.32 g, 89% over two steps). LCMS (ESI) m / z = 366 (M+H) + retention time: 0.88 min (analysis conditions SQDFA05). Synthesis of compound aa021 [Chemical 106] 2-Nitrobenzenesulfonyl chloride (NsCl) (32.37 g, 146 mmol) and L-serine methyl ester hydrochloride (aa021-a, 25 g, 161 mmol, CAS No. 5680-80-8) were dissolved in DCM (874 mL), and DIPEA (51 mL, 292 mmol) was added at 5°C. After stirring at room temperature for 1 hour, the mixture was washed twice with water (440 mL) and once with saturated brine / water (1 / 1, 440 mL), and then dried over magnesium sulfate. After filtering off the magnesium sulfate, the mixture was concentrated under reduced pressure to obtain compound aa021-b as a crude product (39.4 g, 89%). LCMS (ESI) m / z = 302.9 (MH) - Retention time: 0.729 min (Analysis conditions: SMD method_06) Compound aa021-b (23 g, 75.6 mmol) was dissolved in DCM (598 mL) and triphenylphosphine (31.7 g, 121 mmol) was added at room temperature. After cooling to -14°C, DEAD (55.0 mL, 121 mmol) was added over 10 minutes, and the mixture was stirred at -5°C for 50 minutes. n-Hexane (300 mL) was added, and the precipitate was filtered off. The filtrate was purified by silica gel column chromatography (n-Hexane / DCM = 50:50 to 0:100) to obtain compound aa021-c (13.3 g, 62%). LCMS (ESI) m / z = 287 (M+H) + Retention time: 0.872 minutes (Analysis conditions SMDmethod_06) Compound aa021-c (10.7 g, 37.3 mmol) was dissolved in TFE (75 mL) and boron trifluoride diethyl ether complex (BF 3・OEt 2) (0.469 mL, 3.73 mmol) and stirred at 70°C for 30 minutes. TFE was distilled off under reduced pressure, and the resulting crude product was purified by reverse phase column chromatography (acetonitrile with 0.1% formic acid / distilled water with 0.1% formic acid) to obtain compound aa021-d (12.3 g, 85%). LCMS (ESI) m / z = 387 (M+H) + Retention time: 0.72 minutes (Analysis conditions SQDFA05) Compound aa021-d (12 g, 31.1 mmol) was dissolved in methanol (47 mL), and a solution of lithium hydroxide monohydrate (5.21 g, 124 mmol) in water (31 mL) was added. After stirring at room temperature for 90 minutes, formic acid (11.7 mL, 311 mmol) was added. The mixture was diluted with water (30 mL) and purified by reverse phase column chromatography (acetonitrile with 0.1% formic acid / distilled water with 0.1% formic acid) to obtain compound aa021-e (7.90 g, 68%). LCMS (ESI) m / z = 373 (M+H) + Retention time: 0.63 min (Analysis conditions: SQDFA05) Compound aa021-e (7.72 g, 20.7 mmol) was dissolved in acetonitrile (104 mL), potassium carbonate (7.17 g, 51.8 mmol) and dodecane thiol (7.44 mL, 31.1 mmol) were added, and the mixture was stirred at room temperature for 74 hours. The mixture was diluted with water (100 mL) and washed twice with TBME (200 mL). A solution of Fmoc-OSu (3.5 g) in 1,4-dioxane (150 mL) was added to the resulting aqueous solution, and the mixture was stirred for 25 minutes. A solution of Fmoc-OSu (700 mg) in 1,4-dioxane (10 mL) was then added, and the mixture was stirred for 5 minutes. A solution of Fmoc-OSu (350 mg) in 1,4-dioxane (5 mL) was then added, and the mixture was stirred for 5 minutes. A solution of Fmoc-OSu (350 mg) in 1,4-dioxane (5 mL) was added, stirred for 5 minutes, and then formic acid (3.9 mL) was added. The solvent was distilled off under reduced pressure. The crude product was purified by reverse phase column chromatography (acetonitrile with 0.1% formic acid / distilled water with 0.1% formic acid) to obtain compound aa021-f, ((2S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-3-(2,2,2-trifluoroethoxy)propanoic acid, Fmoc-Ser(Tfe)-OH) (5.67 g, 67%). LCMS (ESI) m / z = 410 (M+H) + Retention time: 2.35 minutes (Analysis conditions: SQDFA05long) Compound aa021-f (2.00 g, 4.89 mmol) was used as the starting material and the same method as for the synthesis of compound aa020-e was used to obtain compound aa021-g as a crude product. Compound aa021 (1.80 g, 87% over two steps) was obtained using the same method as for the synthesis of compound aa020. LCMS (ESI) m / z = 424 (M+H)+, retention time: 0.84 min (analysis conditions: SQDFA05). Synthesis of compound aa022 [Chemical 107] Under nitrogen atmosphere, compound aa020-b (1 g, 3.09 mmol) was dissolved in toluene (6.2 mL), ethanol (0.542 mL, 9.28 mmol) was added, and BF was added dropwise over 5 minutes under ice cooling. 3・OEt 2 (0.059 mL, 0.464 mmol). The mixture was returned to room temperature and stirred for 2.5 hours. Saturated NaHCO 3 aqueous solution to stop the reaction, and remove the aqueous layer through a phase separator. After drying the organic layer with anhydrous sodium sulfate, the solvent was distilled off under reduced pressure. Ethyl acetate / hexane (3 / 1, 24 mL) was added to the obtained residue, and the solvent was distilled off under reduced pressure. Hexane / TBME (85 / 15, 24 mL) was added to the obtained solid, stirred for 30 minutes, and the solvent was distilled off to obtain compound aa022-b (787 mg, 69%). LCMS (ESI) m / z=370 (M+H)+ Retention time: 0.86 minutes (Analysis conditions SQDFA05) Calcium chloride (2.25 g, 20.3 mmol) was dissolved in H 2O (5.7 mL), lithium hydroxide monohydrate (227 mg, 5.41 mmol) was added thereto, and the mixture was stirred at room temperature for 5 minutes to prepare aqueous solution A. Compound aa022-b was dissolved in isopropanol (22.6 mL) and THF (57 mL), and the previously prepared aqueous solution A was added, followed by stirring at room temperature for 7 hours. 1N hydrochloric acid (8.1 mL) was then added to the reaction solution, and the isopropanol and THF were removed by concentration under reduced pressure. The obtained aqueous layer was diluted with 20 and extracted with ethyl acetate three times. The organic layer was washed with 20 and saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was triturated with ethyl acetate / n-hexane (1 / 5, 20 v / w) to obtain compound aa022-c (3.5 g, 79%). LCMS (ESI) m / z = 356 (M+H) + retention time: 0.78 min (analysis conditions SQDFA05). Using aa022-c as the starting material, aa022-d was obtained as a crude product (871 mg, 84%) using the same method as compound aa004-b. LCMS (ESI) m / z = 368 (M+H) + retention time: 0.84 min (analysis conditions SQDFA05). Using aa022-d as the starting material, aa022 (254 mg, 90%) was obtained by the same method as compound aa004. LCMS (ESI) m / z = 370 (M+H) + retention time: 0.80 min (analysis conditions SQDFA05) Synthesis of compound aa210 [Chemical 108] Compound aa210-a (5.00 g, 13.7 mmol) was dissolved in toluene (17 mL), and TFA (9.49 mL, 123 mmol) and paraldehyde (5.42 mL, 41.0 mmol) were added. The mixture was stirred at 45°C for 24 hours. The mixture was cooled to 0°C, and toluene (17 mL), TFA (19.0 mL, 246 mmol), and TES (19.6 mL, 123 mmol) were added. The mixture was stirred at 50°C overnight. The solvent was evaporated under reduced pressure, and ethyl acetate was added. The mixture was washed with saturated sodium bicarbonate solution and then with saturated brine. The organic layer was dried over sodium sulfate and filtered, and the solvent was evaporated under reduced pressure. Purification was performed by reverse phase chromatography (acetonitrile with 0.1% formic acid / distilled water with 0.1% formic acid) to obtain aa210 (2.17 g, 40%). LCMS (ESI) m / z = 394 (M+H) + Retention time: 0.94 minutes (Analysis conditions SQDFA05) Synthesis of compound aa201 [Chemical 109] Under a nitrogen atmosphere, compound aa201-a, ((2S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-3-(4-methylphenyl)propionic acid, Fmoc-Phe(4-Me)-OH) (5.62 g, 14.0 mmol, CAS No. 199006-54-7) were suspended in DCE (17.5 mL), and paraldehyde (5.61 mL, 42.0 mmol) and TFA (9.65 mL, 126 mmol) were added, and stirred at 60°C for 6 hours. The reaction solution containing the obtained compound aa201-b was used directly in the next step. LCMS (ESI) m / z = 428 (M+H) + Retention time: 1.03 minutes (Analysis conditions SQDFA05) To the reaction solution of the obtained compound aa201-b, DCE (17.5 mL), TFA (19.3 mL, 252 mmol), and TES (20.1 mL, 126 mmol) were added and stirred at 60°C for 17 hours. After cooling to room temperature and concentrating under reduced pressure, the resulting residue was dissolved in ethyl acetate (40 mL). The organic layer was washed with saturated aqueous sodium bicarbonate solution (40 mL) and saturated brine (40 mL), dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The resulting residue was dissolved in acetonitrile (30 mL), washed twice with hexane (15 mL), and the solvent was distilled off under reduced pressure. The resulting residue was purified by reverse-phase column chromatography (acetonitrile with 0.1% formic acid / distilled water with 0.1% formic acid) to obtain compound aa201, ((2S)-2-[ethyl(9H-fluoren-9-ylmethoxycarbonyl)amino]-3-(4-methylphenyl)propanoic acid, Fmoc-EtPhe(4-Me)-OH) (4.4 g, 73% over two steps). LCMS (ESI) m / z = 430 (M+H)+, retention time: 0.95 min (analysis conditions: SQDFA05). Synthesis of compound aa164 [Chemical 110] Under a nitrogen atmosphere, compound aa164-a, ((2S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-3-[4-(trifluoromethyl)phenyl]propanoic acid, Fmoc-Phe(4-CF3)-OH) (4.04 g, 8.87 mmol, CAS No. 247113-86-6) were suspended in DCE (11.1 mL). Anhydrous magnesium sulfate (4.27 g, 35.4 mmol), paraldehyde (3.55 mL, 26.6 mmol), and TFA (6.11 mL, 80 mmol) were added, and the mixture was stirred at 60°C for 3 hours. Anhydrous magnesium sulfate (2.14 g, 17.7 mmol) was further added, and the mixture was stirred at 60°C for 1 hour. The reaction solution containing the resulting compound aa164-b was used directly in the next step. LCMS (ESI) m / z = 482 (M+H) + Retention time: 1.04 minutes (Analysis conditions SQDFA05) To the reaction solution containing the obtained compound aa164-b, DCE (11.1 mL), TFA (12.2 mL, 159 mmol), and triethylsilane (12.7 mL, 80 mmol) were added, and the mixture was stirred at 60°C for 10 hours. After cooling to room temperature, the magnesium sulfate was filtered off, and the mixture was concentrated under reduced pressure. Since the target reaction was not yet complete, the obtained residue was dissolved in DCE (22.2 mL), TFA (18.3 mL, 239 mmol) and triethylsilane (12.7 mL, 80 mmol) were added, and the mixture was stirred at 60°C for 8 hours. After cooling to room temperature and concentrating under reduced pressure, the obtained residue was dissolved in ethyl acetate (40 mL). The organic layer was washed with saturated sodium bicarbonate aqueous solution (40 mL) and saturated brine (40 mL), dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The obtained residue was dissolved in acetonitrile (30 mL), washed twice with hexane (15 mL), and the solvent was distilled off under reduced pressure. The resulting residue was purified by reverse phase column chromatography (water-acetonitrile containing 0.1% formic acid) to obtain compound aa164 (1.90 g, 44% over 2 steps). LCMS (ESI) m / z = 484 (M+H) + retention time: 0.97 min (analysis conditions SQDFA05). Synthesis of compound aa136 [Chemical 111] Compound aa136-a (10.1 g, 22.1 mmol) was dissolved in toluene (28 mL), and propionaldehyde (14.3 mL, 199 mmol), TFA (15.3 mL, 199 mmol), and magnesium sulfate (7.99 g, 66.4 mmol) were added. The mixture was stirred at 60°C for 3 hours. The solid was filtered off using a silica gel pad, and the filtrate was washed twice with water (100 mL). Acetonitrile (20 mL) was added, and the mixture was washed with 1 M aqueous potassium hydrogen phosphate (30 mL), three times with 3.5% aqueous potassium bicarbonate (40 mL), and finally with saturated brine (100 mL). The mixture was dried over anhydrous magnesium sulfate, filtered, and the solvent was evaporated under reduced pressure to obtain compound aa136-b as a crude product. The crude compound aa136-b was dissolved in toluene (28 mL), and TES (7.07 mL, 44.3 mmol) was added. Cool to 0℃ and add TiCl 4 (4.88 mL, 44.3 mmol) was added and stirred at room temperature for 15 minutes. Water (50 mL) was added dropwise, and the organic layer was washed with water (100 mL) and then washed with a 1M dipotassium hydrogen phosphate aqueous solution (50 mL). n-Hexane (90 mL) was added and extracted three times with a mixed solvent of acetonitrile (15 mL) and a 1% potassium bicarbonate aqueous solution (30 mL). The mixture was then extracted twice with a mixed solvent of acetonitrile (20 mL) and a 1% potassium bicarbonate aqueous solution (30 mL). n-Hexane (90 mL) was added to the organic layer and extracted twice with a mixed solvent of acetonitrile (20 mL) and a 1% potassium bicarbonate aqueous solution (30 mL). The aqueous layers were combined, n-Hexane (80 mL) was added, phosphoric acid was added to adjust the pH to 3, and then the mixture was extracted three times with TBME (150 mL). The organic layer was washed with saturated brine (50 mL), dried over anhydrous magnesium sulfate, and filtered. The solvent was distilled off under reduced pressure to obtain compound aa136 (5.03 g, 46%). LCMS (ESI) m / z = 498 (M+H) + Retention time: 1.02 min (Analysis conditions SQDFA05) Synthesis of compound aa174 [Chemical 112] Using aa174-a as the starting material, aa174 (18.6 g, 84%) was obtained by the same method as compound aa136. LCMS (ESI) m / z = 460 (M+NH 4) + Retention time: 1.41 minutes (Analysis conditions: SMD method_04) Synthesis of compound aa264 [Chemical 113] Compound aa264-a (H-cisHyp(3)-OH, 950 mg, 7.24 mmol) was dissolved in water (22 mL), and DIPEA (3.47 mL, 19.9 mmol) was added. A 1,4-dioxane solution (14.5 mL) of Fmoc-OSu (2.44 g, 7.24 mmol) was added. The resulting solid was crushed with a spatula and then ultrasonically ground. 1,4-dioxane (15 mL) was added to dissolve the solid, and the mixture was stirred at room temperature for 40 minutes. The mixture was washed twice with n-hexane / CPME (3 / 1, 10 mL), and potassium bisulfate (3.70 g, 27.2 mmol) was added. Extraction was performed three times with isopropyl acetate (30 mL). The organic layer was washed with 50% brine (30 mL), dried over anhydrous sodium sulfate, filtered, and the solvent was removed under reduced pressure to obtain compound aa264-b (2.39 g, 93%). LCMS (ESI) m / z = 355 (M+H) + Retention time: 0.64 min (Analysis conditions: SQDFA05). Compound aa264-b (2.39 g, 6.76 mmol) and PPTS (0.170 g, 0.676 mmol) were suspended in DCM (23 mL). DHP (1.39 mL, 15.2 mmol) was added and stirred at room temperature for 19 hours. PPTS (0.085 g, 0.338 mmol) and DHP (0.741 mL, 8.11 mmol) were added and stirred at room temperature for 3 hours. The mixture was washed with water and then with saturated brine. The mixture was dried over anhydrous sodium sulfate, filtered, and the solvent was removed under reduced pressure. This mixture was dissolved in THF (25 mL), phosphate buffer (pH = 8.2, 25 mL) was added, and the mixture was stirred at 50°C for 11 hours. Ethyl acetate (25 mL) was added, the aqueous layer was removed, and the aqueous layer was extracted twice with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate, filtered, and the solvent was removed under reduced pressure. These were dissolved in DCM (30 mL) and n-hexane (30 mL) was added. Only DCM was distilled off under reduced pressure, and then n-hexane was distilled off under reduced pressure. N-hexane was added to the obtained solid, irradiated with ultrasound, and after removing the n-hexane by decantation, it was dried under reduced pressure to obtain compound aa264 as a sodium salt. These were dissolved in isopropyl acetate (50 mL), 0.05M phosphoric acid aqueous solution (pH = 2, 90 mL) was added, and after stirring at room temperature for 10 minutes, the aqueous layer was removed. The aqueous layer was extracted with isopropyl acetate, the organic layer was dried over anhydrous sodium sulfate, filtered off, and the solvent was distilled off under reduced pressure. The crude product was purified by reverse phase chromatography (acetonitrile with 0.1% formic acid / distilled water with 0.1% formic acid) to obtain compound aa264 (2.33 g, 79%). LCMS (ESI) m / z = 456 (M+NH 3) + Retention time: 0.81 minutes (Analysis conditions SQDFA05) Synthesis of compound aa265 [Chemical 114] Using aa265-a as the starting material, aa265 (1.38 g, 78%) was obtained by the same method as for the synthesis of compound aa264. LCMS (ESI) m / z = 439 (M+H)+ retention time: 0.85 min (analysis conditions SQDFA05) Synthesis of compound aa267 [Chemical 115] Using aa267-a as the starting material, aa267 (9.04 g, quant.) was obtained by the same method as for the synthesis of compound aa264. LCMS (ESI) m / z = 460 (M+Na)+ retention time: 0.81 min (analysis conditions SQDFA05) Synthesis of compound aa279 [Chemical 116] Using aa279-a as the starting material, aa279 (5.15 g, 83%) was obtained using the same method as for the synthesis of compound aa264. LCMS (ESI) m / z = 460 (M+Na)+, retention time: 0.85 min (analysis conditions SQDFA05). Synthesis of compound aa244 [Chemical 117] A mixture of compound aa244-a, ((2S)-2-(phenylmethoxycarbonylamino)pentanedioic acid) (50 g, 177.8 mmol), polyoxymethylene (11.87 g), and p-toluenesulfonic acid (1.84 g, 10.69 mmol) in toluene (500 mL) was stirred at 120°C for 16 hours. After cooling to room temperature, the reaction mixture was diluted with ethyl acetate, washed with saturated brine, and dried over anhydrous sodium sulfate. The solvent was evaporated under reduced pressure to obtain compound aa244-b as a crude product (52 g, 96%). This crude product was used in the next reaction without purification. After stirring a solution of compound aa244-b (4 g, 13.64 mmol) in sulfinyl chloride (50 mL) at 85°C for 1 hour, the solvent was distilled off under reduced pressure. The residue was dissolved in THF (20 mL) and cooled to -78°C under a nitrogen atmosphere. A solution of lithium tri-tert-butyloxyaluminum hydride (2.76 g, 10.87 mmol) in THF (20 mL) was added dropwise over 2.5 hours. After stirring at -78°C for 3 hours, water was added to the reaction solution and the precipitate was removed by filtration. The filtrate was extracted with ethyl acetate, and the organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The resulting residue was purified by silica gel column chromatography (ethyl acetate / petroleum ether) to obtain compound aa244-c (2 g). 1 H-NMR (400 MHz, CDCl 3) δ7.41-7.32(m,5H),5.49(br.s,1H),5.27-5.11(m,3H),4.38-4.33(m,1H),2.58-2.19(m,4H) Under a nitrogen atmosphere, (diethylamino)sulfur trifluoride (DAST) (780 mg, 4.84 mmol) was added to a solution of compound aa244-c (450 mg, 1.62 mmol) in DCM (20 mL) at 0°C, and the mixture was stirred at room temperature for 16 hours. After adding water, the reaction solution was diluted with DCM and washed sequentially with aqueous sodium bicarbonate solution and saturated brine. The organic layer was dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The resulting residue was purified by silica gel column chromatography (ethyl acetate / petroleum ether) to obtain compound aa244-d (0.35 g, 72%). This was mixed with other batches of the same synthesis and carried out in the next reaction. 1H-NMR (400 MHz, CDCl 3) δ7.42-7.35(m,5H),5.97-5.58(m,2H),5.25-5.16(m,3H),4.50-4.35(m,1H),2.14-1.68(m,4H) 19 F-NMR (400 MHz, CDCl 3)δ-116.562 Compound aa244-d (1 g, 3.34 mmol) and TES (12.63 g, 109 mmol) were dissolved in TFA / DCM (10 / 10 mL) and stirred at room temperature for 4 days. The solvent was then distilled off under reduced pressure. The residue was diluted with aqueous sodium bicarbonate solution, washed with diethyl ether, and adjusted to pH 3 with 2N hydrochloric acid. The mixture was extracted with DCM, and the organic layer was washed with saturated brine and dried over anhydrous sodium sulfate. The solvent was then distilled off under reduced pressure to obtain compound aa244-e (0.6 g) as a crude product. This crude product was used in the next reaction without purification. Compound aa244-e (0.6 g) and palladium on carbon (10%, 60 mg) in methanol (10 mL) were stirred under a hydrogen atmosphere at approximately 3 atm for 16 hours. The palladium on carbon was removed by filtration, and the solvent was distilled off the filtrate under reduced pressure to obtain compound aa244-f (0.23 g) as a crude product. This crude product was not purified but was mixed with another batch from the same synthesis and used in the next reaction. To a mixture of compound aa244-f (0.3 g, 1.79 mmol) and potassium carbonate (745 mg, 5.4 mmol) in 1,4-dioxane / water (5 / 5 mL), Fmoc-OSu (0.9 g, 1.5 equivalents) was added and stirred for 2 hours. The reaction solution was diluted with water, washed with diethyl ether, and then adjusted to pH 3 with 2N hydrochloric acid. It was extracted three times with ethyl acetate, and the combined organic layers were washed with saturated brine, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The residue was purified by reverse phase column chromatography (acetonitrile with 0.05%-TFA / distilled water with 0.05%-TFA) to obtain compound aa244 (0.2 g, 29%). Other batches of the same synthesis were also used for the peptide synthesis of this example. Retention time: 3.153 minutes (analysis conditions SMDmethod_19) 1 H-NMR (300 MHz, DMSO-d 6)δ12.94(br.s,1H),7.92-7.88(d,J=7.2Hz,2H),7.66-7.61(m,2H),7.44-7.3 1(m,4H),6.35-5.75(m,1H),4.49-4.26(m,4H),2.72(s,3H),1.78-1.65(m,4H) 19 F-NMR (300 MHz, DMSO-d 6)δ-115.730 Synthesis of compound aa043 [Chemical 118] Under a nitrogen atmosphere, aa244-c (18 g, 64.98 mmol) was dissolved in dichloromethane (50 mL), and a solution of phosphorus pentachloride (27 g, 130 mmol) in carbon tetrachloride (550 mL) was slowly added dropwise at 0°C. After stirring the reaction solution at room temperature for 16 hours, dichloromethane was added to dilute it. The resulting solution was washed with water, and the aqueous phase was extracted twice with dichloromethane. The organic phases were mixed and washed with aqueous sodium bicarbonate solution. After drying the resulting solution over anhydrous sodium sulfate, the solvent was distilled off under reduced pressure. The crude product was purified by sequential column chromatography (hexane-ethyl acetate) to obtain aa043-a (7.2 g, 33%). Aa043-a (7.2 g, 21.75 mmol) was dissolved in dichloromethane (150 mL), and triethylsilane (83.2 g, 718 mmol) and trifluoroacetic acid (24.8 g, 218 mmol) were added, and the mixture was stirred at room temperature for 4 days. The reaction solution was concentrated under reduced pressure, the resulting residue was dissolved in an aqueous sodium bicarbonate solution, and the aqueous phase was washed with diethyl ether. The pH of the resulting solution was then adjusted to 3 with 2N hydrochloric acid. After the mixed solution was extracted twice with dichloromethane, the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The resulting crude product aa043-b (5.5 g) was used directly in the next step. A solution of 33% hydrogen bromide in acetic acid (10 mL) diluted with acetic acid (10 mL) was added to the crude product aa043-b (1.1 g) and stirred at room temperature for 2 hours. The reaction mixture was concentrated under reduced pressure, and the residue was diluted with water. The resulting solution was washed with diethyl ether, and the solvent was distilled off under reduced pressure to obtain the crude product aa043-c (1.0 g). The crude product aa043-b was used directly in the next step. LCMS (ESI) m / z = 200 (M+H) + Retention time: 0.88 minutes (Analysis conditions SMD method_12) The crude product aa043-c (1.00 g) and potassium carbonate (1.48 g, 10.7 mmol) were dissolved in water (10 mL), and a 1,4-dioxane solution (10 mL) of Fmoc-OSu (1.8 g, 5.36 mmol) was added. After stirring at room temperature for 2 hours, the reaction solution was diluted with water. The resulting solution was washed with diethyl ether (30 mL) and 2N hydrochloric acid was added to pH 3. Then, the mixed solution was extracted 3 times with ethyl acetate, the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The obtained concentrate was purified by reverse phase column chromatography (water-acetonitrile) to obtain aa043 (0.5 g, 27%, 3 steps). LCMS (ESI) m / z=422 (M+H)+ Retention time: 2.3 minutes (analysis conditions SMD method_13) Synthesis of compound aa056 [Chemical 119] Under a nitrogen atmosphere, aa056-a (90 g, 443 mmol) and iodomethane (314 g, 2.21 mol) were dissolved in tetrahydrofuran (3.15 L). The mixed solution was cooled to 0°C and sodium hydride (60%, 77.56 g, 2.21 mol) was added while stirring. After stirring the reaction solution at 25°C for 3 hours, it was added to ice water. The obtained solution was washed 3 times with tertiary butyl methyl ether / n-hexane (1 / 3). 1N hydrochloric acid was added to the aqueous phase to adjust the pH to 2-3, and extracted 3 times with ethyl acetate. The obtained organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain aa056-b (94 g) as a crude product. The obtained crude product was used directly in the next reaction. LCMS (ESI) m / z=240 (M+Na)+ Retention time: 1.1 minutes (Analysis conditions SMD method_14) The crude product of aa056-b (94 g) was dissolved in dichloromethane (600 mL). The solution was cooled to 0°C and 4N HCl / 1,4-dioxane (660 mL) was added. The reaction solution was stirred at 25°C for 3 hours and concentrated under reduced pressure to obtain the crude product of aa056-c (90 g). LCMS (ESI) m / z = 118 (M+H) + Retention time: 0.25 min (Analysis conditions SMD method_14) The crude product of aa056-c (90 g) was dissolved in water (560 mL) and potassium carbonate was added to adjust the pH to 7. Then, potassium carbonate (149 g, 1.08 mol), Fmoc-OSu (131 g, 389 mmol) and 1,4-dioxane (560 mL) were added to the reaction solution and stirred at 25°C for 3 hours. After that, the reaction solution was washed with tertiary butyl methyl ether / n-hexane (1 / 3), 1N hydrochloric acid was added to adjust the pH to 2-3, and the solid was filtered out. The obtained solid was washed with water and dried under reduced pressure at 50°C for 16 hours to obtain aa056 (130 g, 86% (3 steps)). LCMS (ESI) m / z=362 (M+Na)+ Retention time: 2.0 minutes (Analysis conditions SMD method_15) Synthesis of compound aa246 [Chemical 120] Under a nitrogen atmosphere, aa246-a (30 g, 113 mmol) was dissolved in tetrahydrofuran (300 mL), and sodium hydride (oily, 60%, 5.97 g, 249 mmol) was added at 0°C. After stirring the reaction solution at room temperature for 4 hours, it was cooled to 0°C and 3-bromo-1-propylene (15.73 g, 130 mmol) was added dropwise. The reaction solution was then stirred at room temperature for 2 hours, and ice water was added to stop the reaction. After the resulting mixture was adjusted to pH 2 using concentrated hydrochloric acid, it was extracted twice with ethyl acetate. The organic phase was washed with saturated brine and dried over anhydrous sodium sulfate. The organic phase was concentrated under reduced pressure to obtain a crude product of aa246-b (27.3 g). LCMS (ESI) m / z=306 (M+H)+ Retention time: 2.0 minutes (analysis conditions SMD method_16) The crude product of aa246-b (26 g) was dissolved in methanol (260 mL), and a 2M ammonia-methanol solution (63.9 mL) and 10% palladium on carbon (3.3 g) were added. The reaction solution was stirred at room temperature under a hydrogen atmosphere for 16 hours and then filtered. The resulting filtrate was concentrated under reduced pressure to obtain the crude product of aa246-c (14.2 g). LCMS (ESI) m / z = 174 (M+H) + Retention time: 0.84 minutes (Analysis conditions SMD method_16) The crude product of aa246-c (10 g) was dissolved in 1,4-dioxane (100 mL) and water (100 mL), and potassium carbonate (23.9 g, 172 mmol) was added. Fmoc-OSu (17,4 g, 51.7 mmol) was added to the reaction solution, stirred at room temperature for 16 hours, and then filtered. The filtrate was washed 5 times with tertiary butyl methyl ether / hexane (1 / 3), and the aqueous phase was adjusted to pH 2 with concentrated hydrochloric acid. The resulting solution was extracted twice with ethyl acetate. The organic phase was then washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain aa246 (15.3 g, 58%, 3 steps). LCMS (ESI) m / z=396 (M+H)+ Retention time: 2.0 minutes (Analysis conditions SMD method_11) Synthesis of compound aa281 [Chemical 121] Under a nitrogen atmosphere, aa246-a (10 g, 43.2 mmol) was dissolved in tetrahydrofuran (150 mL). After cooling to -10°C, sodium hydride (60%, 3.8 g, 95.1 mmol) was added. The reaction solution was stirred at room temperature for 1 hour. Subsequently, iodomethane (7.4 g,...

Claims

1. A (1S,4S,10S,13S,17S,20S,26S,28R,32S,38S,42Z)-20-cyclopentyl-28-ethoxy-32-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-N,N,2,14,18,21,24,36-octamethyl-10-[(1S)-1-methylpropyl]-3,9,12,15, Compounds of 19,22,25,31,34,37,45-undecyloxy-13-propyl-38-[[4-(trifluoromethyl)phenyl]methyl]spiro[2,8,11,14,18,21,24,30,33,36,39-undecazatetracyclo[37.5.1.04,8.026,30]thiocene-42-ene-23,1'-cyclobutane]-17-carboxymethylamine.

2. A pharmaceutical composition comprising the compound as described in claim 1.

3. A pharmaceutical composition for selectively inhibiting KRAS in a target, comprising the compound as described in claim 1.

4. A pharmaceutical composition for treating cancer in a subject, comprising an effective amount of the compound as described in claim 1.

5. The pharmaceutical composition as described in claim 4, wherein the cancer is lung cancer.

6. A pharmaceutical composition as described in claim 4, wherein the object is a human being.

7. A (1S,4S,10S,13S,17S,20S,26S,28R,32S,38S,42Z)-20-cyclopentyl-28-ethoxy-32-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-N,N,2,14,18,21,24,36-octamethyl-10-[(1S)-1-methylpropyl]-3,9,12,15, 19,22,25,31,34,37,45-Undecyloxy-13-propyl-38-[[4-(trifluoromethyl)phenyl]methyl]spiro[2,8,11,14,18,21,24,30,33,36,39-Undecazatetetracyclo[37.5.1.04,8.026,30]thiafoc-42-ene-23,1'-cyclobutane]-17-carboxymethylamine hydrate.

8. A pharmaceutical composition comprising the hydrate as described in claim 7.

9. A pharmaceutical composition for selectively inhibiting KRAS in a target, comprising the hydrate as described in claim 7.

10. A pharmaceutical composition for treating cancer in a subject, comprising an effective amount of the hydrate as described in claim 7.

11. The pharmaceutical composition as described in claim 10, wherein the cancer is lung cancer.

12. The pharmaceutical composition as described in claim 10, wherein the object is a human being.

13. A (1S,4S,10S,13S,17S,20S,26S,28R,32S,38S,42Z)-20-cyclopentyl-28-ethoxy-32-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-N,N,2,14,18,21,24,36-octamethyl-10-[(1S)-1-methylpropyl]-3,9,12,15,1 Salts of 9,22,25,31,34,37,45-undecyloxy-13-propyl-38-[[4-(trifluoromethyl)phenyl]methyl]spiro[2,8,11,14,18,21,24,30,33,36,39-undecazatetracyclo[37.5.1.04,8.026,30]thiafoc-42-ene-23,1'-cyclobutane]-17-carboxylamine or their hydrates.

14. A pharmaceutical composition comprising a salt or its hydrate as described in claim 13.

15. A pharmaceutical composition for selectively inhibiting KRAS in a target, comprising a salt or hydrate thereof as described in claim 13.

16. A pharmaceutical composition for treating cancer, comprising an effective amount of the salt or its hydrate as described in claim 13.

17. The pharmaceutical composition as described in claim 16, wherein the cancer is lung cancer.

18. A pharmaceutical composition as described in claim 16, wherein the object is a human being.

Citation Information

Patent Citations

  • Cyclic peptide compound having kras inhibiting action

    TW202132328A